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ABSTRACT 
 
Alysia Kern Lovgren 
 
Determining the Role of Prostanoids in the Pathogenesis of Pulmonary Fibrosis 
 
(Under the direction of Dr. Beverly H. Koller, PhD) 
 
 Idiopathic pulmonary fibrosis is a relentless, fatal disease characterized by alveolar 
epithelial cell injury, proliferation of mesenchymal cell populations, and extracellular matrix 
deposition.  Unknown microinjuries to the lung initiate an aberrant repair process in 
susceptible individuals which ultimately alters lung architecture and leads to progressive loss 
of pulmonary function.  Lipid mediators called prostanoids have been implicated in both 
inflammatory and fibrotic signaling pathways.  It has been postulated that the COX-2 
metabolite prostaglandin E2 (PGE2) is responsible for protection against pulmonary fibrosis.  
To study this lipid mediator, we first generated a mouse line deficient in the putative 
cytosolic PGE2 synthase, cPGES/p23.  These mice died at birth due to respiratory failure, and 
our data shows that cPGES/p23 is a co-chaperone that is important for both DNA-binding-
dependent and -independent mechanisms of the glucocorticoid receptor.  However, 
characterization of primary embryonic fibroblasts derived from the cPGES/p23-deficient 
mice, as well as embryonic tissues, demonstrated that cPGES/p23 is not required for the 
direct production of PGE2 from COX-derived PGH2.  We, therefore, went on to demonstrate 
that upregulation of PGE2 after bleomycin administration was dependent on the microsomal 
PGE2 synthase, mPGES1.  However, neither loss of PGE2 synthesis nor signaling through the 
Gs-coupled EP2 and EP4 receptors had an effect on the development of fibrotic lung disease.  
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Interestingly, we show that COX-2-dependent production of prostacyclin plays an important 
role in the development of disease, limiting both the development of fibrosis and the 
consequential alterations in lung mechanics.  Our studies reveal an important role for the 
COX-2-prostacyclin synthetic pathway in protection from bleomycin-induced pulmonary 
fibrosis.   
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CHAPTER 1 
INTRODUCTION 
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The Significance, Histopathology, and Classification of Idiopathic Pulmonary Fibrosis 
 Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease of the distal 
airways which leads to excessive scarring and decreased lung function.  Symptoms include 
dyspnea and nonproductive cough, and most patients display symptoms for over six months 
before visiting a physician.  Onset is usually in the later stages of life; however, once 
diagnosed, the median survival is only 2-3 years and ultimately results in respiratory failure.  
Currently, no therapies exist to increase life expectancy or improve quality of life.   
 IPF is the most common interstitial lung disease among older adults, and it is more 
prevalent in men than in women.  The disease etiology is unknown.  Although some risk 
factors have been suggested, such as cigarette smoking and environmental hazards, there is 
little evidence indicating any predisposing or etiological factors (59).  Familial IPF has been 
reported in about .5-2.2% of cases and, aside from earlier onset of disease, are 
indistinguishable from non-familial cases (38).  Mutations in various cytokines, structural 
proteins, and even telomerase have been linked to familial IPF in different pedigrees (68).  
    IPF is characterized by patchy subpleural parenchymal fibrosis due to excess 
extracellular matrix deposition and failure of alveolar re-epithelialization after injury.  The 
hallmark characteristics of idiopathic pulmonary fibrosis are temporal heterogeneity and 
myofibroblast foci.  Temporal heterogeneity means that different areas of the lung are 
alternating with healthy lung and various stages of disease: honeycombing and scarring 
(chronic), fibroblastic foci and interstitial fibrosis (subacute), and alveolar epithelial cell 
apoptosis and possibly inflammation (acute).  The honeycomb structure is due to distended 
alveolar septa adjacent to areas of excessive collagen deposition.  Fibroblast foci are dense 
areas of proliferating and transforming fibroblasts.  Fibroblasts recruited to the injury 
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transform into myofibroblasts, which express alpha smooth muscle actin and change the lung 
architecture.  These fibroblasts produce excess collagen and fibronectin that cause the 
thickening of the septal walls.  This thickening leads to an inability to transport oxygen from 
the alveolar spaces into the capillaries. 
 Several acute and chronic lung diseases characterized by variable degrees of 
inflammation and fibrosis are classified as interstitial lung diseases (ILD).  Collagen vascular 
diseases, inhalation of environmental/occupational hazards, drug-induced lung disease, 
connective tissue diseases (such as scleroderma), and granulomatous lung diseases are some 
of the known causes of ILD.  Idiopathic pulmonary fibrosis is a subgroup of the ILDs of 
unknown etiology.  Accurate diagnosis of disease is important for appropriate therapeutic 
options and prognosis to be determined.  The American Thoracic Society/European 
Respiratory Society classification system recognizes seven groups:  idiopathic pulmonary 
fibrosis (IPF)/usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), 
acute interstitial pneumonitis (AIP), respiratory bronchiolitis-associated ILD, desquamative 
interstitial pneumonia, cryptogenic organizing pneumonia (COP), and lymphocyte interstitial 
pneumonia (1).  Compared to IPF/UIP, the majority of the other ILDs have a definitive 
inflammatory stage and tend to improve with corticosteroid therapy and have a better 
prognosis.  The unique combination of histopathological entities and its inevitable 
progression to death demonstrate a huge need to study new therapies. 
 
Pathophysiology 
 Idiopathic pulmonary fibrosis begins from unknown repeated insults or microinjuries 
to the lung epithelia.  These microinjuries lead to dysregulated repair and an epithelial-
 4
fibroblastic disorder.  Activated epithelial cells and possibly inflammatory cells, including 
neutrophils, macrophages, and lymphocytes, induce activation of fibroblasts.  This activation 
includes migration to the injured site, proliferation, and transformation into myofibroblasts.  
Dense extracellular matrix and collagen are deposited in the interstitial spaces.  In IPF, the 
mechanisms necessary for proper re-epithelialization are impaired, such as epithelial cell 
migration, proliferation, and differentiation (59).  Myofibroblasts disrupt the basement 
membrane and may enhance epithelial cell apoptosis.  A loss of signals to reduce fibroblast 
migration and proliferation and increase myofibroblast apoptosis along with continuous 
epithelial cell apoptosis leads to impaired re-epithelialization and aberrant wound healing 
(60). 
 The key morphological alteration linked with the progression of fibrosis is the 
number of fibroblastic foci.  Fibroblasts and myofibroblasts form distinct clusters within the 
alveolar septa.  Fibroblastic foci represent the areas of acute lung injury where the alveolar 
epithelia is disorganized and the basement membrane denuded (34).  In an attempt to repair 
this, fibroblasts assume three general phenotypes: migratory, proliferative, and profibrotic.  
Myofibroblasts, which express α-smooth muscle actin, have been demonstrated to align 
parallel to one another to change the contractile abilities and architecture of the lung 
parenchyma.  They secrete matrix proteins and are the premier source of increased collagen 
production, and their proliferation correlates with a decrease in lung compliance (42, 78, 80).  
Myofibroblasts also secrete profibrotic mediators like TGF-β and matrix metalloproteinases, 
enzymes that can disrupt the basement membrane (79). 
 An imbalance of growth factors, cytokines, and enzymes contributes to abnormal 
wound healing and an enhanced fibrotic response.  Activated fibroblasts, epithelial cells, and 
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possibly inflammatory cells can release these mediators to alter disease development.  
Improper signaling leads to dysregulated repair through altered collagen metabolism, 
apoptotic pathways, and chemotactic gradients.  Profibrotic mediators include TGF-β, IL-8, 
fibroblast growth factor, platelet derived growth factor, thromboxane A2, monocyte 
chemoattractant protein-1, leukotrienes, and tumor necrosis factor α.  Antifibrotic mediators 
include prostaglandin E2, IFN-γ, IL-10, and granulocyte-macrophage colony stimulating 
factor (GM-CSF).  The matrix metalloproteinases and tissue inhibitors of metalloproteinases 
are important enzymes in regulating extracellular matrix turnover, and recent evidence 
suggests that the expression of these is altered in IPF patients (23).  Understanding the role of 
all of these factors is important for unraveling the mystery of this epithelial-fibroblastic 
disorder.   
 
Historical Perspectives and Current Therapies 
 Idiopathic pulmonary fibrosis was originally described by Hamman and Rich in 1935 
at Johns Hopkins Hospital.  The original cases are now classified as acute interstitial 
pneumonia instead of usual interstitial pneumonia.  However, the Hamman-Rich syndrome 
was considered the definition of idiopathic pulmonary fibrosis for many decades.  In the 
1960s, the Liebow classifications started the modern era for interstitial lung diseases by 
describing five histopathological subgroups highlighting the importance of the histological 
patterns.  In the 1980s, the inflammation hypothesis for the pathogenesis of IPF was 
generated by a number of leaders in the pulmonary field (52).  This hypothesis has fallen 
under much scrutiny in recent years; however, these early studies made huge contributions to 
the understanding of many other inflammatory lung diseases.  Another observation from the 
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1980s was the importance of growth factors in the pathogenesis of IPF.  This paved the way 
for the paradigm shift away from inflammation and towards abnormal wound healing.  The 
emergence in recent years of the epithelial-mesenchymal disorder has highlighted the 
importance of re-epithelialization and unregulated proliferation and collagen deposition by 
fibroblasts.  The current understanding of the pathogenesis of pulmonary fibrosis is a 
conglomeration of epithelial and fibroblastic issues, cytokine and growth factor imbalances, 
and inflammation.  The hypothesis will continue to evolve as new studies shed light on this 
complex disease. 
 Chronic inflammation was once believed to be the cause and perpetuating factor in 
idiopathic pulmonary fibrosis.  Although the role of the infiltration of inflammatory cells and 
their secretion of various cytokines is now controversial, anti-inflammatory treatment with 
corticosteroids was the main treatment protocol for many years. The clinical features of 
dyspnea and a restrictive pulmonary test overlap other interstitial lung diseases, and the lack 
of a well-defined disease made diagnosis difficult over the years.  About 15-30% of patients 
were once believed to benefit from anti-inflammatory therapy due to inflated numbers from 
inaccurate diagnosis and inclusion of other ILDs in this statistic (21).  As better technology 
has emerged so has the definition and classification schemes to aid in more accurate 
diagnosis.  Now it is believed that corticosteroid treatment alone is ineffective at treating IPF.  
In addition, the negative side effects far outweigh any negligible improvement.  For this 
reason, corticosteroids alone are not recommended as standard therapy (73). 
 Currently, corticosteroids along with cytotoxic agents are widely prescribed; 
however, this treatment approach is not recommended due to unproven benefits and 
enhanced morbidity (73).  Currently, no specific drug treatment is recommended.  Patients 
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should be evaluated for lung transplant suitability, and doctors should have end-of-life 
discussions with their patients.  Recently, the most promising novel therapies have been the 
antioxidant N-acetylcysteine and the TGF-β inhibitor pirfenidone; however, additional trials 
are necessary to determine efficacy for these new compounds.  These drugs and current 
research into new therapies are targeting the mechanisms and pathways behind the aberrant 
tissue remodeling. 
 
Eicosanoids and Pulmonary Fibrosis 
Overview of Eicosanoid Metabolism 
 The eicosanoids are bioactive lipids that are produced by almost all cells to act as 
autocrine and paracrine mediators.  The term eicosanoid comes from the greek “eicosa” 
which means twenty.  The eicosanoids are lipids produced from the 20 carbon fatty acid, 
arachidonic acid.  The activation of the phospholipase enzymes, such as cytosolic 
phospholipase A2 (cPLA2), causes the release of arachidonic acid from the cell membrane 
phospholipids.  The metabolism of arachidonic acid yields leukotrienes through the 5-
lipoxygenase (5-LO) pathway or the prostanoids through the cyclooxygenase pathway 
(COX-1 or COX-2).  The COX enzymes exist in two specific isoforms, the inducible COX-2 
isoform and the constitutively expressed COX-1 isoform.  The COX enzymes have two 
different functions for converting arachidonic acid into the intermediate prostaglandin 
endoperoxide (PGH2).  First, the cyclooxygenase activity of COX-1 and COX-2 converts 
arachadonic acid into prostaglandin G2 (PGG2).  Second, the peroxidase activity converts 
PGG2 into prostaglandin endoperoxide, PGH2, which is then metabolized to the various 
prostanoids by their corresponding terminal synthases.  The type of prostanoid released from 
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a given tissue depends on the synthases expressed.  The prostanoids include prostacyclin 
(PGI2), thromboxane A2 (TxA2), prostaglandin D2 (PGD2), prostaglandin F (PGF), and 
prostaglandin E2 (PGE2).  Figure 1 shows the arachidonic acid pathway and includes relevant 
enzymes, metabolites, and receptors.   
 Prostanoids mediate their biological actions through binding to specific G-protein-
associated receptors which initiate signal transduction events.  A single receptor binds 
thromboxane and prostacyclin, TP and IP, respectively.  PGE2 has affinity for four receptors 
(EP1-EP4) with different expression patterns and coupling to intracellular signaling 
pathways.  Activation of EP1 increases second messenger Ca2+ levels.  EP2 and EP4 are 
coupled to Gs and increase cAMP levels.  Similar responses have been described for the IP 
receptor.  EP3 can couple to either Gi,s,or q proteins thus can increase and decrease cAMP 
levels and increase Ca2+ .  The expression profile of the receptors is different on given cell 
types to enhance the diversity of action of these mediators. 
 
Leukotrienes and Prostanoids in Pulmonary Fibrosis 
 Eicosanoids are well-known for their role in platelet aggregation, pain, smooth 
muscle contraction, and inflammation and have been linked with diseases such as rheumatoid 
arthritis, cardiovascular disease, and asthma.  However, studies have begun to shed light on 
even more roles for eicosanoids in immune responses, proliferation, and apoptosis.  
Numerous studies have suggested a delicate balance between the profibrotic leukotrienes and 
the antifibrotic prostaglandins in the pathophysiology of pulmonary fibrosis.  Leukotrienes, 
especially cysteinyl leukotrienes, are best known for their involvement in the pathogenesis of 
asthma.  In the 1980s, leukotrienes were demonstrated to have an effect on fibroblast  
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Figure 1.1  
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Figure 1.1.  The Arachidonic Acid Cascade.  Solid arrows designate path from substrate to 
product.  Boxes designate genes whose products catalyze the conversion from substrate to 
product.  Dashed arrows designate path from ligand to receptor. 
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migration and proliferation (4, 41).  Also, elevated levels of leukotrienes were measured in 
bronchoalveolar lavage fluid from patients with pulmonoary fibrosis (74).  In 1996, Wilborn 
et al. demonstrated that patients with pulmonary fibrosis had increased levels of leukotrienes 
in lung homogenates from biopsy samples (76).  Continuing their investigations, this group 
demonstrated that leukotriene-deficient mice were protected from bleomycin-induced 
pulmonary fibrosis (54).  This suggested that leukotrienes play a causal role in the 
development of pulmonary fibrosis.  Leukotriene-deficient mice had a decrease in the initial 
inflammatory response and an increase in anti-fibrotic cytokines that may have contributed to 
their protection from disease.  Currently, 5-LO inhibitors are being investigated as a novel 
therapeutic. 
 COX-2, the inducible cyclooxygenase enzyme, produces prostanoids during 
pathological conditions and has been studied in numerous inflammatory diseases.  COX-2 
expression has also been shown to be reduced in lung fibroblasts isolated from patients with 
pulmonary fibrosis (77).  Originally, COX-2-deficient mice were demonstrated to be more 
susceptible to both vanadium pentoxide and bleomycin-induced pulmonary fibrosis (8, 30).  
However, another study by one of the original groups contradicted these finding and claimed 
that only the COX-2 heterozygous mice had an increased susceptibility to disease (25).  
Despite the slightly contradictory reports, these studies demonstrate the importance of COX-
2 metabolites in the pathogenesis of pulmonary fibrosis. 
 The most well-studied of the prostanoids in pulmonary fibrosis is PGE2.  Numerous 
studies have identified this COX-2 metabolite to be responsible for protection against 
pulmonary fibrosis due to its anti-inflammatory and anti-fibrotic actions.  IPF patients have a 
decrease of PGE2 in bronchoalveolar fluid, and fibroblasts taken from these patients are 
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defective in PGE2 synthesis (9, 77).  It is therefore possible that the increased disease in these 
patients is partly due to their inability to produce sufficient PGE2.  A possible mechanism for 
PGE2 is suggested by numerous ex vivo reports.  PGE2 was shown to suppress fibroblast 
proliferation and suppress collagen synthesis of lung fibroblasts (7, 18, 19, 39).  PGE2 has 
also been shown to inhibit fibroblast migration and fibroblast to myofibroblast transition (32, 
33).  Thus, an increased number of myofibroblasts in the absence of PGE2 is likely to 
contribute to the morphological changes as well as the contractile changes of lung 
parenchyma characteristic of IPF.   
 The ability of PGE2 to alter activity and gene expression of fibroblasts has been 
attributed to engagement of Gs-coupled receptors, particularily EP2, and cAMP release.  
Early studies demonstrated in human embryo lung fibroblasts (IMR90 cells) that PGE2 
reduced collagen mRNA levels (10).  They demonstrated that an EP2/EP4 agonist and a 
cAMP activator, but not an EP3/EP1 agonist, had a similar effect on collagen expression.  
More recently, a similar study was done specifically in adult lung parenchymal fibroblasts 
with identical results (26).  In addition, they used a more specific EP2 agonist, instead of an 
EP2/EP4 agonist, and were able to identify PKA as the major cAMP effector.  Other studies 
have also demonstrated that PGE2 inhibits fibroblasts migration and myofibroblast 
differentiation through an EP2-mediated pathway (33, 75). 
 
PGE2 Synthases 
 Three different genes have been reported to encode proteins capable of generating 
PGE2 from the COX-derived metabolite PGH2 in vitro.  These include microsomal 
prostaglandin E synthase 1 (mPGES1), microsomal prostaglandin E synthase 2 (mPGES2), 
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and cytosolic prostaglandin E synthase (cPGES).  Each synthase has a unique expression 
profile and has been demonstrated to produce PGE2 under varying conditions.  Since PGE2 
plays a critical role in inflammation and proliferation, understanding the synthases 
responsible for its production becomes crucial for determining new targets and potential 
therapeutics for many chronic diseases.   
 The biosynthesis of PGE2 by mPGES1 has been well-established.  mPGES1 is a 
member of the MAPEG (membrane-associated proteins involved in eicosanoid and 
glutathione metabolism) protein superfamily, and both in vitro studies and analysis of mice 
lacking mPGES1 support an important role for this enzyme in PGE2 synthesis, especially 
during inflammatory responses.  The expression of mPGES1 increases rapidly in many 
tissues and cells after exposure to proinflammatory cytokines and lipopolysaccharide (LPS) 
(27, 45).  Specifically, mPGES1 coordinated with COX-2 in the production of PGE2 from 
macrophages after exposure to lipopolysaccharide (LPS) (45).  Also, by using mPGES1-
deficient macrophages, this enzyme was demonstrated to be essential for LPS-induced PGE2 
production (69).  Not surprisingly, in vivo studies of mice lacking this gene indicate that this 
enzyme is responsible for the increased levels of PGE2 measured during inflammatory 
responses.  Uematsu et al. demonstrated that mPGES1-deficient mice were unable to 
upregulate PGE2 after LPS exposure compared to wild-type controls (69).  Since PGE2 is an 
important mediator of pain and leukocyte recruitment, analyzing the mPGES1-deficient mice 
in models of acute and chronic inflammation was important for understanding how this 
synthase contributes to disease pathogenesis.  The mPGES1-deficient mice displayed 
impaired inflammatory pain perception and a reduction in severity and incidence in an 
experimental model of human rheumatoid arthritis, a chronic inflammatory disease (67).  
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This indicates an important contribution of mPGES1 to both PGE2-dependent models of 
inflammatory pain and chronic inflammation.  This evidence for mPGES1 as an inducible 
synthase responsible for elevating PGE2 levels during inflammation demonstrates its 
importance during pathophysiological states.   
 A number of lines of evidence suggest that other means for production of PGE2 in 
vivo are possible.  PGE2 production can still be detected in the mPGES1-deficient animals.  
Also, the mPGES1-deficient mice do not recapitulate all of the phenotypes of the mice 
deficient in the PGE2 EP receptors, such as patent ductus arteriosus in the EP4-deficient mice 
and the fertilization defect observed in the EP2-deficient mice (51, 66).  A possible 
explanation could be basal production of PGE2 from the other identified PGE2 synthases, 
mPGES2 and cPGES, which have been shown to increase PGE2 production when over-
expressed in various cell lines (44) (64).  
 Similar to mPGES1, mPGES2 is a microsomal protein.  However, the expression of 
this gene is not induced by LPS treatment and increased levels are not observed in inflamed 
tissues (44).  This enzyme has been demonstrated to couple with both COX-1 and COX-2 in 
PGE2 production.  Since expression of mPGES2 is ubiquitous and constitutive, it has been 
suggested that this synthase contributes primarily to maintenance of basal PGE2 levels.  
However, determining the role of this protein in vivo is important to establish whether it truly 
has synthase capabilities and how it contributes to PGE2 production in both homeostatic and 
pathological conditions. 
 The third protein capable of in vitro PGE2 production was termed cPGES reflecting 
the fact that, unlike the other two synthases, this protein was purified from rat brain cytosolic 
extracts.  Similar to mPGES1, this synthase was shown to have glutathione-dependent PGE2 
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synthase activity (64).  cPGES is expressed in many cell lines and in a wide range of tissues.  
Similar to mPGES2, expression of the gene is generally not sensitive to inflammatory stimuli 
with one notable exception.  Tanioka et al. demonstrated that LPS treatment increased levels 
of cPGES three-fold in the brain (64).  Co-transfection of human cPGES cDNA with COX-1, 
but not with COX-2, resulted in a large increase in PGE2 production.  These findings led to 
the suggestion that in most cells COX-1 collaborates with cPGES in basal PGE2 production.  
This same research group has also shown that cPGES is regulated by serine phosphorylation 
(31).  Casein kinase II (CKII) mediates this phosphorylation by forming a tertiary complex 
with the molecular chaperone Hsp90 and cPGES.  In vitro experiments demonstrated that 
phosphorylation correlates with increased cPGES activity and Hsp90 association, and Hsp90 
association stimulates phosphorylation by CKII.  This phosphorylation and activation were 
abrogated following treatment with CKII and Hsp90 inhibitors.  This data suggested a unique 
regulation of an enzyme in the eicosanoid biosynthetic pathway; however, the contribution of 
this enzyme to PGE2 production in vivo has yet to been defined. 
 cPGES was determined by peptide microsequencing to be identical to a previously 
identified small acidic protein named p23 (64).  p23 was originally co-purified with the 
inactive avian progesterone receptor/hsp90 complex from cell lysates (61).  Toft and 
colleagues demonstrated p23 to be expressed in many tissues, highly conserved in numerous 
species, and an important co-chaperone of the hsp90 complex that aids in the progesterone 
receptor complex formation (28). 
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p23 and the Hsp90 Chaperone System 
 Hsp90 is a ubiquitous and essential chaperone protein for nearly 100 different client 
proteins including transcription factors, protein kinases, and growth and hormone receptors 
involved in signal transduction.  This highly conserved and abundant stress protein forms a 
multiprotein chaperone system that is critical for the conformational change of the client 
protein to a state that is ready to respond to signal transduction.  In steroid receptors, Hsp90 
is responsible for the conformational change that opens the binding cleft for the steroid 
substrate.   
 The association of steroid receptors, especially the glucocorticoid receptor (GR), and 
the hsp90 chaperone system has been used extensively to study this model.  The chaperone 
system consists of five proteins including hsp90, hsp70, Hop, hsp40, and p23.  In an ATP-
dependent fashion, hsp70 and hsp40 bind to the receptor to prepare the receptor for the 
conformational change.  Then, in another ATP-dependent reaction, Hsp90 and Hop, bind to 
the primed GR/Hsp70 complex.  Dittmar et al. demonstrated that only Hsp90, hsp70, and 
Hop were necessary to carry out the folding change that converts the hormone binding 
domain to a steroid binding conformation (15).  After Hsp90 binding, another ATP-
dependent step leads to opening of the hydrophobic binding cleft.  p23 can now bind directly 
to Hsp90 in its ATP-dependent conformation (15).  p23 appears to protect Hsp90/GR 
heterocomplexes against disassembly while increasing steroid binding activity in reticulocyte 
lysate.  The rate of heterocomplex formation does not seem to be altered by p23 (15).  This 
finding was strengthened by a study demonstrating that p23 was a limiting component 
responsible for stabilizing the Hsp90/client protein complex in Sf9 cells (43).  At the point of 
p23 binding, Hop dissociates from the heterocomplex to allow immunophilins to bind to the 
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steroid receptor/Hsp90 heterocomplex and assist in trafficking.  Specifically, TPR 
(tetratricopeptide repeat) domain immunophilins have been shown to link Hsp90 to a dynein 
motor protein through direct binding of the peptidylprolyl isomerase domain to aid in GR 
translocation to the nucleus (20).  The complicated functions of p23 and the Hsp90 
chaperone system in the maturation and stability of the GR still remain to be elucidated in 
vivo.    
 
The Biological Functions of Glucocorticoids and the Glucocorticoid Receptor 
 Glucocorticoids are a class of steroid hormones that mediate many important 
biological functions.  The adrenal cortex synthesizes and secretes glucocorticoids.  The term 
glucocorticoid came from early studies that demonstrated a role for glucocorticoids in 
glucose metabolism.  Glucocorticoids have since been shown to have a multitude of 
biological functions including roles in inflammation and lung development.  The GR is a 
ligand-activated transcription factor that mediates the biological effects of glucocorticoids.  
GR is primarily in the cytoplasm sequestered by a multi-protein complex as described above.  
Upon hormone binding to the ligand binding domain, a conformational change occurs in GR 
and the multi-protein complex is released.  GR can now translocate to the nucleus and 
regulate gene expression by both DNA-binding-dependent and –independent mechanisms.  
GR can bind to glucocorticoid response elements (GREs) upstream of specific target genes to 
induce transcription.  GR has been shown to modify chromatin structure to allow for binding 
of cofactor complexes to stimulate gene transcription (24).  Also, GR can bind to other 
transcription factors via direct protein-protein interactions, or tethering, to inhibit 
transcription of their target genes. 
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Glucocorticoids in Glucose Metabolism 
 Glucose is essential for animals as both a fuel and as a precursor for other 
carbohydrates.  Intricate mechanisms exist to ensure that proper blood glucose levels are 
maintained.  Glucose is primarily stored in the liver in the form of glycogen.  The amount of 
glycogen stored in the liver is only enough to supply glucose to the brain for half a day, and 
glucose is the primary energy source for the brain.  Thus, the intricate mechanisms, 
gluconeogenesis and glycogenolysis, become extremely important metabolic processes 
during times of limited food intake.  Glycogenolysis is the catabolism of glycogen into 
glucose-1-phosphate, which can then be used to release free glucose into the bloodstream.  
Gluconeogenesis is the production of glucose from noncarbohydrate precursors.  Again, the 
goal is to release free glucose into the blood to maintain homeostasis.  Glucose-6-
phosphatase is the final enzyme in both the gluconeogenic and glycogenolytic pathways.  
The glucose-6-phosphatase promoter has a glucocorticoid response element, and 
glucocorticoids have been demonstrated to stimulate its expression as well as other genes 
involved in gluconeogenesis, such as tyrosine aminotransferase (TAT) (11, 70).  GR-
deficient mice show reduced expression of enzymes involved in gluconeogenesis confirming 
their role in this process. 
 The role of glucocorticoids in metabolism was first noted over 60 years ago.  
Adrenalectomized animals could not maintain blood glucose levels or liver glycogen stores, 
and these defects could be corrected by treatment with glucocorticoids (13, 37).  In 1970, 
adrenal corticosteroids were demonstrated to increase glycogen in fetal rat livers (22).  
Shortly thereafter, studies demonstrated that glycogen synthase, the final enzyme responsible 
for glycogen production, is stimulated by glucocorticoids (17, 71).   
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Glucocorticoids in Lung Development 
 Lung development is an intricate process involving growth and differentiation factors 
as well as circulating hormones that are temporally and spacially regulated.  Glucocorticoids 
are important hormones that regulate the expression of genes necessary for proper lung 
maturation.  During the final stages of lung development, glucocorticoids are important for 
epithelial cell differentiation and terminal saccule development (36, 62).  Thinning of the 
mesenchyme is important to form the epithelial-endothelial junction necessary for efficient 
gas exchange.  Glucocorticoids decrease the interstitial tissues in numerous animal species, 
and this is most likely through regulation of glucocorticoid-sensitive growth factors such as 
TNF-α, epithelial growth factor, and fibrocyte-pneumocyte factor (5, 55). 
 Administration of glucocorticoids is widely used to accelerate lung maturation and 
increase lung surfactant production in preterm infants (62).  Lung surfactant is a lipoprotein 
that is synthesized by type II alveolar epithelial cells.  Surfactants form a thin film on the 
alveolar surface that promotes lung compliance and prevents alveolar collapse.  Lung 
surfactant contains four associated proteins SP-A, SP-B, SP-C, and SP-D, and numerous 
studies have demonstrated that glucocorticoids stimulate the expression of the surfactant 
protein genes (40).  Glucocorticoids also regulates gene expression of the epithelial sodium 
channel (ENaC) which is essential for clearance of lung liquid at birth to improve compliance 
and gas exchange (72).   
 To further study the role of glucocorticoids in fetal lung development, mice lacking a 
functional glucocorticoid receptor were generated.  These mice died at birth due to improper 
lung maturation (12).  Surfactant protein expression was reduced in these mice, and the lungs 
were hypercellular and had reduced septal thinning.  Ultrastructural analysis demonstrated a 
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reduction in type I alveolar epithelial cells, and this observation was confirmed by Northern 
analysis demonstrating reduced mRNA expression of type I AEC markers, T1α and 
aquaporin-5.  Type I alveolar epithelial cells are flat cells with long cytoplasmic extensions 
that cover 90% of the alveolar space.  These cytoplasmic extensions form thin boundaries 
with the endothelial cells to allow oxygen diffusion into the capillary bed.  Thus, loss of these 
type I cells and lack of mesenchymal thinning can lead to a condensed lung architecture and 
respiratory insufficiency.  The phenotypes of the glucocorticoid-deficient mice emphasize the 
importance of glucocorticoids in lung development and epithelial cell differentiation. 
 
Glucocorticoids in Inflammation 
 Inflammation plays a key role in many chronic diseases, such as asthma, COPD, and 
rheumatoid arthritis.  Sophisticated molecular mechanisms exist that involve the interaction 
of cytokines, chemokines, and lipid mediators in perpetuating disease pathology.  
Glucocorticoids have the ability to alter expression of these numerous inflammatory 
mediators and thus have been widely used for the treatment of inflammatory diseases.  As 
discussed earlier, for many years, glucocorticoids have also been the primary treatment for 
pulmonary fibrosis although they have not demonstrated to improve life expectancy or 
quality of life.  Three different mechanisms can account for the anti-inflammatory capabilites 
of glucocorticoids.  GR can bind to GREs upstream of target genes to induce transcription of 
anti-inflammatory mediators.  Glucocorticoids can also inhibit the expression of multiple 
proinflammatory genes through direct protein-protein interactions with transcription factors.  
Lastly, protein production and mRNA stability has also been shown to be affected by 
glucocorticoids (3, 46). 
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 The most notable is the ability of glucocorticoids to inhibit the expression of many 
genes including those encoding cytokines, enzymes, receptors, and adhesion molecules that 
regulate inflammatory responses.  Many of these genes do not have typical GRE sites to 
modify gene expression.  Instead, GR tethers other transcription factors in a direct protein-
protein interaction independent of DNA binding.  This phenomenon was first described for 
the collagenase gene which is induced by activator protein-1 (AP-1) (29).  Phorbol esters and 
tumor necrosis factor α (TNF-α) activate AP-1 which induces the collagenase gene.  
However, glucocorticoids inhibit this induction of the collagenase gene by forming a protein-
protein complex with AP-1.  Adcock et al. demonstrated that, in human lung, phorbol ester 
increased AP-1 binding to DNA, and glucocorticoids reversed the effect (2).  This 
phenomenon has also been described for NF-κB, which is important in regulating expression 
of numerous inflammatory genes.   
 GR can also induce the transcription of anti-inflammatory mediators.  For example, 
lipocortin-1 expression is induced by glucocorticoids.  Lipocortin-1 inhibits phospholipase 
A2, which is important for release of AA and eicosanoid metabolism (14).  This decreases 
the production of inflammatory lipid mediators.  Glucocorticoids can also induce the 
transcription of Iκ-B-α, the inhibitor of NF-κB (58).  The concentration of glucocorticoids 
necessary to stimulate gene transcription is much higher than necessary to inhibit expression 
by binding other transcription factors, and the induction of these genes is relatively slow (24-
48hrs) compared to the more rapid anti-inflammatory effects observed after glucocorticoid 
treatment.  Thus, the transactivation of anti-inflammatory genes is probably secondary to the 
ability of glucocorticoids to inhibit proinflammatory genes.  The negative side effects from 
effecting metabolic processes is the more prominent effect from transactivation by GR (3). 
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 Lastly, glucocorticoids have post-transcriptional and translational control of gene 
expression.  Glucocorticoids have been shown to reduce protein production by decreasing 
mRNA stability, and it has been suggested that this is due to the induction of mRNA-
degrading ribonucleases (53).  These enzymes target AU-rich sequences located within the 3’ 
untranslated region of many cytokines, growth factors, and inflammatory genes such as GM-
CSF and COX-2 (6).  These regions play an important role in mRNA stabilization and 
translational blockage. 
 Interestingly, COX-2 has been shown to be regulated by glucocorticoids by all three 
of the mechanisms described here: induction of transcription by transactivation, inhibition of 
transcription by tethering mechanisms, and post-transcriptional/translational control.  
Glucocorticoids can induce the expression of lipocortin-1 which indirectly regulates COX-2, 
as described above.  Also, potential GRE elements have been defined in the COX-2 promoter 
regions which may play a role in the induction of gene transcription (65).  Interestingly, the 
ability of glucocorticoids to stimulate production of prostanoids in specific cell types has 
been reported, particularily in primary amniotic fibroblasts (16, 63).  These studies show that 
dexamethasone increases expression of COX-2 in these cells.  In the majority of cell types, 
however, glucocorticoids are better known for their inhibition of COX-2 expression to reduce 
inflammation.  Glucocorticoids have been shown to reduce COX-2 activity in cells by 
decreasing COX-2 transcription via tethering of transcription factors, such as NF-κB, 
essential for induction of this gene during inflammation (47, 48).  In addition, post-
transcriptional and translational regulation of COX-2 activity have been reported (35, 49, 
50).  For example, glucocorticoids have been shown to inhibit mitogen-activated protein 
kinase p38 which results in COX-2 mRNA destabilization (35).  The numerous regulatory 
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mechanisms of COX-2 illustrates the complex interactions that are possible for mediating the 
anti-inflammatory effects of glucocorticoids. 
 
DNA-binding-dependent versus –independent mechanisms of the glucocorticoid receptor 
 To elucidate the mechanism for glucocorticoid regulation of metabolic genes and 
other biological functions, a mouse line was generated in which GR could not homodimerize 
and bind DNA (56).  This offered the unique opportunity to determine which biological 
effects of glucocorticoids were dependent on DNA binding to GREs to induce transcription 
or independent of DNA binding and involved tethering of other transcription factors.  These 
mice, named GRdim, survived to adulthood and had normal lung development.  This suggests 
that lung development is a DNA-binding-independent process.  In contrast, these mice did 
not induce genes involved in gluconeogenesis.  Thus, metabolic processes require the DNA-
binding ability of the GR to alter gene expression.  In addition, glucocorticoids repressed 
both local and systemic inflammatory responses effectively in these mice (57).  This study 
also demonstrated the appropriate repression of an NF-κB reporter gene by glucocorticoids in 
CD4+ splenocytes from these mice.  This data supports that the tethering mechanism of GR 
with other transcription factors is the crucial mechanism for altering inflammatory responses 
especially in the case of human diseases.  These mice provide in vivo evidence to confirm the 
in vitro studies that had separated the DNA-binding-dependent and –independent functions 
of GR. 
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Summary and Organization of Dissertation 
 The overall aim of this dissertation was to determine the role of prostanoids in the 
pathogenesis of pulmonary fibrosis.  We first chose to analyze the role of PGE2 in the 
development of disease due to its anti-fibrotic and anti-inflammatory properties in the lung.  
The work presented in Chapter 2 examines the in vivo role of the putative PGE2 synthase, 
cPGES/p23, to elucidate the involvement of this protein in prostanoid metabolism and thus 
its subsequent value in fibrosis studies.  This chapter also includes a detailed assessment of 
cPGES/p23 as a co-chaperone necessary for glucocorticoid receptor function.  Chapter 3 
discusses the use of the well-established bleomycin-induced pulmonary fibrosis model to 
investigate the pathogenesis of disease in mouse lines deficient in synthases or receptors that 
alter prostanoid signaling.  Bleomycin-induced fibrosis has both pathological and 
biochemical similarities to human idiopathic pulmonary fibrosis and has been used 
extensively to model aspects of disease pathogenesis.  Chapter 4 discusses possible 
mechanisms for the enhanced disease susceptibility of mice deficient in prostacyclin 
signaling.    
 
    
  
 
 
 
 
 
 
 
 
 24
REFERENCES 
 
 
1. American Thoracic Society/European Respiratory Society International 
Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This 
joint statement of the American Thoracic Society (ATS), and the European Respiratory 
Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS 
Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304, 2002. 
 
2. Adcock IM, Shirasaki H, Gelder CM, Peters MJ, Brown CR, and Barnes PJ. The 
effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor 
activation in human lung. Life Sci 55: 1147-1153, 1994. 
 
3. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. 
Clin Sci (Lond) 94: 557-572, 1998. 
 
4. Baud L, Perez J, Denis M, and Ardaillou R. Modulation of fibroblast proliferation by 
sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 138: 1190-1195, 1987. 
 
5. Beck JC, Mitzner W, Johnson JW, Hutchins GM, Foidart JM, London WT, Palmer 
AE, and Scott R. Betamethasone and the rhesus fetus: effect on lung morphometry and 
connective tissue. Pediatr Res 15: 235-240, 1981. 
 
6. Bickel M, Iwai Y, Pluznik DH, and Cohen RB. Binding of sequence-specific proteins 
to the adenosine- plus uridine-rich sequences of the murine granulocyte/macrophage colony-
stimulating factor mRNA. Proc Natl Acad Sci U S A 89: 10001-10005, 1992. 
 
7. Bitterman PB, Wewers MD, Rennard SI, Adelberg S, and Crystal RG. Modulation of 
alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J 
Clin Invest 77: 700-708, 1986. 
 
8. Bonner JC, Rice AB, Ingram JL, Moomaw CR, Nyska A, Bradbury A, Sessoms AR, 
Chulada PC, Morgan DL, Zeldin DC, and Langenbach R. Susceptibility of cyclooxygenase-
2-deficient mice to pulmonary fibrogenesis. Am J Pathol 161: 459-470, 2002. 
 
9. Borok Z, Gillissen A, Buhl R, Hoyt RF, Hubbard RC, Ozaki T, Rennard SI, and 
Crystal RG. Augmentation of functional prostaglandin E levels on the respiratory epithelial 
surface by aerosol administration of prostaglandin E. Am Rev Respir Dis 144: 1080-1084, 
1991. 
 
10. Choung J, Taylor L, Thomas K, Zhou X, Kagan H, Yang X, and Polgar P. Role of 
EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen alpha1, 
lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell 
Biochem 71: 254-263, 1998. 
 25
11. Cole TJ, Blendy JA, Schmid W, Strahle U, and Schutz G. Expression of the mouse 
glucocorticoid receptor and its role during development. J Steroid Biochem Mol Biol 47: 49-
53, 1993. 
 
12. Cole TJ, Solomon NM, Van Driel R, Monk JA, Bird D, Richardson SJ, Dilley RJ, and 
Hooper SB. Altered epithelial cell proportions in the fetal lung of glucocorticoid receptor null 
mice. Am J Respir Cell Mol Biol 30: 613-619, 2004. 
 
13. Cori C and Cori G. Fate of sugar in animal body: carbohydrate metabolism of 
adrenalectomized rats and mice. Journal of Biological Chemistry 74: 473, 1927. 
 
14. Croxtall JD, Choudhury Q, Tokumoto H, and Flower RJ. Lipocortin-1 and the control 
of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) 
inhibit G protein-dependent activation of cPLA2 activity. Biochem Pharmacol 50: 465-474, 
1995. 
 
15. Dittmar KD, Demady DR, Stancato LF, Krishna P, and Pratt WB. Folding of the 
glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The 
role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70. J Biol 
Chem 272: 21213-21220, 1997. 
 
16. Economopoulos P, Sun M, Purgina B, and Gibb W. Glucocorticoids stimulate 
prostaglandin H synthase type-2 (PGHS-2) in the fibroblast cells in human amnion cultures. 
Mol Cell Endocrinol 117: 141-147, 1996. 
 
17. Eisen HJ, Goldfine ID, and Glinsmann WH. Regulation of hepatic glycogen synthesis 
during fetal development: roles of hydrocortisone, insulin, and insulin receptors. Proc Natl 
Acad Sci U S A 70: 3454-3457, 1973. 
 
18. Elias JA, Rossman MD, Zurier RB, and Daniele RP. Human alveolar macrophage 
inhibition of lung fibroblast growth. A prostaglandin-dependent process. Am Rev Respir Dis 
131: 94-99, 1985. 
 
19. Fine A, Poliks CF, Donahue LP, Smith BD, and Goldstein RH. The differential effect 
of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen 
formation in lung fibroblasts. J Biol Chem 264: 16988-16991, 1989. 
 
20. Galigniana MD, Harrell JM, Murphy PJ, Chinkers M, Radanyi C, Renoir JM, Zhang 
M, and Pratt WB. Binding of hsp90-associated immunophilins to cytoplasmic dynein: direct 
binding and in vivo evidence that the peptidylprolyl isomerase domain is a dynein interaction 
domain. Biochemistry 41: 13602-13610, 2002. 
 
21. Gay SE, Kazerooni EA, Toews GB, Lynch JP, 3rd, Gross BH, Cascade PN, Spizarny 
DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R, and Martinez FJ. Idiopathic 
pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 
157: 1063-1072, 1998. 
 26
22. Greengard O and Dewey HK. The premature deposition or lysis of glycogen in livers 
of fetal rats injected with hydrocortisone or glucagon. Dev Biol 21: 452-461, 1970. 
 
23. Hayashi T, Stetler-Stevenson WG, Fleming MV, Fishback N, Koss MN, Liotta LA, 
Ferrans VJ, and Travis WD. Immunohistochemical study of metalloproteinases and their 
tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic 
pulmonary fibrosis. Am J Pathol 149: 1241-1256, 1996. 
 
24. Hebbar PB and Archer TK. Chromatin remodeling by nuclear receptors. 
Chromosoma 111: 495-504, 2003. 
 
25. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan 
GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, and McAnulty RJ. Severity of lung 
injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) 
production. Am J Pathol 165: 1663-1676, 2004. 
 
26. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, and Peters-Golden M. 
Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal 
lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell 
Mol Physiol 292: L405-413, 2007. 
 
27. Jakobsson PJ, Thoren S, Morgenstern R, and Samuelsson B. Identification of human 
prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, 
constituting a potential novel drug target. Proc Natl Acad Sci U S A 96: 7220-7225, 1999. 
 
28. Johnson JL, Beito TG, Krco CJ, and Toft DO. Characterization of a novel 23-
kilodalton protein of unactive progesterone receptor complexes. Mol Cell Biol 14: 1956-
1963, 1994. 
 
29. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, and Herrlich P. 
Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by 
glucocorticoid hormone. Cell 62: 1189-1204, 1990. 
 
30. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, 
Laurent GJ, Hart SL, Foster ML, and McAnulty RJ. Cyclooxygenase-2 deficiency results in a 
loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic 
lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 
158: 1411-1422, 2001. 
 
31. Kobayashi T, Nakatani Y, Tanioka T, Tsujimoto M, Nakajo S, Nakaya K, Murakami 
M, and Kudo I. Regulation of cytosolic prostaglandin E synthase by phosphorylation. 
Biochem J 381: 59-69, 2004. 
 
32. Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M, Nakamura Y, Veys T, 
Allegra L, Romberger D, and Rennard SI. Prostaglandin E(2) inhibits fibroblast chemotaxis. 
Am J Physiol Lung Cell Mol Physiol 281: L1257-1263, 2001. 
 27
33. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, and Moore BB. 
Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 
signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29: 537-
544, 2003. 
 
34. Kuhn C and McDonald JA. The roles of the myofibroblast in idiopathic pulmonary 
fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular 
matrix synthesis. Am J Pathol 138: 1257-1265, 1991. 
 
35. Lasa M, Brook M, Saklatvala J, and Clark AR. Dexamethasone destabilizes 
cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 
21: 771-780, 2001. 
 
36. Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. J 
Endocrinol 45: 515-523, 1969. 
 
37. Long C, Katzin B, and Fry E. The adrenal cortex and carbohydrate metabolism. 
Endocrinology 26: 309, 1940. 
 
38. Marshall RP, Puddicombe A, Cookson WO, and Laurent GJ. Adult familial 
cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 55: 143-146, 2000. 
 
39. McAnulty RJ, Hernandez-Rodriguez NA, Mutsaers SE, Coker RK, and Laurent GJ. 
Indomethacin suppresses the anti-proliferative effects of transforming growth factor-beta 
isoforms on fibroblast cell cultures. Biochem J 321 ( Pt 3): 639-643, 1997. 
 
40. Mendelson CR. Role of transcription factors in fetal lung development and surfactant 
protein gene expression. Annu Rev Physiol 62: 875-915, 2000. 
 
41. Mensing H and Czarnetzki BM. Leukotriene B4 induces in vitro fibroblast 
chemotaxis. J Invest Dermatol 82: 9-12, 1984. 
 
42. Mitchell J, Woodcock-Mitchell J, Reynolds S, Low R, Leslie K, Adler K, Gabbiani 
G, and Skalli O. Alpha-smooth muscle actin in parenchymal cells of bleomycin-injured rat 
lung. Lab Invest 60: 643-650, 1989. 
 
43. Morishima Y, Kanelakis KC, Murphy PJ, Lowe ER, Jenkins GJ, Osawa Y, Sunahara 
RK, and Pratt WB. The hsp90 cochaperone p23 is the limiting component of the multiprotein 
hsp90/hsp70-based chaperone system in vivo where it acts to stabilize the client protein: 
hsp90 complex. J Biol Chem 278: 48754-48763, 2003. 
 
44. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, Ohmiya Y, 
Watanabe K, and Kudo I. Cellular prostaglandin E2 production by membrane-bound 
prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 278: 37937-
37947, 2003. 
 28
45. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, 
Fueki M, Ueno A, Oh S, and Kudo I. Regulation of prostaglandin E2 biosynthesis by 
inducible membrane-associated prostaglandin E2 synthase that acts in concert with 
cyclooxygenase-2. J Biol Chem 275: 32783-32792, 2000. 
 
46. Newton R. Molecular mechanisms of glucocorticoid action: what is important? 
Thorax 55: 603-613, 2000. 
 
47. Newton R, Kuitert LM, Bergmann M, Adcock IM, and Barnes PJ. Evidence for 
involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-
1beta. Biochem Biophys Res Commun 237: 28-32, 1997. 
 
48. Newton R, Kuitert LM, Slater DM, Adcock IM, and Barnes PJ. Cytokine induction of 
cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids 
in human epithelial cells. Life Sci 60: 67-78, 1997. 
 
49. Newton R, Seybold J, Kuitert LM, Bergmann M, and Barnes PJ. Repression of 
cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional 
and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 
273: 32312-32321, 1998. 
 
50. Newton R, Seybold J, Liu SF, and Barnes PJ. Alternate COX-2 transcripts are 
differentially regulated: implications for post-transcriptional control. Biochem Biophys Res 
Commun 234: 85-89, 1997. 
 
51. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, 
Malouf NN, and Koller BH. The prostaglandin receptor EP4 triggers remodelling of the 
cardiovascular system at birth. Nature 390: 78-81, 1997. 
 
52. Noble PW and Homer RJ. Back to the future: historical perspective on the 
pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 33: 113-120, 2005. 
 
53. Peppel K, Vinci JM, and Baglioni C. The AU-rich sequences in the 3' untranslated 
region mediate the increased turnover of interferon mRNA induced by glucocorticoids. J Exp 
Med 173: 349-355, 1991. 
 
54. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, and Moore 
BB. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care 
Med 165: 229-235, 2002. 
 
55. Pinkerton KE, Willet KE, Peake JL, Sly PD, Jobe AH, and Ikegami M. Prenatal 
glucocorticoid and T4 effects on lung morphology in preterm lambs. Am J Respir Crit Care 
Med 156: 624-630, 1997. 
 
 29
56. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, 
Schmid W, Herrlich P, Angel P, and Schutz G. DNA binding of the glucocorticoid receptor 
is not essential for survival. Cell 93: 531-541, 1998. 
 
57. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, 
and Schutz G. Repression of inflammatory responses in the absence of DNA binding by the 
glucocorticoid receptor. Embo J 20: 7168-7173, 2001. 
 
58. Scheinman RI, Cogswell PC, Lofquist AK, and Baldwin AS, Jr. Role of 
transcriptional activation of I kappa B alpha in mediation of immunosuppression by 
glucocorticoids. Science 270: 283-286, 1995. 
 
59. Selman M, King TE, and Pardo A. Idiopathic pulmonary fibrosis: prevailing and 
evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 
134: 136-151, 2001. 
 
60. Selman M and Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic 
cross-talk disorder. Respir Res 3: 3, 2002. 
 
61. Smith DF, Faber LE, and Toft DO. Purification of unactivated progesterone receptor 
and identification of novel receptor-associated proteins. J Biol Chem 265: 3996-4003, 1990. 
 
62. Snyder JM, Rodgers HF, O'Brien JA, Mahli N, Magliato SA, and Durham PL. 
Glucocorticoid effects on rabbit fetal lung maturation in vivo: an ultrastructural 
morphometric study. Anat Rec 232: 133-140, 1992. 
 
63. Sun K, Ma R, Cui X, Campos B, Webster R, Brockman D, and Myatt L. 
Glucocorticoids induce cytosolic phospholipase A2 and prostaglandin H synthase type 2 but 
not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured 
primary human amnion cells. J Clin Endocrinol Metab 88: 5564-5571, 2003. 
 
64. Tanioka T, Nakatani Y, Semmyo N, Murakami M, and Kudo I. Molecular 
identification of cytosolic prostaglandin E2 synthase that is functionally coupled with 
cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275: 32775-
32782, 2000. 
 
65. Tazawa R, Xu XM, Wu KK, and Wang LH. Characterization of the genomic 
structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. 
Biochem Biophys Res Commun 203: 190-199, 1994. 
 
66. Tilley SL, Audoly LP, Hicks EH, Kim HS, Flannery PJ, Coffman TM, and Koller 
BH. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin 
E2 receptor. J Clin Invest 103: 1539-1545, 1999. 
 
67. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, 
Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish 
 30
JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, and Audoly LP. Impaired inflammatory 
and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad 
Sci U S A 100: 9044-9049, 2003. 
 
68. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, 
Shay JW, and Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. 
Proc Natl Acad Sci U S A 104: 7552-7557, 2007. 
 
69. Uematsu S, Matsumoto M, Takeda K, and Akira S. Lipopolysaccharide-dependent 
prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) 
synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 168: 
5811-5816, 2002. 
 
70. Vander Kooi BT, Onuma H, Oeser JK, Svitek CA, Allen SR, Vander Kooi CW, 
Chazin WJ, and O'Brien RM. The glucose-6-phosphatase catalytic subunit gene promoter 
contains both positive and negative glucocorticoid response elements. Mol Endocrinol 19: 
3001-3022, 2005. 
 
71. Vanstapel F, Dopere F, and Stalmans W. The role of glycogen synthase phosphatase 
in the glucocorticoid-induced deposition of glycogen in foetal rat liver. Biochem J 192: 607-
612, 1980. 
 
72. Wallace MJ, Hooper SB, and Harding R. Effects of elevated fetal cortisol 
concentrations on the volume, secretion, and reabsorption of lung liquid. Am J Physiol 269: 
R881-887, 1995. 
 
73. Walter N, Collard HR, and King TE, Jr. Current perspectives on the treatment of 
idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3: 330-338, 2006. 
 
74. Wardlaw AJ, Hay H, Cromwell O, Collins JV, and Kay AB. Leukotrienes, LTC4 and 
LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J 
Allergy Clin Immunol 84: 19-26, 1989. 
 
75. White ES, Atrasz RG, Dickie EG, Aronoff DM, Stambolic V, Mak TW, Moore BB, 
and Peters-Golden M. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 
receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 32: 135-141, 2005. 
 
76. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, and Peters-Golden M. 
Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary 
fibrosis. J Clin Invest 97: 1827-1836, 1996. 
 
77. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, and Peters-Golden M. 
Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a 
diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin 
Invest 95: 1861-1868, 1995. 
 31
78. Zhang HY, Gharaee-Kermani M, Zhang K, Karmiol S, and Phan SH. Lung fibroblast 
alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced 
pulmonary fibrosis. Am J Pathol 148: 527-537, 1996. 
 
79. Zhang K, Flanders KC, and Phan SH. Cellular localization of transforming growth 
factor-beta expression in bleomycin-induced pulmonary fibrosis. Am J Pathol 147: 352-361, 
1995. 
 
80. Zhang K, Rekhter MD, Gordon D, and Phan SH. Myofibroblasts and their role in 
lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical 
and in situ hybridization study. Am J Pathol 145: 114-125, 1994. 
 
 
CHAPTER 2 
cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not 
PGE2 synthesis 
 33
cPGES/p23 is required for glucocorticoid receptor function and embryonic 
growth but not PGE2 synthesis 
 
Alysia Kern Lovgren, Martina Kovarova, Beverly H. Koller* 
 
 
 
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina 27599-7248. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published in the June 2007 issue of Molecular and Cellular Biology.  I 
would like to thank the contributing authors:  Martina Kovarova for help with the 
translocation experiments and flow cytometry for the proliferation assay and Bev Koller for 
her guidance and support. 
 
 
 
 
 
 34
ABSTRACT 
A number of studies have identified cPGES/p23 as a cytoplasmic protein capable of 
the metabolism of prostaglandin E2 (PGE2) from the cyclooxygenase metabolite 
prostaglandin endoperoxide (PGH2).  However, this protein has also been implicated in a 
number of other pathways, including the stabilization of the glucocorticoid receptor (GR) 
complex.  To define the importance of the functions assigned to this protein, mice lacking 
detectible cPGES/p23 expression were generated.  cPGES/p23-/- pups die during the perinatal 
period and display retarded lung development reminiscent of the phenotype of GR-deficient 
neonates.  Furthermore, GR-sensitive gluconeogenic enzymes are not induced in the prenatal 
period.  However, unlike GR-deficient embryos, cPGES/p23-/- embryos are small in size, and 
a proliferation defect is observed in cPGES/p23-/- fibroblasts.  Analysis of arachidonic acid 
metabolites in embryonic tissues and primary fibroblasts failed to support a function for this 
protein in PGE2 biosynthesis.  Thus, while the growth retardation of the cPGES/p23-/- pups 
and decreased proliferation of primary fibroblasts identifies functions for this protein in 
addition to GR stabilization, it is unlikely that these functions include metabolism of PGH2 to 
PGE2.   
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INTRODUCTION 
 Prostaglandin E2 (PGE2) is a lipid mediator involved in a wide range of normal 
biological functions as well as pathological processes such as chronic inflammation.  
Biosynthesis begins with the metabolism of arachidonic acid into prostaglandin endoperoxide 
(PGH2) by cyclooxygenase enzymes (COX-1 or COX-2).  Three terminal synthase enzymes, 
capable of producing PGE2 from COX-derived PGH2 in vitro, have been reported.  These 
include microsomal PGE2 synthase 1 (mPGES1), microsomal PGE2 synthase 2 (mPGES2), 
and the cytosolic PGE2 synthase (cPGES) (24, 59, 60).  mPGES1 is a member of the 
MAPEG (membrane-associated proteins involved in eicosanoid and glutathione metabolism) 
protein superfamily and its expression increases rapidly in many cells after exposure to 
proinflammatory cytokines and lipopolysaccharide (LPS) (24, 62, 65).  Not surprisingly, in 
vivo studies of mice lacking this gene indicate that this enzyme is responsible for the 
increased levels of PGE2 measured in many inflammatory responses (62).  However, PGE2 
production can still be detected in the mPGES1-deficient animals, supporting the contention 
that additional pathways are present that, at least under some circumstances, can produce 
PGE2.  One candidate is mPGES2.  Similar to mPGES1, mPGES2 is a microsomal protein.  
However, as the expression of this gene is not induced by LPS treatment and increased levels 
are not observed in inflamed tissues, it has been suggested that this synthase contributes 
primarily to maintenance of basal PGE2 levels (38).   
 The third protein capable of in vitro PGE2 production was termed cPGES reflecting 
the fact that, unlike the other two synthases, this protein was purified from rat brain cytosolic 
extracts.  Similar to mPGES1, this synthase was shown to have glutathione-dependent PGE2 
synthase activity (60).  cPGES is expressed in many cell lines and in a wide range of tissues.  
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Similar to mPGES2, expression of the gene is generally not sensitive to inflammatory stimuli 
with one notable exception.  Tanioka et al. demonstrated that LPS treatment increased levels 
of cPGES three-fold in the brain (60).  Co-transfection of human cPGES cDNA with COX-1, 
but not with COX-2, resulted in a large increase in PGE2 production (60).  These findings led 
to the suggestion that in most cells COX-1 collaborates with cPGES in basal PGE2 
production.   
 Peptide mapping demonstrated that cPGES was identical to human p23, a highly 
conserved protein that functions as a co-chaperone for Hsp90 (25, 55, 60).  The Hsp90 
chaperone system has been shown to be critical for the function of a variety of hormone and 
growth factor receptors, including glucocorticoid receptor (GR), mineralocorticoid receptor , 
androgen receptor, epidermal growth factor receptor, and platelet-derived growth factor 
receptor (48).  Steroid receptors, particularily GR, are used extensively to model the 
interactions of p23 with Hsp90 chaperone system and its client proteins.  An important 
function of the Hsp90 complex is to facilitate folding of the hormone binding domain to a 
conformation capable of binding substrate.  GR forms a heterocomplex with Hsp90, Hsp70, 
and p60, which are sufficient to carry out this folding change.  p23 has been reported to 
increase the stability and hormone binding activity of the GR/Hsp90 complex (12).  p23 
binds directly to Hsp90 with bound ATP to stabilize the GR/Hsp90 complex from 
inactivation and disassembly. 
GR is a ligand-activated transcription factor that mediates the biological effects of 
glucocorticoids.  Upon steroid binding, GR translocates into the nucleus, dimerizes, and 
binds to glucocorticoid response elements (GREs) upstream of specific target genes.  GR has 
also been shown to have DNA-binding-independent mechanisms of gene regulation through 
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direct protein-protein interactions, or tethering, of transcription factors, such as AP-1 and 
NF-κB (40).  Many of these glucocorticoid-regulated genes, such as the epithelial sodium 
channel subunit γ (ENaCγ) and the surfactant proteins (SP-A, SP-B, SP-C), are important in 
the final stages of mouse lung development.  These genes are responsible for the production 
of lung surfactant which increases alveolar stability by decreasing surface tension and the 
clearance of lung liquid to improve lung tissue compliance and gas exchange upon birth (33, 
70).  Glucocorticoids are also known to promote the differentiation of alveolar epithelial cells 
and development of terminal alveoli required for the transition to air breathing (30, 56).   
A multifunctional role has been proposed for cPGES/p23, as both a terminal PGE2 
synthase and a co-chaperone for the GR/Hsp90 complex.  In addition, many other functions 
linked to its association with Hsp90 have been assigned to this protein.  To date, the role of 
cPGES/p23 in these processes has been primarily characterized in vitro, so the in vivo role of 
cPGES/p23 remains unclear.  We have generated a mouse line deficient in cPGES/p23 to 
better characterize this protein and elucidate its role in vivo.  The cPGES/p23-deficiency 
causes perinatal lethality due to improper lung maturation.  We demonstrate that cPGES/p23 
is required for both DNA-binding-dependent and -independent GR functions.  However, 
additional phenotypes of this animal suggest GR-independent functions for this protein in 
development.  Characterization of primary embryonic fibroblasts derived from the 
cPGES/p23-deficient mice, as well as embryonic tissues, demonstrates that cPGES/p23 is not 
required for PGE2 synthesis.   
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MATERIALS AND METHODS 
Experimental Animals 
All studies were conducted in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina at Chapel Hill.   
 
Generation of cPGES/p23-deficient mice 
A mouse ES cell line (RST271) containing an insertional mutation in cPGES/p23 was 
obtained from BayGenomics, a gene-trapping resource (57).  A gene-trap vector, 
pGTOTMpfs, was used that contained a splice-acceptor sequence upstream of a reporter 
gene, β-geo (a fusion of β-galactosidase and neomycin phosphotransferase II).  This vector 
inserted into the first intron of cPGES/p23 creating a fusion transcript containing sequences 
from the first exon joined to the β-geo marker.  5’ rapid amplification of cDNA ends (5’ 
RACE) followed by automated DNA sequencing was used to determine the identity of the 
trapped gene as cPGES/p23.  Male chimeras generated from this ES cell line were bred to 
B6/D2 females to generate mice heterozygous for the mutated allele.  These heterozygotes 
were intercrossed to produce mice homozygous for the mutation.  Pregnant heterozygous 
females were euthanized with CO2, and embryos were removed by cesarean section.  The 
genotypes of the offspring were determined by Southern blot analysis.  A specific probe was 
designed 3’ of exon 2 and used to screen genomic DNA digested with PvuII.  Insertion of the 
vector in the first intron results in a reduced fragment size for the mutant allele compared to 
the endogenous wild-type allele. 
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Northern Blot Analysis 
Total RNA was isolated from embryonic day (E) 18.5 embryos with RNA-Bee (Tel-Test Inc) 
according to manufacturer’s instructions.  Total RNA (20µg) was separated by gel 
electrophoresis on a 1.2% agarose/formaldehyde gel and transferred to a nitrocellulose 
(Immobilon NC, Amersham Biosciences) membrane overnight.  Northern blots were 
hybridized with a [32P]dCTP (Amersham Biosciences)-labeled cPGES cDNA probe prepared 
with a random primed labeling kit (Roche Diagnostics).  The cPGES cDNA probe was 
generated from commercially available EST clones (Invitrogen Laboratories).  Membranes 
were hybridized with a β-actin cDNA probe to verify similar RNA loading. 
 
Prostanoid Measurements in Whole Embryos and Embryo lungs 
Tissues were flash frozen in liquid nitrogen and stored in the -80°C freezer until use.  Samples 
were pulverized and then homogenized in 1x PBS with 1mM EDTA pH 7.4 and 10 mM 
indomethacin and sonicated.  Lipids were purified through an Amprep Octadecyl C18 mini 
column (Amersham Biosciences), and prostanoid content was determined by using enzyme 
immunoassay kits (Assay Designs) according to manufacturer’s instructions. 
 
Generation of MEFs 
E13.5 embryos were used to generate MEFs.  The embryos were washed with sterile PBS, 
finely minced, and trypsinized twice for 30 minutes in a 37° H2O bath.  Tissue debris was 
discarded, and the fibroblasts were cultured in Dulbecco modified Eagles medium (DMEM) 
with 10% fetal bovine serum and supplemented with 100 µg/ml streptomycin sulfate and 100 
units/ml penicillin G sodium at 37° C with 5% CO2. 
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Prostanoid Measurements in MEFs 
MEFs were seeded in nickel-well plates (105 cells/well) and grown to 80% confluence.  
Fibroblasts were washed and cultured in 1.5 ml serum-free media for 1 hour.  Supernatant 
was collected, and the cells were trypsinized and pelleted for total protein determination by 
the BCA method (Pierce).  Enzyme immunoassay kits (Assay Designs) were used to 
determine the amount of PGE2 and thromboxane B2 (TxB2) in the supernatants.  All assays 
were performed in triplicate, and cells treated with indomethacin were used as a negative 
control. 
 
Proliferation Assay 
Carboxyfluorescein diacetate succinimidyl ester (CFSE, CellTrace Cell Proliferation kit, 
Invitrogen) was used to stain primary fibroblasts to monitor cell proliferation.  Primary 
fibroblasts were plated in a 6-well plate, and 16 hours later, the cells were stained with 5 µM 
CFSE according to manufacturer’s instructions.  Cells were harvested, counted, and analyzed by 
FACScalibur flow cytometer (Becton Dickinson) and CellQuest software at the indicated time 
points.  The doubling time has been calculated by using the equation: 
Yt = Y(o) * 2nt.  Y(t) = number of cells at time (t); Y(o) =  initial number of cells; n = cell 
cycles/hour.   
 
Light Microscopy and Histological Analysis 
Tissues were removed from embryos, fixed overnight in 10% formalin, and embedded in 
paraffin.  Sections of lung and liver tissues were stained with hematoxylin/eosin for routine 
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histology.  Liver sections were also stained with periodic acid-Schiff (PAS) for glycogen 
content.  Sections were observed using a light microscope (Nikon FXA). 
 
Transmission Electron Microscopy 
Lungs were dissected from E18.5 embryos and fixed in 2% paraformaldehyde/2.5% 
glutaraldehyde in .15M sodium phosphate pH 7.4.  Following three rinses with phosphate buffer, 
the samples were post-fixed for 1 hour in 1% osmium tetroxide/1.25% potassium ferrocyanide in 
sodium phosphate buffer.  The tissues were rinsed in deionized water and dehydrated through 
increasing concentrations of ethanol (30%, 50%, 75%, 100%, 100%, 10 minutes each) and put 
through two changes of propylene oxide (15 minutes each).  Tissue samples were infiltrated with 
a 1:1 mixture of propylene oxide: Polybed 812 epoxy resin (1A:2B formulation, Polysciences, 
Inc.,Warrington, PA) for 3 hours followed by an overnight infiltration in 100% resin.  The tissue 
pieces were embedded in fresh epoxy resin and polymerized for 24 hours at 60˚C.  The blocks 
were trimmed, and 1 micrometer sections of the tissue were mounted on glass slides and stained 
with 1% toluidine blue O in 1% sodium borate.  Representative areas were selected by light 
microscopy, and 70nm ultrathin sections were cut using a diamond knife.  Ultrathin sections 
were collected on 200 mesh copper grids and stained with 4% aqueous uranyl acetate for 15 
minutes, followed by Reynolds’ lead citrate for 7 minutes.  Sections were observed using a LEO 
EM910 transmission electron microscope at 80kV (LEO Electron Microscopy, Thornwood, NY) 
and photographed using a Gatan Bioscan Digital Camera (Gatan, Inc., Pleasanton, CA).  
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Isolation of RNA and Quantitative Real-Time PCR 
Lung tissue was removed from E18.5 embryos, and total RNA was isolated by RNA-Bee (Tel-
Test Inc) according to manufacturer’s instructions.  RNA concentration was determined by 
absorbance at 260 nm.  RNA was purified using the RNeasy mini kit (Qiagen), and 5µg was used 
to generate cDNA with the High-Capacity cDNA Archive kit (Applied Biosystems).  cDNA (2.5 
ng) was used in amplification reactions with Taqman PCR Universal Mastermix and 
commercially available primer and probe sets (Applied Biosystems) on an ABI Prism 7900 
Thermocycler.  Expression levels were normalized to an endogenous control, β-actin.  
Quantification of samples was performed using the comparative Ct (∆∆Ct) method, as described 
in the Assays-on-Demand Users Manual (Applied Biosystems).  Relative gene expression was 
determined by the formula x = 2-∆∆Ct.  Results were expressed as fold change relative to wild-
type expression levels. 
 
Western Blot Analysis 
Total protein was isolated from tissue by homogenizing frozen tissue in lysis buffer (50 mM 
HEPES, .15M NaCl, 1.5mM MgCl2, 1% Triton-X 100, 10% glycerol, 10µg/ml leupeptin, 500µM 
Na3VO4, .1M PMSF, and Roche Complete mini protease inhibitor tablet).  Homogenates were 
centrifuged at 14,000 rpm for 5 minutes at 4°C, and protein content of the supernatant was 
measured using BCA assay (Pierce).  A quantity of 75 µg of protein per sample was separated by 
SDS-PAGE and electrophoretically transferred onto polyvinylidene difluoride membranes 
(Hybond-P, Amersham Biosciences).  Membranes were blocked in 5% nonfat milk in 1x TBST 
(Tris-buffered saline and .05% Tween 20) for 1 hr at room temp.  Immunoblots were probed with 
primary antibody to GR (abcam, ab3579, dilution 2.5 µg/ml, incubated at 4°C overnight), 
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cPGES/p23 (Cayman, dilution 1:500, incubated at room temp for 1 hr), and ß-actin (Sigma, 
dilution 1:5,000, incubation at room temp for 1 hr) followed by goat anti-rabbit or goat anti-
mouse secondary antibody (dilution 1:5000 and 1:10000 respectively) for 45 minutes at room 
temp.  Membranes were incubated with ECL reagent and signal was detected by autoradiography 
after exposure to Hyperfilm (Amersham Biosciences). 
For the nuclear localization analysis, 1.5 x106 fibroblasts were starved from serum for 24 hr and 
activated with 10nM dexamethasone for 0, 30, and 60 min.  Cell pellet was resuspended in 200 
µl of lysis buffer (HBSS buffer, 1.26 mM calcium, 1 mM magnesium, 0.1% NP-40, 200 nM 
PMSF and Roche Complete mini protease inhibitor tablet) and kept on ice for 20 min before 
centrifugation at 700xg for 20 min at 4°C.  Nuclear pellet was washed in 200 µl lysis buffer, 
centrifuged at 700xg for 20 min at 4°C, resuspended in protein sample buffer, and processed for 
Western blot.  Cytoplasmic supernatant was recentrifuged at 12,000xg for 20 min, and the 
supernatant was mixed with 80µl of protein sample buffer and processed for Western blot.  GR 
was detected on Western blot by M20 antibody (Santa Cruz Biotechnology).  The blots were 
reprobed with antibodies to α- tubulin (Sigma) and histone H1 (Santa Cruz Biotechnology). 
 
Transfection Assay 
Primary fibroblasts were immortalized by transfection with pSV3-neo (ATCC), a plasmid 
expressing SV40 large T antigen.  Transformed fibroblasts (~2 x 105 cells) were seeded in a 6-
well plate, and after 24 hours, fibroblasts were transfected with either 3 µg of pGRE-luc 
(Clontech) and .05 µg of pCMVβ (Applied Biosystems) or 3 µg of pTAL-luc (Clontech) and .05 
µg pCMVβ using Lipofectamine PLUS reagent (Invitrogen) according to manufacturer’s 
instructions.  After transfection, the fibroblasts were incubated with dexamethasone (10nM) for 
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24 hours.  Cell lysates were collected and analyzed for luciferase and β-galactosidase expression 
using the Dual-Light Luciferase/β-galactosidase Reporter Gene Assay kit (Applied Biosystems).  
Luciferase activity was normalized to β-galactosidase activity.  Negative control values from the 
transformed fibroblasts transfected with pTAL-luc were subtracted from the experimental values.   
 
Immunofluorescence Staining of Transformed MEFs for GR  
Coverslips (number 1; 12 mm circle, thickness range, 0.13–0.17 mm; Fisher Scientific, 
Pittsburgh, PA) were coated with 0.1% gelatin.  Cells were resuspended in growth medium at 
a final concentration of 4 x 104 cells/ml. 500 or 1000 µl of suspension was applied to a  
coverslip in 24-well plate, and the cells were allowed to adhere for 3 hr at 37˚C.  Cultivation 
medium was replaced by medium without serum and cells were starved for 16 hr. Cells were 
activated by 10nM dexamethasone for 0, 30, and 60 min in medium without serum. 
Activation was stopped by ice cold PBS and cells were immediately fixed by methanol for 20 
min at -20˚C and permeabilized for 1 min by acetone at -20˚C. Cells were blocked in 
blocking buffer (20% FBS, 5% BSA, 0.05% gelatin) for 30 min at room temperature and 
incubated with GR antibody (M-20, Santa Cruz Biotechnnology Inc., Santa Cruz, CA) 
diluted 1:150 in TBST buffer (10 mM Tris, 150 mM NaCl, 0.1% Tween) overnight at 4˚C.  
Coverslips were washed 3 times in TBST buffer and incubated with FITC-conjugated anti-
rabbit antibody (Jackson ImmunoResearch, West Grove, PA) diluted 1:100 at room 
temperature for 1 hr. Coverslips were washed 3 times with TBST buffer and 2 times with 
PBS, dried and mounted on slides (SuperFrost Plus Microscope Slides; Fisher Scientific) in 
mounting solution and visualized with Nikon Microphot FXA Upright fluorescence 
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microscope (Nikon Inc.,Garden City, NY) using a x60 objective.  ImageJ software (NIH) 
was used to measure the mean pixel density in the nucleus. 
Statistical Analysis 
Values are presented as mean +/- standard error of the mean and are analyzed by Student’s two-
tailed t-test (Mann-Whitney or Tukey-Kramer test for multiple comparisons where indicated).  A 
p-value less than 0.05 is considered statistically significant. 
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RESULTS 
Generation of cPGES/p23-/- mice  
 Mouse ES cells with a gene-trap inserted in the first intron of cPGES/p23 were obtained 
from BayGenomics (57).  The gene-trap contains splice acceptors, which direct anomalous 
splicing of the primary transcript, resulting in loss of cPGES/p23 expression.  Male chimeras 
generated from this ES cell line were bred to B6/D2 females to generate mice heterozygous for 
the mutated allele.  No pups homozygous for the mutant allele were identified at weaning in 
litters obtained by intercross of these heterozygous animals.  In contrast, Southern blot analysis 
of E18.5 embryos demonstrated the presence of homozygous fetuses at normal Mendelian 
frequency (Figure 1a).  Examination and monitoring of neonates indicated that at least some 
cPGES/p23-/- pups were alive at birth, but these died shortly thereafter, after taking several 
agonal breaths.    
 To verify that the insertion of the gene-trap into intron 1 of the cPGES/p23 gene resulted 
in loss of expression, RNA was prepared from cPGES/p23-/- and cPGES/p23+/+ embryos and 
expression of cPGES/p23 determined by Northern blot analysis.  No cPGES/p23 transcript was 
detected by this method (Figure 1b).  Similarly, cPGES/p23 could not be detected by Western 
blot analysis of protein extracts prepared from the livers and primary fibroblasts of cPGES/p23-/- 
embryos (Figure 1c).    
 Mice lacking COX-2, as well as mice lacking the PGE2 EP4 receptor, die in the perinatal 
period due to a patent ductus arteriosus (31, 45).  The majority of mice lacking both COX-1 and 
COX-2 die within 30 minutes of delivery.  We therefore examined the possibility that 
cPGES/p23 was required for the PGE2 production essential for maturation of the vessel.  Similar 
to mice lacking EP4 and COX-2, the ductus failed to close in the cPGES/p23-deficient mice; 
 47
however, in contrast to the EP4-/- and COX-2-/- mice, death of the cPGES/p23-deficient neonates 
preceded the inflation of the lungs.  Although this early death of the cPGES/p23-deficient mice 
excludes the assessment of this protein in PGE2 production under various physiological stress in 
the mature animal, survival of these embryos to full-term allowed us to assess prostanoid 
production both in fetal tissues and in cell lines derived from the cPGES/p23-deficient embryos.   
 
Analysis of prostaglandin production in cPGES/p23-/- embryos 
 To identify a role for cPGES/p23 in PGE2 production, we determined PGE2 levels in full-
term embryos and E18.5 lungs.  Consistent with the PGE2 synthase function assigned to this 
protein, PGE2 levels were reduced in the cPGES/p23-/- embryos and embryonic lungs compared 
to the wild-type tissues.  However, a similar decrease in the level of other COX-dependent 
metabolites, thromboxane (TxB2) and prostacyclin, in these tissues was also observed (Figure 
2a).  This finding was not consistent with loss of expression of a PGE2 synthase, but rather 
suggested cPGES/p23 might have a pleotropic function in prostaglandin synthesis.   
 The first step in the synthesis of prostanoids is the release of arachidonic acid from the 
plasma membrane by cPLA2.  A small decrease in the expression of this enzyme was detected by 
quantitative RT-PCR of RNA prepared from cPGES/p23-/- E18.5 lungs (Figure 2b).  However, 
this change did not achieve statistical significance.  COX-1 and COX-2 are essential for the 
production of PGH2, the common substrate for all prostanoids.  We, therefore, next determined 
whether loss of cPGES/p23 resulted in altered expression of these two enzymes.  A 50% 
reduction in COX-2 and a 30% reduction in COX-1 transcripts were observed in RNA prepared 
from the cPGES/p23-/- lungs (Figure 2b).   
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Increased basal PGE2 and TxB2 levels in Mouse Embryonic Fibroblasts (MEFs) 
To further examine the impact of decreased expression of cPGES/p23 on prostanoid 
biosynthesis, we examined the production of PGE2 in MEFs derived from E13.5 embryos.  Since 
MEFs produce high levels of PGE2, even in the absence of stimuli (14), we measured 
constitutive production of PGE2 in cultures of cPGES/p23-/- and cPGES/p23+/+ fibroblasts.  Equal 
numbers of cells were seeded and grown to confluence in 24-well plates.  The cells were cultured 
in serum-free DMEM for 1 hour, and the PGE2 released into the medium during this time period 
was measured.  Surprisingly, basal levels of PGE2 were higher in the cPGES/p23-/- fibroblasts 
compared to the wild-type fibroblasts, which again is not consistent with loss of a PGE2 synthase 
(Figure 3).  Parallel cultures treated with indomethacin, which inhibits the enzymatic activity of 
both COX-1 and COX-2, served as a negative control in this assay.  Compared to these negative 
control indomethacin-treated cells, thromboxane levels were below the detectable limit in the 
wild-type fibroblasts.  However, thromboxane was easily measured in the supernatant collected 
from the cPGES/p23-/- cells (Figure 3), thus, similar to the in vivo measurements, the change in 
PGH2 metabolites was not limited to PGE2.   
 
Growth retardation of the cPGES/p23-deficient embryos 
Our failure to define a role for cPGES/p23 in the direct regulation of PGE2 levels makes it 
unlikely that this previously assigned function contributes to the perinatal lethality of these mice.  
Further analysis of the mutant animals was carried out to determine whether the phenotype of the 
cPGES/p23-/- embryos would support other functions assigned to this protein.  Embryos were 
removed at E15.5 and E18.5, and each embryo was weighed and the crown-rump length 
determined.  The weight and length of the E15.5 cPGES/p23-deficient pups tended to be less 
 49
than that of the wild-type littermates, but this difference did not achieve statistical significance 
with this small group of animals.  However, later in gestation, a significant decrease in both the 
weight and crown-rump length of the mice lacking cPGES/p23 became apparent (Figure 4a).   
 To determine whether the smaller size of the cPGES/p23 embryos reflected a role for 
cPGES/p23 in proliferation, embryonic fibroblast cultures were established from control and 
mutant E13.5 embryos.  After isolation of these cells and establishment of the primary cultures, 
equal numbers of wild-type and cPGES/p23-/- cells were seeded and the growth monitored daily.  
Attached viable cells, as well as the dead cells present in the culture media, were counted at 
twenty-four, forty-eight, and seventy-two hours after plating.  As can be seen in Figure 4b, the 
growth of the cPGES/p23-deficient cells lagged behind that of the wild-type.  This did not appear 
to represent a loss of cells due to cell death as no difference was observed in the number of dead 
cells present in the media.  The average doubling time for the two wild-type primary cell 
cultures, derived from two different embryos, was calculated to be 18.3 hours while the average 
doubling time for two cPGES/p23-/- cell cultures was 25.4 hours.  An additional two cultures of 
each genotype were examined, and the average doubling times were 17.0 hours and 33.1 hours 
for the wild-type and cPGES/p23-/- cell cultures, respectively.  To further examine this point, 
cells were labeled with CFSE.  This dye is retained in the cells but diminishes in intensity with 
each round of proliferation.  Cells were stained 24 hours after plating, and flow cytometric 
analysis was performed to determine proliferation rate at 24 and 48 hours after staining.  As 
shown in Figure 4c, the cPGES/p23-/- fibroblasts were not proliferating as rapidly as the wild-
type to produce the next generations at both 24 and 48 hours after addition of the dye.  Overall, 
this supports a role of cPGES/p23 either directly or indirectly in cell cycle progression of 
primary fibroblasts.   
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cPGES/p23-/- mice have abnormal lung development 
The small decrease in growth of the cPGES/p23-/- pups alone is unlikely to account for the 
perinatal lethality of this mutation.  As discussed above, necropsy of the pups indicated 
minimal inflation of the cPGES/p23-/- lungs after birth.  In contrast to the impact of 
cPGES/p23 on the overall growth of the pup, the size of the cPGES/p23-/- lungs did not differ 
from that of wild-type embryos, and, in fact, measurement of total RNA content indicated an 
increase in the cellularity of the lungs at E18.5 (Figure 5a).  We, therefore, compared the 
architecture of the cPGES/p23-/- and wild-type lungs at various stages of development.  Lung 
development can be divided into four stages (9).  The embryonic stage is marked by the 
initial branching of the lung from the primitive foregut and the development of the broncho-
pulmonary segments.  During the pseudoglandular stage (E12.5-E16.0) there is further 
branching of the duct system generating the conducting portion of the respiratory system 
including the terminal bronchioles.  These early developmental events were not altered in the 
mice lacking cPGES/p23.  As shown in Figure 5b, no apparent differences are observed 
between the E15.5 wild-type and cPGES/p23-/- lung.  During the next two stages of 
development, the canalicular phase (E16.0-17.5) and the saccular/alveolar phase (E17.5 to 
postnatal day 5), the terminal bronchioles undergo further branching to form the respiratory 
bronchioles.  This is followed by the formation of terminal sacs and thinning of the stroma 
that separated these saccules from the developing vascular bed, thus forming the thin 
diffusible interface between the airways and the pulmonary circulation required after birth.  It 
is during the canalicular stage that differences in the development of the cPGES/p23-/- lungs 
become apparent.   At E18.5, the cPGES/p23-/- lungs still display morphology similar to the 
wild-type lungs early in the canalicular stage (Figure 5b).  Terminal sac development appears 
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absent in the cPGES/p23-/- embryos resulting in a more condensed lung architecture.  Thus, 
the development of the cPGES/p23-/- lungs appears arrested in the canalicular stage (E16.0-
E17.5). 
Transmission electron microscopy was used to compare the epithelial cell profile as 
well as other ultrastructural features of the lungs from cPGES/p23-/- and wild-type full-term 
embryos.  In the wild-type embryonic lung, type II alveolar epithelial cells (type II AECs), 
progenitors of type I alveolar epithelial cells (type I AECs), can easily be distinguished 
within each saccule by their cuboidal shape, apical microvilli, and the presence of the 
lamellar bodies, structures essential for the intracellular storage of surfactant.  The saccules 
are largely lined by type I AECs (Figure 6a).  The thin cytoplasmic extensions of this cell 
type reduces the air-capillary interface.  Thus, the differentiation of these cells from their 
type II AEC precursors is essential for survival.  Marked differences are observed in the 
ultrastructure of the distal lungs obtained from cPGES/p23-/- embryos.  Most notably, no type 
I AECs were observed in the cPGES/p23-/- lungs (Figure 6b).  Type II AECs could, however, 
be identified based on their unique apical microvilli and lamellar bodies.  Consistent with 
differentiation of this cell type, surfactant can be identified in the airways of the cPGES/p23-/- 
lung.  The distal airway of the cPGES/p23-/- embryos also contains a large number of 
cuboidal cells which cannot be classified, based on morphological characteristics.  It is likely 
that these represent precursors of type II AECs.     
To further examine the developmental changes in the cPGES/p23-/- lungs, we 
prepared RNA from E18.5 embryo lungs and quantitated the expression of genes which are 
commonly used as cell-specific markers for airway epithelia, type I AECs, and type II AECs.  
In the lung, especially in the neonatal period, the airway epithelia expresses high levels of the 
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Na+-K+-2Cl- cotransporter (NKCC1) (53).  The thyroid transcription factor (TTF-1) is 
expressed in both type II AECs and in Clara epithelial cells and has been used previously as a 
specific marker of lung epithelial cell demarcation (76, 79).  No difference in expression of 
these two genes was observed between wild-type and cPGES/p23-/- animals indicating 
normal proximal-distal epithelial cell patterning (Figure 6c).   
To quantitate the loss of type I AECs, quantitative RT-PCR was used to compare 
expression of type I cell-specific markers, T1α and aquaporin 5, in RNA prepared from wild-
type and E18.5 cPGES/p23-/- lungs (72).  A dramatic decrease in expression of T1α and 
aquaporin 5 is observed in the cPGES/p23-/- lungs, consistent with our failure to identify type 
I cells in these lung (Figure 6c).   
Analysis of a type II cell-specific marker, dendritic-cell lysosomal-associated 
membrane protein (DC-LAMP) (54), showed a significant decrease in the cPGES/p23-/- 
lungs (Figure 6c).  Similarly, a dramatic decrease in the expression of surfactant genes (SP-
A, SP-B, SP-C) was observed (Figure 6c).  The remarkable changes in the expression of 
these genes were greater than predicted given our ability to identify type II AECs and 
surfactant in cPGES/p23-deficient lungs.   
 
Expression of GR-sensitive genes in the cPGES/p23-/- lungs  
The severe lung phenotype of the cPGES/p23-deficient mice is similar to the lung phenotype 
of the GR-deficient mice (5, 8).  We, therefore, next determined whether expression of GR-
sensitive genes was altered in the cPGES/p23-/- lungs.  The best studied of these genes are 
those encoding the surfactants.  As described above, we observed a significant decrease in 
mRNA levels for these genes in the cPGES/p23-/- embryos.  The expression of DC-LAMP 
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has also been shown to be sensitive to glucocorticoids (32).  Again, a significant decrease in 
the expression of this gene was observed in the mutant lungs.  However, interpretation of 
these differences is complicated since these genes are expressed almost exclusively by type II 
AECs, and thus the paucity of mRNA may reflect both decreased numbers of mature type II 
AECs and regulation of these genes by GR.  We therefore also examined the expression of 
ENaCγ, whose expression has also been shown to be sensitive to glucocorticoids (53, 68).  
mRNA levels of ENACγ were analyzed by quantitative RT-PCR, and a significant decrease 
in expression was measured in the cPGES/p23-/- lungs (Figure 7a).   
 Recently, glucocorticoids have been shown to be important in regulating the growth 
factor midkine (MK).  From E16.5 to E17.5, a significant decrease in the expression of this 
gene is observed in wild-type mice but not embryos lacking GR.  Thus, in these mutant 
animals, levels at birth are 3-fold higher that wild-type littermates (27).  We reasoned that if 
cPGES/p23 is essential for GR function, we would expect a similar pattern of expression in 
cPGES/p23-/- lungs.  Consistent with this, MK expression is 3-fold higher in the cPGES/p23-
deficient mice compared to the wild-type mice (Figure 7a).  Taken together, the decreased 
expression of ENACγ and the increased expression of MK indicated that cPGES/p23 is 
essential in the regulation of glucocorticoid-sensitive genes in the mouse lung.  To determine 
whether this loss of GR function was the result of decreased levels of GR, protein extracts 
were prepared from wild-type and cPGES/p23-/- fetal lungs.  No significant difference in the 
level of the steroid receptor was observed, suggesting that loss of cPGES/p23 primarily 
altered the activity of the receptor (Figure 7b).   
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cPGES/p23 is necessary for the induction of gluconeogenic enzymes 
The analysis of expression of glucocorticoid-regulated genes in the lung is complicated by 
the dramatic alterations in the development of this organ in the cPGES/p23-/- animals.  To 
further verify the relationship between cPGES/p23 and expression of GR-sensitive 
transcripts, we examined the expression of genes required for gluconeogenesis in the liver of 
the E18.5 wild-type and cPGES/p23-/- embryos.  While gluconeogenesis in the mouse does 
not occur until after birth, the induction of some of the enzymes, including glucose-6-
phosphatase and serine dehydratase, is observed late in gestation (2, 18).  The final step of 
both gluconeogenic and glycogenolytic pathways is carried out by glucose-6-phosphatase 
and contribution of glucocorticoids to the regulation of the expression of this gene has been 
noted (66).  The promoter contains a number of GRE elements and the binding of GR 
together with other accessory factors form the glucocorticoid response unit which regulates 
gene expression.  Expression of both glucose-6-phosphatase and serine dehydratase were 
significantly decreased in the cPGES/p23-/- livers (Figure 8a).  A similar decrease has been 
reported for these genes in GR-deficient mice (7).  To further examine the role of cPGES/p23 
in maturation of the liver, we examined the accumulation of glycogen which normally begins 
to accumulate late in gestation.  Previous studies have suggested a role for glucocorticoids in 
this induction (67).  The cPGES/p23-deficient mice have abnormal liver morphology 
compared to the wild-type mice at E17.5 (Figure 8b,c).  Analysis of the livers by PAS 
staining confirmed the failure of glycogen to accumulate in the cPGES/p23-/- livers (Figure 
8d,e) 
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Delayed maturation of the skin in cPGES/p23-/- embryos 
Upon external examination, the skin of the cPGES/p23-/- mice appeared more translucent 
than that of their littermates.  Histological examination of the dorsal stratified epithelium 
from one pair of E17.5 wild-type and cPGES/p23-/- embryos and three pairs of genetically-
matched E18.5 embryos showed that loss of cPGES/p23 had indeed altered the development 
of this organ.  As expected, all of the structures of the skin were apparent on examination of 
the sections obtained from the E17.5 wild-type fetus (Figure 9).  A single basal layer of 
proliferating cells and the suprabasal layers of terminally differentiating cells transitioning as 
they move towards the surface of the skin are observed.  Transcriptionally active spinous and 
granular cells, as well as several layers of stratum corneum, consisting of metabolically inert 
enucleated cells are apparent at this embryonic stage.  Similar to the wild-type pups, the basal 
epithelia cells were easily identified in the cPGES/p23-/- animals.  A well-defined stratum 
spinosum was also observed.  However, remarkable differences were noted in the terminal 
differentiation of the kerotinocytes.  A well-defined stratum granulosum, characterized by 
darkly stained keratohyaline granules, was not present in the cPGES/p23-/- skin, although a 
few cells with some keratohyalin granules could be identified.  A dramatic deficit in the 
stratum corneum was also observed.  By E18.5 the stratum granulosum was more apparent in 
the mutant fetuses, although the development of this layer and the degree of granulation 
varied between the mutant pups.  However, in all three animals, the lamellar organization of 
the granulocytic layer, the flattening of the cells, and the discarding of the nucleus had not 
progressed to the same degree as in the skin of the control animals.  In fact, in many 
instances, numerous nucleated cells with some keratohyalin granules were present at the 
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epithelia surface.  In all the cPGES/p23 mutant animals, deficiencies in the development of 
the stratum corneum were apparent.    
 
Loss of GR transactivation and tethering mechanisms in cPGES/p23-/- fibroblasts  
As normal levels of GR protein were measured in the cPGES/p23-/- fetal tissue, we next 
examined directly the ability of these receptors to activate gene transcription in cells lacking 
cPGES/p23.  Transformed embryonic fibroblasts were transiently transfected with pGRE-luc, 
a reporter plasmid with three GRE enhancer elements.  Binding of ligand-bound GR to the 
GREs drives luciferase expression.  The fibroblasts were co-transfected with pCMVβ, and β-
galactosidase expression was used to normalize for transfection efficiency.  pTAL-luc, a 
reporter plasmid with no GRE enhancer elements, was independently transfected as a 
negative control, and these baseline expression values were subtracted from the experimental 
values.  Upon incubation with dexamethasone, a synthetic glucocorticoid, the wild-type 
fibroblasts had a significant increase in luciferase expression.  The cPGES/p23-deficient 
fibroblasts had a significantly lower luciferase expression compared to the wild-type 
suggesting that loss of cPGES/p23 reduces GR transactivation (Figure 10a). 
 GR has been shown to inhibit gene transcription through direct protein-protein 
interaction, or tethering, with transcription factors, such as AP-1.  This interaction was first 
established for the AP-1-regulated gene, collagenase-3 (47).  Relative expression of 
collagenase-3 was determined after activating AP-1 with phorbol 12-myristate 13-acetate 
(PMA).  The cPGES/p23-/- fibroblasts had a similar induction of collagenase-3 compared to 
the wild-type fibroblasts suggesting that the ability of AP-1 to induce gene transcription is 
not affected by loss of cPGES/p23.  Wild-type fibroblasts treated with dexamethasone and 
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PMA had a significant reduction in collagenase-3 expression (Figure 10b).  However, the 
AP-1-induced expression of collagenase-3 in the cPGES/p23-/- fibroblasts was not inhibited 
upon treatment with dexamethasone suggesting that loss of cPGES/p23 reduces the ability of 
GR to negatively regulate transcription factors such as AP-1. 
 
Defective nuclear translocation of GR in cPGES/p23-/- fibroblasts 
To determine the mechanism for the reduction in GR transactivation and tethering in the 
cPGES/p23-/- fibroblasts, we investigated the ability of GR to translocate to the nucleus after 
dexamethasone stimulation.  Using immunofluorescent staining, the wild-type fibroblasts 
showed an increase in GR in the nucleus after 30 and 60 minutes of dexamethasone 
stimulation (Figure 11a).  cPGES/p23-/- fibroblasts showed no increase in GR in the nucleus 
after 30 and 60 minutes of dexamethasone stimulation.  The nuclear localization of GR was 
quantitated by measuring mean pixel density of the nucleus.  A slight increase in GR in the 
nucleus was measured at 60 minutes of dexamethasone stimulation in the cPGES/p23-/- 
fibroblasts; however, only the wild-type measurements taken at 30 and 60 minutes of 
dexamethasone stimulation had a statistically significant increase in pixel density in the 
nucleus compared to the non-stimulated cells.  
 To further verify the translocation defect, western blot analysis was performed on 
nuclear and cytosolic extracts from the fibroblasts after stimulation with dexamethasone.  
Similar to the immunofluorescence, the wild-type fibroblasts had an increase of GR in the 
nucleus and a decrease of GR in the cytosol at both 30 and 60 minutes of dexamethasone 
treatment.  The cPGES/p23-/- fibroblasts had no change in GR in either the nuclear or the 
cytosolic fraction (Figure 11b). 
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Figure 2.1.  Generation of cPGES/p23-/- mice.  A) Southern blot analyses of DNA from 
embryonic day (E) 18.5 embryos generated by the intercross of mice heterozygous for the 
cPGES/p23 mutant allele.  B)  Northern blot analyses of cPGES/p23 mRNA expression in 
whole E18.5 embryos.  Analysis with a β-actin-specific probe verifies equal RNA sample 
loading.  C) Western blot analysis of cPGES/p23 protein expression in E18.5 liver and mouse 
embryonic fibroblasts (MEFs).  β-actin expression shown as a loading control. 
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Figure 2.2  
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Figure 2.2.  cPGES/p23-deficient embryos have a significant decrease in prostanoid 
levels and a corresponding decrease in cPLA2 and COX expression.  A) PGE2, 
thromboxane (TxB2), and 6-keto-PGF1α (a stable metabolite of prostacyclin (PGI2)) levels in 
whole E18.5 embryos and lungs dissected from E18.5 embryos were measured by enzyme 
immunoassay (EIA).  n = 4, * p < .05, # p ≤ .09 by Student’s t-test or p ≤ .05 by Mann-
Whitney.  B)  Determination of cPLA2, COX-2, and COX-1 expression in total RNA isolated 
from E18.5 lungs by RT-PCR.  Expression levels were normalized to β-actin, an endogenous 
control, and the results were expressed as fold change relative to wild-type expression levels.  
cPGES/p23-/- lungs, n = 7; wild-type lungs, n = 9; * p < .05, # p = .06. 
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Figure 2.3 
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Figure 2.3.  cPGES/p23-deficient primary fibroblasts have a significant increase in 
PGE2 and TxB2 levels.  MEFs were isolated from cPGES/p23-/- and wild-type embryos.  
Cells were seeded in 24-well plates and grown to 80% confluence.  After 1 hour incubation 
in serum-free media, the supernatant was removed, and PGE2 and TxB2 levels in the 
supernatant were determined by EIA.  The cells in each well were harvested for total protein 
determination by the BCA method.  Results are expressed as picograms of prostanoid per 
microgram of total cell protein per well.  Parallel cultures treated with indomethacin, which 
inhibits the enzymatic activity of both COX-1 and COX-2, served as a negative control in 
this assay.  n = 6, * p < .01. 
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Figure 2.4 
A
0
0.5
1
1.5
2
2.5
E15.5 E18.5
Le
ng
th
 (c
m
)
+/+
-/- *
0
200
400
600
800
1000
1200
1400
E15.5 E18.5
W
ei
gh
t (
m
g)
+/+
-/-
*
B
0
2
4
6
8
10
12
14
16
18
20
-24 0 24 48
Hours
To
ta
l C
el
ls
 (x
10
4 )
+/+
-/-
0 Hour
24 Hour
48 Hour
CFSE
C
 65
Figure 2.4.  Loss of cPGES/p23 results in growth defects in embryos and proliferation 
defects in the primary embryonic fibroblasts.  A) E15.5 and E18.5 embryos were removed 
by cesarean section and weight and crown-rump length determined.  E15.5: cPGES/p23-/-, n 
= 6; wild-type, n = 4; E18.5: cPGES/p23-/-, n = 6; wild-type, n = 7; * p < .05.  B) Growth 
curve for cPGES/p23-/- and wild-type primary embryonic fibroblasts.  An equal number of 
cells of each genotype was plated in a 6-well plate (3 wells per time point for each genotype).  
At 24 hour intervals, cells were harvested and counted.  The supernatant was collected from 
each well, and the number of dead cells present in the supernatant did not differ between 
samples.  In contrast, a marked reduction in the number of cells present in the wells seeded 
with cPGES/p23-/- cells was observed.  This data is representative of two independent 
experiments, each performed with two different -/- and +/+ MEF cultures.  C) Proliferation 
assay comparing cPGES/p23-/- and wild-type primary fibroblasts.  Cells were stained with 
CFSE and analyzed by flow cytometry 24 and 48 hours after staining.  The CFSE intensity at 
the time of labeling is shown at 0 hr.  A shift left at 24 and 48 hours represents a decrease in 
CFSE intensity which corresponds to the rate of proliferation in the population.  Shown is the 
representative result from 3 independent experiments.  Purple = wild-type; Green = 
cPGES/p23-/-. 
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Figure 2.5   
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Figure 2.5.  Histological analysis of lung tissue from E15.5-E18.5 wild-type and 
cPGES/p23-/- embryos by light microscopy.  A) Total RNA was extracted from E18.5 
embryo lungs.  Quantitation of RNA revealed a significant increase in the cPGES/p23-/- lungs 
suggesting hypercellularity.  B) Lungs were removed from embryos at E15.5, E16.5, E17.5, 
and E18.5 and fixed overnight in 10% formalin.  Lung sections were stained with 
hematoxylin/eosin.  The cPGES/p23-/- lung development appears arrested at the canalicular 
stage (E16.0-17.5).  Notable is the failure of the development of terminal sacs.  Original 
magnification, x10. 
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Figure 2.6 
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Figure 2.6.  Abnormal ultrastructure of the distal airway in cPGES/p23-/- embryos.  
Transmission electron microscopy was used to analyze ultrastructural morphology in E18.5 
lung tissue from wild-type (A) and cPGES/p23-/- (B) embryos.  The electron micrographs 
demonstrate squamous type I AECs (black arrowhead) and cuboidal type II AECs containing 
lamellar bodies (white arrows) and apical microvilli (black arrows) in the wild-type lung.  In 
contrast, while type II AECs were detected in the cPGES/p23-/- lungs, type I AECs could not 
be identified.  s, surfactant.  C)  RT-PCR analysis was used to determine expression of a 
bronchial epithelial cell marker (NKCC1), a Clara cell-specific marker (TTF-1), type I AEC 
markers (aquaporin-5 and T1α), and type II AEC markers (DC-LAMP, SP-A, SP-B, SP-C).  
Expression levels were normalized to β-actin, an endogenous control, and the results were 
expressed as fold change relative to wild-type expression levels.  cPGES/p23-/- lungs, n = 7; 
wild-type lungs, n = 9; * p < .05. 
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Figure 2.7.  cPGES/p23-/- mice have alterations in expression of glucocorticoid-
regulated genes in the lung.  A)  RT-PCR analysis was used to determine expression levels 
of glucocorticoid-regulated genes, including ENaCγ and MK, in total RNA isolated from 
E18.5 lungs.  Expression levels were normalized to β-actin, an endogenous control, and the 
results were expressed as fold change relative to wild-type expression levels.  cPGES/p23-/- 
lungs, n = 7; wild-type lungs, n = 9; * p < .05.  B) Western blot analysis of GR expression in 
E18.5 lungs from wild-type and cPGES/p23-/- embryos demonstrates similar GR protein 
levels.  ß-actin expression verifies equal sample loading. 
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Figure 2.8 
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Figure 2.8.  cPGES/p23-/- mice display abnormal liver morphology and have alterations 
in expression of glucocorticoid-regulated genes in the liver.  A)  RT-PCR analysis was 
used to determine expression levels of gluconeogenic enzymes, glucose-6-phosphatase 
(G6pc) and serine dehydratase (Sds), in total RNA isolated from E18.5 livers.  Expression 
levels were normalized to β-actin, an endogenous control, and the results were expressed as 
fold change relative to wild-type expression levels.  n = 5, * p < .01.  B-E) Livers were 
removed from embryos at E17.5 and fixed overnight in 10% formalin.  Liver sections from 
wild-type (B) and cPGES/p23-/- (C) embryos were stained with hematoxylin/eosin for routine 
histological examination.  Glycogen content in the liver was assessed by periodic acid-Schiff 
(PAS) staining.  Note the intense staining in the wild-type liver (D) compared to the 
cPGES/p23-/- liver (E).  Representative of four embryo livers analyzed for each genotype.  
Original magnification, x10. 
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Figure 2.9 
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Figure 2.9.  Delayed maturation of the skin in cPGES/p23-/- embryos. 
Aberrations in differentiation and formation of the cornified envelope in cPGES/p23-/- 
stratified epithelia.  Skin from wild-type and cPGES/p23-/- E17.5 and E18.5 fetuses was fixed 
in formalin, embedded in paraffin, and sections cut (5µm) and stained with hematoxylin and 
eosin.  Sections correspond to the dorsal skin above the scapular region of the embryo.  SC, 
stratum corneum; GR, granular layer; KG, kerotohyalin granules; SP, suprabasal layer; BL, 
basal layer; DE, dermis
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Figure 2.10 
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Figure 2.10.  Loss of cPGES/p23 results in defective GR transcriptional activation and 
protein-protein tethering mechanisms.  A)  Transformed fibroblasts were transfected with 
the reporters pGRE-luc or pTAL-luc (negative control) and pCMV-β to normalize for 
transfection efficiency.  The transfected fibroblasts were incubated in the presence or absence 
of dexamethasone (10 nM) for 24hr.  Luciferase and β-galactosidase expression were 
measured in the cell lysates.  The luciferase values were normalized to the β-galactosidase 
values, and the values obtained from the fibroblasts transfected with the negative control 
(pTAL-luc) were subtracted from the values obtained from the fibroblasts transfected with 
pGRE-luc (3 replicates for each treatment and genotype).  As expected, dexamethasone 
treatment resulted in a significant increase in luciferase expression in the wild-type 
fibroblasts.  This induction was significantly attenuated in the fibroblasts lacking 
cPGES/p23.  * p < .01.  This data is representative of three independent experiments 
performed with two different cell cultures per genotype. 
B)  Treatment of embryonic fibroblasts with PMA (10-7 M for 6 hr.), which induces 
transcription of genes via AP-1, increased expression of collagenase-3 in both wild-type and 
cPGES/p23-/- cultures.  However, subsequent treatment with dexamethasone (10-6 M for 6hr.) 
and PMA disrupts induction of this gene in wild-type but not in the cPGES/p23-/- fibroblasts.  
RT-PCR analysis was used to determine expression levels of collagenase-3 in total RNA 
isolated from the treated fibroblasts.  Expression levels were normalized to β-actin, an 
endogenous control, and the results were expressed as fold change relative to untreated 
controls.  Data is representative of two independent experiments with different MEF cultures.  
n = 3, * p < .05 compared to controls,  # p < .05 compared to all groups by the Tukey-Kramer 
test for multiple comparisons. 
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Figure 2.11 
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Figure 2.11.  Defective nuclear translocation of GR in cPGES/p23-/- fibroblasts.  A)  
Immunofluorescent staining of transformed fibroblasts for GR after treatment with 
dexamethasone demonstrates defective translocation in the cPGES/p23-/- fibroblasts.  
Fibroblasts were treated with dexamethasone (10nM) for 0, 30, and 60 minutes in serum-free 
medium.  Software (ImageJ, NIH) was used to determine the mean pixel density of the 
nucleus of representative cells in each culture.  n = 12; * p < .05 compared to all other groups 
by the Tukey-Kramer test for multiple comparisons.  B)  Western blot analysis demonstrates 
increases in GR in the nucleus and decreases in GR in the cytoplasm after dexamethasone 
stimulation (10nM) for 0, 30, and 60 minutes in the wild-type fibroblasts.  No alterations in 
GR localization are observed in the cPGES/p23-/- fibroblasts after stimulation.  Sample 
loading was verified by expression of α- tubulin for the cytoplasmic fraction and histone H1 
for the nuclear fraction.  Fold change was determined by densitometric analysis and 
normalized to the loading controls. 
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DISCUSSION 
 We show that cPGES/p23 is essential for progression of lung development from the 
early to the late canalicular stage and that pups lacking cPGES/p23 die in the perinatal period 
as a result of neonatal respiratory insufficiency.  Loss of cPGES/p23 results in delayed 
maturation of the skin.  cPGES/p23-/- pups also fail to induce high levels of gluconeogenic 
enzymes in the prenatal period.  These phenotypes are consistent with the proposed function 
of cPGES/p23 as an Hsp90 co-chaperone essential for stabilization of GR.  However, the 
cPGES/p23-/- embryos are smaller in size, and primary cultures of embryonic fibroblast show 
decreased proliferation.  As these phenotypes are not observed in the GR-deficient mice, they 
likely define cPGES/p23 functions that are independent of GR.  Evaluation of prostaglandin 
production in the cPGES/p23-/- embryos and in the embryo-derived primary fibroblasts does 
not support a direct role for cPGES/p23 in PGE2 synthesis.   
 We noted differences in the terminal differentiation of the skin of the cPGES/p23-/- 
pups.  In all mice, a severe deficiency in the cornification of the epithelium was noted both at 
17.5 and 18.5 days gestation.  However, at 17.5 days, the skin of the cPGES/p23-/- mice was 
also deficient in granulocytes, while this stratum was easily identified in wild-type mice.  
Interestingly, previous studies have shown that injection of glucocorticoids accelerate the 
functional, morphological, and lipid biochemical maturation of the permeability barrier of the 
skin (1).  Later studies of the glucocorticoid-deficient animals supported the role of this 
hormone in the differentiation of this organ (20).  Similar to the cPGES/p23-/- mice, 
differences between the wild-type and mutant animals were more pronounced earlier in 
development.  At E17.5, neither a well-defined granular layer nor a stratum corneum was 
evident by light microscopy in the glucocorticoid-deficient fetuses; however, these deficits 
 81
diminished later in gestation.  Taken together, this suggests that the alterations in 
differentiation of the skin of the cPGES/p23-/- mice are likely the consequence of loss of GR 
function.   
 Morphologically the lungs of the cPGES/p23 full-term embryos resemble those of the 
early canalicular stage of development (E16.5).  Most notable is the absence of the terminal 
saccules characteristic of the full-term embryo.  Examination of the ultrastructure of the lung 
and analysis of the expression of genes specific to distinct populations of airway epithelia 
indicates normal development of the airways, likely attenuated differentiation and/or 
maturation of type II AECs, and little to no differentiation of type I AECs from type II 
precursors.  This phenotype is very similar to that described for GR-deficient mice.  A GR 
hypomorphic (GRhypo) mouse line, with extremely low levels of GR activity, was generated 
from ES cells in which the neomycin marker gene was inserted into exon 2 by homologous 
recombination (8, 63).  While 10% of theses hypomorphs survive on a mixed genetic 
background, the co-isogenic 129 die of respiratory insufficiency in the immediate perinatal 
period.  Similar to the cPGES/p23-/- pups, the lungs of these pups had failed to complete the 
final stages of maturation, and their architecture was comparable to that of an E16.5 embryo.  
However, unlike the cPGES/p23-/- embryonic lung, some type I AECs were identified in the 
GRhypo lungs.  Two possible explanations for these differences noted in the differentiation of 
the lungs and survival of the GR and cPGES/p23-/- mice are possible.  First, this difference 
may reflect a GR-independent cPGES/p23 function in lung development.  cPGES/p23 may 
play a role in stabilizing other Hsp90 clients, such as the retinoic acid receptor and the 
estrogen receptor, and many of these have documented roles in lung development (21, 28, 46, 
74).  An alternate possibility is that analysis of the GRhypo mice may reflect residual activity 
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of the GR in these animals compared to the cPGES/p23-/- animals.  Mice carrying a deletion 
of the second or third exon have a more severe phenotype with no animals surviving the 
perinatal period (GRnull); however, a detailed description of the lung phenotype, as in the 
GRhypo mice, has not been described for these mice (5, 63).  Final determination of whether 
GR-independent cPGES/p23 pathways contribute to lung development will require the direct 
comparison of congenic GRnull animals and cPGES/p23-/- animals under identical breeding 
and experimental conditions.  However, the remarkable similarities in the phenotype of the 
GRhypo and cPGES/p23-/- animals is consistent with the hypothesis that cPGES/p23 is 
essential for GR actions during lung development and that the failure of the cPGES/p23-/- 
lungs to mature reflects primarily the loss of this function of cPGES/p23. 
 The GR-regulated pathways critical for lung development have not been identified.  
Interestingly, a recent study showed that GR-deficient mice fail to downregulate the 
expression of midkine (MK), a heparin-binding growth/differentiation factor, which plays a 
role in mesenchymal-epithelial interactions during organogenesis (26, 27, 35).  The 
expression pattern of MK during lung development is complex, but expression is 
dramatically reduced during sacculation of the lung at day 17 of gestation.  It has been 
suggested that the decrease in expression of MK signals the lung to initiate maturation 
including the thinning of the mesenchyme critical to this stage of development (36).  The 
high levels of MK in the lungs of E18.5 GR-deficient embryos are also observed in the 
cPGES/p23-deficient embryos.  This continued expression of MK in the cPGES/p23-/- 
embryos supports the hypothesis that the failure to observe normal transition from the 
canalicular stage to the saccular stage of lung development is secondary to the loss of GR 
activity in the cPGES/p23-/- embryos.   
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 The GR modulates gene expression through both DNA-binding-dependant and -
independent mechanisms.  The relative importance of these two pathways in development 
has been determined by generation of mice expressing a mutant GR (GRdim) (52).  This 
mutation prevents dimerization of the receptor, binding of the receptor to GRE sites in 
promoters, and transactivation of genes.  Study of these mice showed that lung maturation 
requires DNA-binding-independent regulatory functions of GR since GRdim mice survive into 
adulthood and have no severe respiratory defects.  The cPGES/p23-/- mice die at birth, with a 
phenotype similar to that of the GRhypo mice, indicating that cPGES/p23 is important in 
regulating the GR in its DNA-binding-independent processes.  In contrast, similar to the GR-
deficient mice, gluconeogenic enzymes are not induced in the post-natal period in GRdim 
mice demonstrating that expression of these genes is dependant on DNA binding and 
transactivation (40).  The loss of expression of glucose-6-phosphatase and serine dehydratase 
in the livers from full-term cPGES/p23-/- pups indicates that cPGES/p23 is essential for the 
prenatal activation of enzymes involved in gluconeogenesis.  Again, the most likely 
interpretation of this phenotype is that cPGES/p23 is required for the stabilization of the GR 
receptor conformation required for ligand binding, subsequent nuclear translocation, and 
transactivation.  Consistent with this, we show that the glucocorticoid dexamethasone failed 
to induce GRE-dependant expression of reporter genes in fibroblast lines established from 
the cPGES/p23-deficient mice.  Our studies also indicate that cPGES/p23 is essential for the 
regulation of AP-1 by GR, a function that is not lost in the GRdim mice and thus is a DNA-
binding-independent function.  Furthermore, we demonstrate that the loss of both DNA-
binding-dependent and -independent mechanisms is due to the requirement of cPGES/p23 for 
the translocation of GR to the nucleus.   
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 The cPGES/p23-/- pups are approximately 10% smaller in size than wild-type pups.  
No similar defect has been reported for GR-deficient pups, neither the GRhypo or the GRnull 
lines, suggesting this growth retardation is not the result of decreased GR activity (5, 8).  
Primary fibroblasts derived from the cPGES/p23-/- embryos have a decreased rate of 
proliferation.  Again, a similar defect has not been reported for the GR-deficient primary 
fibroblasts.  In fact, addition of glucocorticoids to fibroblast cultures has been shown to 
inhibit proliferation (50, 71).  cPGES/p23 together with Hsp90 has been implicated in a 
number of pathways which, if dysfunctional, could alter growth, cell cycle transition, and 
senescence of cells (3, 34, 39, 49).  For example, the Saccharomyces cerevisiae homologue 
of p23, Sba1, and Wos2, the Saccharomyces pombe homologue, together with the 
corresponding Hsp90 analogues have been shown to regulate Cdc2, a protein kinase involved 
in mitotic control (37).  A possible role for cPGES/p23 and Hsp90 in the function of 
telomerase has also been reported (22).  However, it is unlikely that dysfunction of this 
complex would manifest itself in the first generation of the cPGES/p23-/- pups.  Mouse 
chromosomes possess much longer telomeres than human cells, and several generations of 
breeding are required before loss of telomerase activity results in altered growth of mice (6).  
Additional studies will be required to fully characterize the role of cPGES/p23 in growth and 
proliferation.  
 cPGES/p23 was independently identified as a cytosolic protein with GSH-dependant 
PGE2 synthase activity.  The identification was based not only on the activity of protein 
purified from cellular extracts but also on the increase in PGE2 production by cells co-
transfected with a cDNA encoding this protein and COX-1 (60).  This led to the hypothesis 
that the cPGES/COX1 pathway was responsible for the production of PGE2 detected in mice 
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and cell lines lacking mPGES1 (62).  Analysis of the cPGES/p23-/- mice fails to support the 
hypothesis that cPGES/p23 is a bona fide PGE2 synthase.  While loss of cPGES/p23 altered 
PGE2 production, a corresponding alteration in the production of other COX-dependant 
prostanoids suggests a more complex and indirect role for cPGES/p23 in this pathway.   
 Our demonstration that cPGES/p23 is essential for the non-DNA-binding actions of 
GR and extensive studies documenting a role for GR in regulation of the arachidonic acid 
pathway provides an explanation for our results as well as the assignment of a synthase 
function to this protein.  A number of negative regulatory targets for GR in the arachidonic 
acid pathway have been identified including lipocortin-1 and p11, proteins capable of 
modifying the release of arachidonic from membrane phospholipids (11, 77).  The primary 
enzyme responsible for the release of arachadonic acid from the membrane for metabolism 
by the prostanoid pathway is cPLA2 (4, 17).  Glucocorticoids have been shown to inhibit the 
expression and activity of this protein during inflammatory responses (13, 23, 42).  
Glucocorticoids have also been shown to reduce COX-2 activity in cells by decreasing COX-
2 transcription via tethering of transcription factors, such as NF-κB, essential for induction of 
this gene during inflammation (40-42, 51).  Furthermore, post-transcriptional and 
translational regulation of COX-2 activity have been reported (29, 43, 44).  Consistent with 
our studies of primary embryonic fibroblasts, decreased GR activity secondary to loss of 
cPGES/p23 would result in loss of this inhibitory pathway resulting in an increase in PGE2 
and other COX-2-dependant metabolites.  Transfection of cell lines with p23 expression 
vectors has been reported, similar to loss of cPGES/p23, to result in inhibition of GR activity 
in cells lines (16, 73).  This raises the possibility that the increased PGE2 production noted in 
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cells transfected with cPGES/p23 was the indirect consequence of decreased GR function in 
this line.   
 Interestingly, the impact of loss of cPGES/p23 on prostanoid production by fetal 
tissues was very different from that observed with cultured cells.  Here loss of this protein 
resulted in decreased levels of PGE2 and other COX-dependant prostanoids.  A number of 
possible explanations can be proposed.  First, the ability of GR to stimulate the production of 
prostanoids in specific cell types has been reported, particularily in primary amniotic 
fibroblasts (15, 58, 78).  These studies show that dexamethasone increases expression of both 
cPLA2 and COX-2 in these cells.  Consistent with this finding, prenatal dexamethasone 
increased prostaglandin synthesis in rat fetal lung (64).  Potential GRE elements have been 
defined in the COX-2 and cPLA2 promoters which may play a role in the induction of gene 
transcription (61, 75).  It is interesting to speculate that, in the mouse embryo, 
glucocorticoids, which increase in levels as gestation progress, contribute to the increase in 
prostaglandin production observed late in gestation.  Alternatively, the diminished prostanoid 
production might be the indirect consequence of alterations in development of the 
cPGES/p23-/- embryos.  Finally, the decreases in prostanoids in the cPGES/p23-/- mice may 
reflect an, as of yet unidentified GR-independent function for cPGES/p23 in regulation of the 
arachidonic acid pathway.  For example, cPGES/p23 has been shown to facilitate signaling 
of the aryl hydrocarbon receptor which in turn modulates the COX-2 pathway (10, 69).  
While additional experiments will be necessary to address these questions, taken together our 
data does not support the designation of cPGES/p23 as the third PGE2 synthase, cPGES, and 
we suggest that this protein simply be referred to as p23.   
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  While this manuscript was in preparation, Grad et al. reported the generation of mice 
from the identical ES cell clone carrying an insertional mutation in the cPGES/p23 gene (19).  
A similar defect in lung and skin development was noted, and co-transfection of a GR 
reporter construct and a GR-expressing construct in fibroblasts derived from the embryos 
demonstrated decreased GR-dependant transcription.  In contrast to the results shown here, 
the growth retardation of the pups and decreased proliferation in the primary fibroblasts were 
not noted in these studies.  We also report the defective induction of gluconeogenic enzymes 
and decreased glycogen accumulation in the fetal livers.  In addition, we show that the ability 
of GR to regulate the activity of other transcription factors, namely AP-1, is dependant on 
expression of p23.  These deficiencies, as well as decreased expression of genes involved in 
lung development, suggests a role for p23 in both the DNA-binding-dependent and -
independent mechanisms of GR.  Lastly, our analysis of prostanoids in the p23-deficient 
animals and primary fibroblasts failed to support a role for this protein as a PGE2 synthase. 
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ABSTRACT 
Prostacyclin is one of a number of lipid mediators elaborated from the metabolism of 
arachidonic acid by the cyclooxygenase (COX) enzymes.  This prostanoid is a potent 
inhibitor of platelet aggregation, and its production by endothelial cells and protective role in 
the vasculature are well established.  In contrast, much less is known regarding the function 
of this prostanoid in other disease processes.  We show here that COX-2-dependent 
production of prostacyclin plays an important role in the development of fibrotic lung 
disease, limiting both the development of fibrosis and the consequential alterations in lung 
mechanics.  In stark contrast, loss of prostaglandin E2 (PGE2) synthesis and signaling through 
the Gs-coupled EP2 and EP4 receptors had no effect on the development of disease.  These 
findings suggest that prostacyclin analogues will protect against bleomycin-induced 
pulmonary fibrosis in COX-2-/- mice.  If such protection is observed, investigation of these 
agents as a novel therapeutic approach to pulmonary fibrosis in humans may be warranted. 
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INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a relentless, progressive, and heterogeneous 
disease characterized by alternating areas of normal lung, fibrosis, and interstitial 
inflammation affecting the peripheral subpleural parenchyma (19).  Hallmarks of fibrosis 
include subepithelial myofibroblast/fibroblastic foci and increased deposition of collagen and 
extracellular matrix.  This excess scar tissue causes stiffening of the alveolar walls and a 
decrease in compliance, which leads to the irreversible loss of total lung capacity and the 
reduced ability to transport oxygen into the capillaries (1, 19, 38, 47).  Prostanoids, COX-
dependant arachidonic acid metabolites, have been implicated in the development of 
pulmonary fibrosis. 
Two COX enzymes, COX-1 and COX-2, both capable of converting arachidonic acid 
into prostaglandin endoperoxide (PGH2), have been characterized (48).  PGH2 produced by 
either COX isoenzyme is further metabolized by specific synthases into the various 
prostanoids, including prostaglandin F2 (PGF2), thromboxane, prostaglandin D2 (PGD2), 
prostacyclin, and PGE2.  While many cell types express both COX isoforms and multiple 
synthases, co-localization of various enzymes allows the metabolite of an enzyme to be 
directly transferred to a specific synthase for further metabolism.  Many examples of 
cooperation between specific COX isoforms and synthases have been described.  COX-1 and 
thromboxane synthase couple in the production of thromboxane by platelets (41).  In 
contrast, increasing evidence suggests that COX-2 provides PGH2 for production of 
prostacyclin by endothelial cells (30, 57).  The pathways responsible for production of a 
particular prostanoid have important clinical implications.  For example, the collaboration 
between COX-1 and thromboxane synthase in the production of thromboxane by platelets 
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forms the basis for the use of low dose aspirin for prevention of stroke (41).  In contrast, 
dependence of prostanoid production by endothelial cells on COX-2 may result in loss of a 
critical pool of prostacyclin in patients using COX-2 specific inhibitors, leading to increased 
risk for cardiac events in high risk patients (7).  Another important concept regarding the 
COX pathway relates to changes in COX expression following cellular stimulation.  While 
constitutive expression of both COX isoforms has been described in certain tissues, COX-2, 
in contrast to COX-1, is highly inducible (48).  As a result, the prostanoid profile of a resting 
cell can change following activation.  For example, COX-1 and thromboxane synthase 
collaborate in production of thromboxane in resting macrophages.  After activation, 
increased expression of microsomal PGE2 synthase 1 (mPGES1) and COX-2 parallels a drop 
in thromboxane production and increased PGE2 production by these cells (6).  Such a shift in 
prostanoid profiles is believed to be an important protective response under various 
pathophysiological conditions including pulmonary fibrosis, where lack of PGE2 is 
speculated to contribute to disease pathogenesis. 
The biosynthesis of PGE2 is mediated primarily by mPGES1, one of three enzymes 
capable of catalyzing the conversion of PGH2 to PGE2.  Both in vitro studies and analysis of 
mice lacking mPGES1 support an important role for this enzyme in PGE2 synthesis, 
especially during inflammatory responses (54, 56).  Microsomal PGE2 synthase 2 (mPGES2) 
and cytosolic PGE2 synthase (cPGES) increase PGE2 production when over-expressed in 
various cell lines (34, 52).  However, the contribution of these two enzymes to PGE2 
production in vivo has not yet been defined.  Similar to most eicosanoids, the half life of 
PGE2 in vivo is very short due to rapid metabolism by 15-hydroxyprostaglandin 
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dehydrogenase (PGDH).  Important to this study, PGDH is expressed at high levels in the 
healthy lung and mice lacking this enzyme have elevated lung PGE2 levels (21).   
Prostanoids mediate their actions by binding to G-protein-associated receptors.  
Thromboxane and prostacyclin each act through a single receptor, termed TP and IP, 
respectively.  TP is Gq-coupled, and activation of this receptor leads to increased intracellular 
calcium levels while activation of the Gs-coupled IP receptor leads to increased intracellular 
cAMP.  Unlike prostacyclin and thromboxane, PGE2 binds four different E prostanoid 
receptors, designated EP1, EP2, EP3, and EP4 (11).  These receptors have unique expression 
patterns and differ in their activation of intracellular signaling pathways.  Activation of the 
EP1 receptor increases intracellular calcium (59).  EP2 and EP4 are coupled to Gs and 
increase intracellular cAMP, although differential activation of downstream signaling 
components, specifically, MAPK and PI3K, has been noted (43).  EP3 has multiple isoforms 
that can couple to Gi, Gs, or Gq proteins; however, Gi predominates in most systems and 
decreases cAMP levels (36, 51).   
A number of lines of evidence suggest that PGE2 may play a role in limiting fibrotic 
responses in the lung and that this pathway may be compromised in patients with pulmonary 
fibrosis.  First, patients with IPF have decreased PGE2 levels in bronchoalveolar fluid, and 
fibroblasts taken from these patients have decreased COX-2 expression and reduced PGE2 
production (5, 58, 60).  Ex vivo studies have shown that PGE2 can decrease proliferation and 
suppress collagen synthesis of lung fibroblasts  (3, 9, 13, 14, 18, 31).  Other studies have 
shown that PGE2 is capable of inhibiting fibroblast migration and fibroblast to myofibroblast 
transition (26, 28).  Myofibroblasts express α-smooth muscle actin and have increased 
collagen gene expression.  Thus, the increased number of myofibroblasts is likely to 
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contribute to the morphological changes as well as the contractile changes of lung 
parenchyma characteristic of IPF (63, 64).  The ability of PGE2 to alter activity and gene 
expression of fibroblasts has been attributed to engagement of Gs-coupled receptors, as these 
actions can be mimicked by agents that elevate cAMP (8, 28).  Prostacyclin, which is also 
capable of increasing cAMP levels in many cell types, including fibroblasts, may also have a 
role in the development of pulmonary fibrosis.  A study on lung fibroblasts from patients 
with IPF demonstrated decreased levels of prostacyclin production in IPF fibroblasts versus 
normal fibroblasts (12).       
The studies reported here were designed to elucidate the role of prostanoids in fibrotic 
lung disease in vivo.  Using the well-established bleomycin mouse model, seven congenic 
mouse lines deficient in either the metabolism of a prostanoid or in the ability to respond to a 
prostanoid were examined.  In addition to using traditional histological and biochemical 
methods for evaluation of disease progression, the impact of disease on lung mechanics was 
also evaluated.  Our studies reveal an important role for the COX-2-prostacyclin synthetic 
pathway in limiting the fibrotic response to bleomycin. 
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MATERIAL AND METHODS 
Experimental Animals 
All studies were conducted in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina at Chapel Hill.  All experiments were 
carried out using 8-12 week old mice unless otherwise specified.  Mice lacking COX-2 (Ptgs2), 
COX-1 (Ptgs1), mPGES1 (Ptges), PGDH (Hpgd), EP2 (Ptger2), EP4 (Ptger4), and IP (Ptgir) 
were generated as previously described (7, 10, 29, 33, 39, 53, 54).  Congenic COX-1-/-, EP2-/-, 
and IP-/- mice were generated by backcrossing onto a C57BL/6 background for at least 12 
generations.  The PGDH-/- mice were backcrossed onto a C57BL/6 background for 7 generations.  
The mPGES1-/- mice were generated on a DBA/1J genetic background and backcrossed five 
generations onto a C57BL/6 background.  EP4-/- mice only survive on a recombinant inbred 
background (39).  Few COX-2-/- mice survive on the 129Sv/Ev or C57BL/6 genetic background.  
Most die with a patent ductus arteriosis within 48 hours of birth.  COX-2-/- mice were generated 
by the intercross of 129/SvEv co-isogenic COX-2+/- mice with congenic C57BL/6 COX-2+/- 
animals (N8).  Thus, all offspring, including the COX-2-/- and control COX-2+/+ animals 
generated from these intercrosses will carry maternal 129Sv/Ev alleles and paternal C57BL/6 
alleles and will differ only at the COX-2 locus.  Animals in different experimental groups were 
age- and sex-matched for each experiment.  Body weights did not differ between the 
experimental and control mice for all genotypes.  Lung mechanics were assessed first in each 
experimental group, and then the entire lung was removed for either histological analysis or 
hydroxyproline measurements. 
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Bleomycin Treatment 
Mice were anesthetized with approximately 20µl/g body weight of 2,2,2-tribromoethanol and 
administered 50 µl of saline or bleomycin (.05U unless specified otherwise) diluted in saline by 
intratracheal instillation.   
 
Measurements of lung mechanics   
Mice were anesthetized 21 days after bleomycin administration with 70-90 mg/kg 
pentobarbital sodium (American Pharmaceutical Partners, Los Angeles, CA), 
tracheostomized, and mechanically ventilated at a rate of 350 breaths/min, tidal volume of 6 
cc/kg, and positive end-expiratory pressure of 3-4 cm H2O with a computer-controlled small-
animal ventilator (Scireq, Montreal, Canada).  Once ventilated, mice were paralyzed with 0.8 
mg/kg pancuronium bromide (Baxter Healthcare Corp., Deerfield, IL).  Using custom 
designed software (Flexivent, Scireq), airway pressure, volume, and airflow were recorded 
using a precisely controlled piston during maneuvers to evaluate lung mechanics. 
Pressure-volume curves were generated by a sequential delivery of 7 increments of air 
into the lungs from resting pressure to total lung capacity followed by 7 expiratory steps during 
which air was incrementally released.  Plateau pressure was recorded when airflow returned to 
zero at each step.  The Salazar-Knowles equation (Equation 1) was applied to the plateau 
pressure measurements obtained between total lung capacity (TLC) and functional residual 
capacity (FRC) during the expiratory phase of the pressure-volume loop to determine static 
compliance  (Cst) of the lung (45).  
 
V = Vmax – Ae-KP    (Equation 1) 
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Where  Vmax = volume extrapolated to infinite P, V = lung volume above FRC, A and K are 
constants 
 
Forced oscillation technique measures the impedance of the lung to an oscillatory flow of 
mutually prime frequencies.  These impedance values are applied to a mathematical model of the 
lung developed by Hantos et al. (20) called the constant phase model.  This model provides a 
means of distinguishing central airways from peripheral airways and lung parenchyma.  The 
computer-controlled piston applies a 4-s perturbation to the lungs consisting of 13 sinusoidal 
components having mutually prime frequencies from 1 to 20.5 Hz with approximately 
hyperbolically decreasing amplitudes.  Multiple linear regression is used to fit impedance spectra 
derived from measured pressure and volume changes to the constant phase model of the lung 
using Equation 2. 
 
Z(f) = Raw + iIaw + (Gti – iHti/(2πf) α)         (Equation  2) 
 
where i = square root of –1, Z(f) = resistance of the lung as a function of frequency, Raw = a 
measure of central airways caliber, Iaw = airway inertance, Gti = dissipative(resistive) mechanical 
properties of the lung tissue, Hti = conservative (elastic) mechanical properties of the lung tissue.  
α = (2/π)arctan(Hti/Gti).   
 To ensure proper recruitment of all alveolar spaces, a pressure-volume curve was 
generated first for each animal.  After this maneuver, a 4-s prime wave was performed followed 
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by a second pressure-volume curve to obtain reported values.  Each perturbation was followed 
by 10 seconds of ventilation before the next measurement was taken. 
 
Histology   
After assessing lung mechanics, the lungs were inflated with 10% formalin via a tracheal 
cannula, removed from the thoracic cavity, and fixed overnight in formalin.  Lung sections were 
stained with hematoxylin/eosin for routine histology and Masson’s trichrome for evaluation of 
collagen deposition.  Histology was quantitated by digital imaging of the hemotoxylin/eosin 
stained sections.  While blinded to genotype and treatment, at least five images were captured of 
representative areas of each lung lobe and analyzed for septal thickening due to increased 
cellular infiltrate, extracellular matrix, and fibroblasts.  Using software (ImageJ, NIH), the 
threshold was set to count the number of pixels contained within areas of the digital images that 
had increased inflammation and extracellular matrix deposition.  The threshold number of pixels 
was then divided by the total number of pixels in the entire image and multiplied by 100 to 
generate a percentage of area affected by fibrosis and inflammation (2). 
 
Hydroxyproline Assay 
 
After assessing lung mechanics, mice were exsanguinated, and the lungs were perfused with 
sterile PBS and removed.  Tissue samples were homogenized in 5ml PBS and sonicated.  
Aliquots (500µl) of each sample were lyophilized for 24 hours until dry and then hydrolyzed in 
500µl 6N hydrochloric acid at 120°C overnight.  Samples were then dried in a speed vacuum for 
two hours, resuspended in water, applied to a filter Eppendorf tube (Fisher Scientific), and spun 
at maximum speed for five minutes.  Aliquots were assayed by adding chloramines-T for 20 
minutes at room temperature and then developing with Ehrlich-perchloric acid at 65°C for 15 
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minutes.  Absorbance was read at 561 nm in a spectrophotometer, and samples were compared to 
a standard curve generated from known concentrations of hydroxyproline standard (Sigma)(23). 
 
PGE2 Analysis 
Mice were euthanized 7 days post-bleomycin instillation with sodium pentobarbital and 
exsanguinated.  Lungs were removed and flash frozen in liquid nitrogen.  Samples were 
homogenized in 1x PBS with 1mM EDTA pH 7.4 and 10 mM indomethacin and sonicated.  
Lipids were purified through a C18 column, and PGE2 content was determined by using enzyme 
immunoassay kits (Assay Designs). 
 
Statistical Analysis 
Values are presented as mean +/- standard error of the mean and are analyzed by Student’s two-
tailed t-test or ANOVA followed by Tukey-Kramer HSD post-hoc test.  A p-value less than 0.05 
is considered statistically significant. 
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RESULTS 
Contribution of COX-1- and COX-2-derived prostanoids to bleomycin-induced pulmonary 
fibrosis 
A number of early studies using mice lacking COX-2 suggested that COX-2-derived 
prostanoids could limit some aspects of the histological changes and increases in collagen 
production observed in the bleomycin and vanadium pentoxide (V2O5) models of interstitial 
fibrosis (4, 25).  However, in a recent study, this difference in disease progression in the 
COX-2-/- mice was not as apparent (22).  A possible explanation for inconsistent findings is 
suggested on examination of genetic background of the COX-2 mice used in the various 
studies.  To address this potential concern, we examined the role of COX-2 in the bleomycin 
model of fibrosis using congenic F1 animals.  In addition to using traditional histological and 
biochemical methods for evaluating disease progression in the COX-2-/- mice, we assessed 
the impact of loss of COX-2 on changes in airway mechanics characteristic of pulmonary 
fibrosis.   
Bleomycin or saline was administered to cohorts of sex-matched COX-2-/- mice and 
wild-type littermates.  Lungs were harvested 21 days after treatment, and histological 
changes were assessed by analysis of hematoxylin/eosin and Masson’s trichrome stained 
sections of lung.  As expected, no histological changes were observed in the lungs from the 
saline-treated animals (Figure 1 A,B).  As previously described for this model, remarkable 
structural alterations including increased collagen deposition and cellularity were observed in 
lungs from animals exposed to bleomycin.  These histological changes appeared more 
pronounced in the COX-2-/- animals (Figure 1 C,D,E,F).  A digital imaging program was 
used to quantitate the extent of fibrosis and inflammation in the lungs as described in the 
materials and methods (2).  Figure 1G demonstrates increased disease progression in lungs of 
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the COX-2-/- mice compared to the congenic controls.  The extent of collagen deposition was 
assessed biochemically by quantitating hydroxyproline levels in lung homogenates from 
similarly treated cohorts of COX-2-/- and COX-2+/+ animals.  Consistent with qualitative 
differences observed on examination of trichrome stained sections, COX2-/- mice had 
increased levels of hydroxyproline after bleomycin administration compared to wild-type 
mice (Table 1). 
In humans, interstitial fibrosis leads to alterations in lung mechanics characterized by 
a decrease in lung compliance.  We, therefore, determined whether similar changes in airway 
mechanics could be observed in the bleomycin model of pulmonary fibrosis and, 
furthermore, whether these changes were sensitive to the presence or absence of COX-2-
derived prostanoids.  For this analysis, we utilized a computer-controlled small animal 
ventilator, highly sensitive pressure transducers, and software (Flexivent) to record airway 
opening pressures, volume, and airflow.  Changes in lung mechanics were determined using 
two different methods.  Static compliance (Cst) was determined from analysis of pressure-
volume curves, and tissue elastance (H) was measured by applying the constant phase model 
to prime wave impedance values obtained using the forced oscillation technique.  Decreases 
in compliance and increases in elastance are anticipated in the bleomycin-exposed lung if this 
treatment indeed models pulmonary fibrosis.  Consistent with this expectation, wild-type 
bleomycin-injured mice showed a significant decrease in static compliance (Cst) and a 
significant increase in tissue elastance (H) compared to saline-treated mice (p < .005).  The 
constant phase model of the lung also provides information concerning two additional 
parameters, airway resistance (Raw) and tissue resistance (G).  Consistent with the sparing of 
the conducting airways in this model, no change in Raw was observed in the mice after 
  111
bleomycin treatment.  A small, but significant, increase in G was observed in all animals 
treated with bleomycin; however, this parameter did not allow us to distinguish between mice 
with differences in disease severity.   
Sex-matched COX-2-/- mice and their littermate controls were administered either 
bleomycin or saline, and lung mechanics were assessed 21 days later.  Both groups had a 
significant decrease in static compliance after bleomycin administration compared to the 
saline controls.  However, the static compliance of the bleomycin-treated COX-2-/- mice was 
significantly lower than the static compliance of the bleomycin-treated COX-2+/+ mice 
(Figure 2A).  Accordingly, a significantly higher tissue elastance was measured in the COX-
2-/- mice compared to COX-2+/+ mice after bleomycin administration (Figure 2B).  The 
significant increase in tissue elastance and significant decrease in static compliance along 
with the histological and biochemical differences suggest that COX-2-derived prostanoid(s) 
protect against the development of bleomycin-induced pulmonary fibrosis. 
In addition to COX-2, the lung expresses high levels of COX-1.  We next determined 
whether a similar role for COX-1-derived prostanoids could be observed in this model.  As 
COX-1-/- mice survive on the C57BL/6 genetic background, C57BL/6 COX-1-/- animals and 
their congenic controls were used for these studies.  Unlike the COX-2-/- mice, no discernable 
difference in disease pathogenesis was observed between the COX-1-/- animals and their 
controls in any of the disease parameters.  Table 1 shows a similar increase in hydroxyproline 
content in the COX-1-/- and COX-1+/+ mice after bleomycin administration.  Consistent with 
this, both histological analysis and measurements of lung mechanics demonstrate no 
difference in disease progression between the two groups (Supplemental Figure S1).  Thus, 
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development of fibrotic lung disease after exposure to bleomycin is modulated by COX-2-, 
but not COX-1-, dependant prostanoid production.   
 
Alterations in PGE2 levels fail to alter susceptibility to bleomycin-induced pulmonary 
fibrosis 
 COX-2-derived PGH2 can be further metabolized into prostacyclin, thromboxane, and 
the prostaglandins - PGE2, PGD2, and PGF2.  Both anti-inflammatory and anti-fibrotic 
properties have been attributed to PGE2, which suggests that this prostanoid, acting through 
either the EP2 or EP4 Gs-coupled receptor, can limit progression of fibrotic lung disease.  To 
test this hypothesis, we examined the development of lung disease after bleomycin treatment 
in mice lacking mPGES1, the inducible PGE2 synthase.     
Three enzymes have been reported to metabolize PGH2 into PGE2 in vitro; however, 
only one of these, mPGES1, has been demonstrated to contribute to PGE2 production in vivo.  
We first established the contribution of mPGES1 to the increases in PGE2 levels in the lungs 
observed after exposure to bleomycin.  Mice lacking mPGES1 and congenic control animals 
were treated with bleomycin or saline.  PGE2 levels were measured in whole lung 
homogenates seven days after treatment.  As expected, significant increases in lung PGE2 
levels were observed in wild-type mice following bleomycin treatment.  In contrast, increases 
in lung PGE2 was severely attenuated in mPGES1-/- mice (Figure 3).  Thus, the marked 
increase in PGE2 levels after bleomycin administration is almost completely dependant on 
mPGES1 expression.    
We next determined the impact of this relative PGE2 deficiency on the pathogenesis 
of bleomycin-induced fibrotic lung disease.  C57BL/6 mPGES1-/- mice and congenic controls 
were administered bleomycin or saline, and histological changes in the lung were evaluated 
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21 days after treatment.  Surprisingly, no difference could be discerned in development of 
disease in the two groups.  Quantitation of inflammation and extracellular matrix deposition 
by digital analysis demonstrated a similar extent and severity of interstitial inflammation and 
fibrosis (Figure 4A).  We further evaluated disease progression in the mPGES1-/- mice by 
measuring changes in lung function following bleomycin administration.  Both loss of 
compliance and increase in elastance as a result of bleomycin exposure were of similar 
magnitude in mPGES1-/- vs. mPGES1+/+ mice (Figure 4 B,C).   
We next considered the possibility that an increase in disease severity resulting from 
decreased PGE2 production may be difficult to observe in these experiments because of the 
extensive disease induced even in the wild-type controls.  To address this concern, we 
repeated our comparison of the mPGES1-/- and control animals inducing a milder disease by 
decreasing the dose of bleomycin (0.025U rather than 0.05U).  As expected, the severity of 
the fibrotic response was reduced in the wild-type mice.  However, no difference could be 
discerned between the mPGES1-/- and mPGES1+/+ mice.  Both the mPGES1-/- and 
mPGES1+/+ mice had a significant but similar decrease in static compliance and increase in 
tissue elastance after both high and low dose bleomycin administration compared to the 
saline-treated controls (Figure 4 B,C).  Thus, loss of mPGES1-dependent PGE2 production 
does not cause enhanced susceptibility to bleomycin-induced fibrosis. 
To further address the role of PGE2 in bleomycin-induced pulmonary fibrosis, we 
examined mice lacking PGDH, the major catabolic enzyme for PGE2.  Previous studies in 
our laboratory have shown that these mice have increased lung PGE2 levels (21).  If PGE2 
can limit the initiation or progression of fibrosis, we anticipate that the loss of PGDH and 
consequential increased PGE2 levels might protect these mice from developing pulmonary 
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fibrosis.  However, both pathological and physiological measurements revealed no difference 
in disease progression between the PGDH-/- and PGDH+/+ mice after bleomycin 
administration (Supplemental Figure S2). 
 
Loss of PGE2 Gs-coupled receptors does not enhance susceptibility to bleomycin-induced 
fibrosis 
 While the majority of PGE2 production in the bleomycin-treated mouse lung is 
dependant on mPGES1, it is possible that it is the loss of local discrete pools of mPGES1-
independent PGE2 that plays a critical role in limiting the extent of fibrosis within the lung 
parenchyma.  To address this possibility, mice lacking the receptors through which PGE2 
activates fibroblasts and other cell types important to disease pathogenesis were examined.  
Development of disease in the EP2-/- mice was examined first, anticipating that the Gs-
coupled EP2 and EP4 receptors, rather than the Gi/Gq-coupled EP3 receptor or the Gq-
coupled EP1 receptor, would be more likely to mediate the protective actions of PGE2 in the 
lung.  Quantitative analysis of the histological changes revealed no significant differences 
between the EP2-/- mice and wild-type mice in the extent and severity of interstitial 
inflammation and fibrosis after bleomycin administration (Figure 5A).  Consistent with these 
findings, hydroxyproline analysis revealed similar increases in collagen deposition after 
bleomycin administration in the wild-type and EP2-/- mice (Table 1).  Disease progression in 
the EP2-/- mice was further analyzed by assessing alterations in lung mechanics.  Both EP2-/- 
and wild-type mice had a similar decrease in static compliance and increase in tissue 
elastance after bleomycin administration (Figure 5 B,C).  A similar result was obtained 
following treatment of 4-6 month old EP2-/- and wild-type animals with 0.1U of bleomycin 
(Figure 5 D,E).   
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Since EP4-/- mice only survive on a mixed genetic background, a recombinant inbred 
(RI) background permissive to this mutation was generated (39).  Congenic animals have 
been produced by the successive intercross of -/- and +/- animals for twenty generations, 
after which EP4-/- and control animals were generated.  This recombinant inbred strain is 
sensitive to bleomycin-induced lung injury, with treated mice showing both histological 
changes and alterations in lung function characteristic of this model.  In fact, exposure to 
bleomycin induces a more robust increase in collagen deposition in the RI mouse strain than 
is observed in either C57BL/6 or the F1 (C57BL/6 and 129/SvEv) mice.  The RI strain also 
displays a lower basal lung compliance than other mouse strains.  Age- and sex-matched 
EP4-/- mice and their congenic controls were administered either bleomycin or saline, and 
lung mechanics were assessed 21 days later.  A similar decrease in static compliance and 
increase in tissue elastance was observed in both EP4-/- and control animals after exposure to 
bleomycin (Figure 6).  Consistent with these physiological observations, hydroxyproline 
levels were similar between the EP4-/- mice and the EP4+/+ controls after bleomycin 
administration (Table 1).  Taken together, these studies with mice lacking the Gs-coupled 
PGE2 receptors and mice lacking the dominant enzyme responsible for PGE2 synthesis in the 
lung suggest that a COX-2-derived prostanoid other than PGE2 is responsible for limiting 
lung fibrosis in this model.   
    
IP-/- mice are more susceptible to bleomycin-induced fibrosis 
The failure to observe increased disease in mice deficient in PGE2 production, 
together with a recent collaborative study showing increased fibrotic lesions in the hearts of 
mice lacking the IP receptor (16), suggested that COX-2-dependent production of 
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prostacyclin, and not PGE2, may be critical in limiting development of fibrotic lung disease.  
To test this hypothesis, congenic C57BL/6 IP-/- and wild-type mice were administered 
bleomycin or saline, and disease was assessed 21 days later by histological analysis, 
hydroxyproline measurements, and lung mechanics.  As expected, no difference was 
observed between the histology of the saline-treated IP-/- and wild-type lungs (Figure 7 A,B).  
Interestingly, and similar to the COX-2-/- mice, the IP-/- mice had more severe disease 
demonstrated by a significant increase in all disease parameters.  Histological analysis of the 
IP-/- mice demonstrated increased collagen deposition and cellularity after bleomycin 
administration compared to the wild-type mice (Figure 7 C,D,E,F).  This correlated with a 
significant increase in the quantitative histology score and lung hydroxyproline levels in the 
IP-/- mice compared to the wild-type mice (Figure 7G and Table 1).  These increased 
morphological and structural changes corresponded to a more pronounced decrease in lung 
function in the bleomycin-treated IP-/- mice compared to controls.  No difference was 
observed in the IP-/- mice compared to the wild-type controls after saline administration.  
However, after bleomycin administration, the IP-/- mice had a significant decrease in static 
compliance and increase in tissue elastance compared to the wild-type mice (Figure 8 A,B).  
Collectively, these results suggest that the increased fibrotic lung disease observed in the 
absence of COX-2 is due to loss of prostacyclin, acting through the IP receptor, rather than 
loss of PGE2.  Moreover, the similar magnitude of changes, physiologically, biochemically, 
and histopathologically, in COX2-/- and IP-/- mice following exposure to bleomycin suggests 
that loss of prostacyclin alone may account for the enhanced disease observed in COX2-/- 
animals. 
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Table 3.I Changes in Hydroxyproline Content 
(µg/lung) 
  +/+ -/- 
   
COX-2 50.85 ± 10.86 125.12 ± 27.94* 
COX-1 64.75 ± 19.82 75.95 ± 22.55 
EP2 78.77 ± 25.29 56.46 ± 20.93 
EP4 212.78 ±19.46 193.50 ± 17.40 
IP 51.22 ± 8.81 105.48 ± 18.03* 
 
Lungs were removed for hydroxyproline analysis 21 days after treatment.  Mean saline value 
for each experimental group was subtracted from the bleomycin-treated values to obtain the 
change in hydroxyproline content in µg/lung.  Values presented are mean ± SEM.  * p < .05 
compared to corresponding wild-type value; n = 8-11. 
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Figure 3.1.  Histological analysis reveals increased cellularity and deposition of collagen 
in the lungs of COX-2-/- mice compared to wild-type mice after bleomycin instillation.  
Lungs were harvested 21 days following treatment and fixed overnight in formalin.  Lung 
sections were stained with hematoxylin/eosin or Masson’s trichrome.  Original 
magnification, 10x.  A) Saline-treated wild-type mouse, hematoxylin/eosin stain.  B) Saline-
treated COX-2-/- mouse, hematoxylin/eosin stain.  C) Bleomycin-treated wild-type mouse, 
hematoxylin/eosin stain.  D) Bleomycin-treated COX-2-/- mouse, hematoxylin/eosin stain.  E) 
Bleomycin-treated wild-type mouse, Masson’s trichrome stain.  F)  Bleomycin-treated COX-
2-/- mouse, Masson’s trichrome stain.  G) Morphological changes observed in lungs obtained 
from bleomycin-treated mice were quantitated by digital imaging of hematoxylin/eosin 
stained lung sections and presented as a percentage of septal thickening.  Saline-treated 
COX-2+/+, n = 9; saline-treated COX-2-/-, n = 6; bleomycin-treated COX-2+/+, n = 12; 
bleomycin-treated COX-2-/-, n = 11.  * p < .01 compared with corresponding saline value, # p 
< .01 compared with COX-2+/+ bleomycin value.
  120
Figure 3.2 
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Figure 3.2.  Analysis of lung mechanics demonstrates increased disease susceptibility in 
the COX-2-/- mice.  Lung mechanics were measured in anesthetized, paralyzed, and 
mechanically ventilated mice 21 days following bleomycin or saline instillation.  A) Static 
compliance (Cst) determined by fitting the Salazar-Knowles equation to pressure-volume 
curves; n = 6-9 animals; * p < .05 compared with corresponding saline value, # p < .05 
compared with COX-2+/+ bleomycin value.  B) Tissue elastance (H) determined by applying 
prime wave impedance values to the constant phase model; n = 9-11 animals; * p < .05 
compared with corresponding saline value, # p < .05 compared with COX-2+/+ bleomycin 
value.   
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Figure 3.3 
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Figure 3.3.  Reduced PGE2 levels in the lung homogenates of mPGES1-/- mice compared 
to wild-type mice after bleomycin administration.  The lungs were harvested 7 days after 
bleomycin or saline administration.  n = 3; * p < .01 compared with corresponding saline 
value, # p < .01 compared with mPGES1+/+ bleomycin value. 
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Figure 3.4 
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Figure 3.4.  Histological analysis and measurements of lung mechanics fail to 
distinguish mPGES1-/- mice from wild-type mice after bleomycin administration.  A)  
Morphological changes observed in lungs obtained from bleomycin-treated mice were 
quantitated by digital imaging of hematoxylin/eosin stained lung sections and presented as a 
percentage of septal thickening.  Saline-treated groups, n = 6; bleomycin-treated groups, n = 
15; * p < .05 compared with corresponding saline values.  B)  Static compliance (Cst) in the 
mPGES1-/- and wild-type mice after .05U and .025U of bleomycin.  C) Tissue elastance (H) 
in the mPGES1-/- and wild-type mice after .05U and .025U of bleomycin.  Saline-treated 
groups and bleomycin-treated groups for .025 dose, n = 8-10; saline-treated groups and 
bleomycin-treated groups for .05 dose, n = 14-18.  * p < .05 compared to corresponding 
saline values.   
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Figure 3.5 
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Figure 3.5.  Histological analysis and lung mechanics demonstrate similar disease 
susceptibility in the EP2-/- and wild-type mice after bleomycin administration.  A) 
Morphological changes observed in lungs obtained from bleomycin-treated mice were 
quantitated by digital imaging of hematoxylin/eosin stained lung sections and presented as a 
percentage of septal thickening.  Saline-treated groups, n = 7; bleomycin-treated groups, n = 
10.  * p < .05 compared with corresponding saline values.  B)  Static compliance (Cst) in the 
EP2-/- and wild-type mice (8-12 weeks) treated with .05U of bleomycin.  C) Tissue elastance 
(H) in the EP2-/- and wild-type mice (8-12 weeks) treated with .05U of bleomycin.  D) Static 
compliance (Cst) in an older cohort of mice (4-6 months) treated with 0.1U of bleomycin.  E) 
Tissue elastance (H) in an older cohort of mice (4-6 months) treated with 0.1U of bleomycin.  
Saline-treated and bleomycin-treated groups from younger cohort, n = 8-11; saline-treated 
and bleomycin-treated groups from older cohort, n = 7-10; * p < .05 compared with 
corresponding saline values.   
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Figure 3.6 
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Figure 3.6.  Analysis of lung mechanics reveal similar disease susceptibility in the EP4-/- 
and wild-type mice after bleomycin administration.  Lung mechanics were measured in 
anesthetized, paralyzed, and mechanically ventilated mice 21 days following bleomycin or 
saline instillation.  A) Static compliance (Cst) determined by fitting the Salazar-Knowles 
equation to pressure-volume curves.  B) Tissue elastance (H) determined by applying prime 
wave impedance values to the constant phase model.  n = 8-10 animals; * p < .05 compared 
with corresponding saline values.    
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Figure 3.7.  Histological analysis reveals increased cellularity and deposition of collagen 
in the lungs of IP-/- mice compared to wild-type mice after bleomycin instillation.  Lungs 
were harvested 21 days following treatment and fixed overnight in formalin.  Lung sections 
were stained with hematoxylin/eosin or Masson’s trichrome.  Original magnification, x10.  
A) Saline-treated wild-type mouse, hematoxylin/eosin stain.  B) Saline-treated IP-/- mouse, 
hematoxylin/eosin stain.  C) Bleomycin-treated wild-type mouse, hematoxylin/eosin stain.  
D) Bleomycin-treated IP-/- mouse, hematoxylin/eosin stain.  E) Bleomycin-treated wild-type 
mouse, Masson’s trichrome stain.  F) Bleomycin-treated IP-/- mouse, Masson’s trichrome 
stain.  G) Morphological changes observed in lungs obtained from bleomycin-treated mice 
were quantitated by digital imaging of hematoxylin/eosin stained lung sections and presented 
as a percentage of septal thickening.  Saline-treated IP+/+, n = 5; saline-treated IP-/-, n = 5; 
bleomycin-treated IP+/+, n = 13; bleomycin-treated IP-/-, n = 10; * p < .05 compared with 
corresponding saline value, # p < .05 compared with IP+/+ bleomycin value. 
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Figure 3.8 
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Figure 3.8.  Analysis of lung mechanics demonstrates increased disease susceptibility in 
the IP-/- mice.  Lung mechanics were measured in anesthetized, paralyzed, and mechanically 
ventilated mice 21 days following bleomycin or saline instillation.  A) Static compliance 
(Cst) determined by fitting the Salazar-Knowles equation to pressure-volume curves.  B) 
Tissue elastance (H) determined by applying prime wave impedance values to the constant 
phase model.  Saline-treated, n =  8-10; bleomycin-treated, n = 15-18. * p < .05 compared 
with corresponding saline value,  # p < .05 compared with IP+/+ bleomycin value.   
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Supplemental Figure S1. 
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Supplemental Figure S1.  Histological analysis and lung mechanics demonstrate similar 
disease susceptibility in the COX-1-/- and wild-type mice after bleomycin 
administration.  Lung mechanics were measured in anesthetized, paralyzed, and 
mechanically ventilated mice 21 days following bleomycin or saline instillation, and then the 
lungs were inflated with 10% formalin via a tracheal cannula, removed from the thoracic 
cavity, and fixed overnight in formalin.  A) Morphological changes observed in lungs 
obtained from bleomycin-treated mice were quantitated by digital imaging of 
hematoxylin/eosin stained lung sections and presented as a percentage of septal thickening.  
No difference was measured between the two bleomycin-treated groups.  * p < .05 compared 
with corresponding saline values.  n = 8-12.  B) Static compliance (Cst) determined by fitting 
the Salazar-Knowles equation to pressure-volume curves.  C) Tissue elastance (H) 
determined by applying prime wave impedance values to the constant phase model.  No 
difference in either static compliance or tissue elastance was measured between the two 
bleomycin-treated groups.  * p < .05 compared with corresponding saline values.  Saline-
treated animals, n = 14; bleomycin-treated animals, n = 20.   
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Supplemental Figure S2. 
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Supplemental Figure S2.  Histological analysis and lung mechanics demonstrate similar 
disease susceptibility in the PGDH-/- and wild-type mice after bleomycin administration.  
Lung mechanics were measured in anesthetized, paralyzed, and mechanically ventilated mice 
21 days following bleomycin or saline instillation, and then the lungs were inflated with 10% 
formalin via a tracheal cannula, removed from the thoracic cavity, and fixed overnight in 
formalin.  A) Morphological changes observed in lungs obtained from bleomycin-treated 
mice were quantitated by digital imaging of hematoxylin/eosin stained lung sections and 
presented as a percentage of septal thickening.  No difference was measured between the two 
bleomycin-treated groups.  * p < .05 compared with corresponding saline values.  n = 6-8.  
A) Static compliance (Cst) determined by fitting the Salazar-Knowles equation to pressure-
volume curves.  B) Tissue elastance (H) determined by applying prime wave impedance 
values to the constant phase model.  No difference in either static compliance or tissue 
elastance was measured between the two bleomycin-treated groups.  * p < .05 compared with 
corresponding saline values.  Saline-treated animals, n = 9; bleomycin-treated animals, n = 
15. 
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Supplemental Figure S3. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
IP PGIS
R
el
at
iv
e 
Ex
pr
es
si
on
Saline
Bleo*
  139
Supplemental Figure S3.  Real-time quantitative PCR analysis of expression levels of IP 
and PGIS in total RNA isolated from day 21 bleomycin-treated and saline-treated 
lungs.  Each sample was subjected to quantitative RT-PCR analysis on an ABI Prism 7900 
Thermocycler.  Expression of each was detected using commercially available primer and 
probe sets (Applied Biosystems).  Expression levels were normalized to an endogenous 
control, 18s, and the results were expressed as fold change relative to saline-treated 
expression levels.  Quantification of samples was performed using the comparative Ct 
(∆∆Ct) method, as described in the Assays-on-Demand Users Manual (Applied Biosystems).  
Relative gene expression was determined by the formula x = 2-∆∆Ct.  Saline-treated lungs, n = 
7; bleomycin-treated lungs, n = 9; * p < .05. 
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DISCUSSION  
Bleomycin-induced fibrosis is extensively used to model aspects of the pathogenesis 
of interstitial pulmonary fibrosis.  Here we show that intratracheally administered bleomycin 
leads to changes in lung mechanics that parallel those observed in patients with pulmonary 
fibrosis, providing an additional means of assessing the severity of disease in the mouse.  We 
examined the development of fibrotic lung disease in seven congenic mouse lines, each 
carrying a null allele in a gene required for the normal synthesis or response to prostanoids.  
These studies show that COX-2-dependant prostacyclin production limits the development of 
fibrosis and subsequent loss of lung function after exposure to bleomycin.  In contrast, 
alterations in PGE2 levels or in the ability of mice to respond to PGE2 have no effect on the 
development of disease.  
 Pulmonary function testing is commonly used to monitor the progression of 
pulmonary fibrosis in humans.  Reductions in forced vital capacity reflect changes in lung 
compliance as collagen is synthesized by myofibroblasts and deposited within the 
interstitium of the lung parenchyma.  Similar measurements have not typically been utilized 
in evaluation of disease in this mouse model of interstitial pulmonary fibrosis.  Rather, the 
severity of disease induced by bleomycin treatment is assessed using semi-quantitative 
histological examination and changes in lung hydroxyproline content.  In our studies, in 
addition to these traditional criteria, we measured lung mechanics of both saline and 
bleomycin-exposed animals.  In all experiments, treatment of both wild-type and congenic 
lines with bleomycin results in a significant decrease in static compliance, determined by 
analysis of pressure-volume loops from tracheostomized, mechanically ventilated animals.  
In addition to detecting differences between control and bleomycin-treated animals, 
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assessment of static compliance allows us to distinguish differences in disease severity in 
various experimental groups.  The increase in fibrotic disease in the bleomycin-treated COX-
2-/- and IP-/- animals detected using histological and biochemical measurements was 
paralleled by a significant decrease in static compliance of the lungs.  In the other mice 
tested, when histological evaluation and hydroxyproline measurements failed to distinguish 
between the two experimental groups of mice, no difference could be observed in the static 
lung compliance of these animals.  
We also evaluated the changes in lung mechanics after bleomycin exposure using the 
forced oscillatory technique.  This method, pioneered by Schuessler, Bates, and Irvin (24, 
46), measures the impedance of the lung to an oscillatory flow of mutually prime 
frequencies.  The constant phase model of the lung developed by Hantos et al. (20) is then 
utilized to calculate a value termed tissue elastance (H), which reflects the conservative 
(elastic) mechanical properties of the lung tissue.  Tissue elastance was increased in all mice 
exposed to bleomycin.  Experimental groups with more severe disease, based on histological 
and biochemical parameters, also displayed a significant increase in tissue elastance.  Thus, 
both tissue elastance and static compliance provide a sensitive means of assessing changes in 
lung mechanics that parallel the morphological changes induced by exposure to bleomycin.   
Our observation of increased disease in the COX-2-/- bleomycin-treated mice is 
consistent with the report by Keerthisingam et al. (25) using this same model of fibrotic lung 
disease.  In their study, histological examination of a small group of mice of mixed genetic 
background revealed more severe disease in the COX-2-/- animals.  However, in a more 
recent report by these investigators, the degree of fibrosis in the lungs was similar between 
bleomycin-treated COX-2-/- mice and similarily treated wild-type controls (22).  Mice used in 
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these studies were generated from selection and breeding of populations of F2 mice carrying 
both 129Sv/Ev and C57BL/6 genes, mice much less susceptible to patent ductus arteriosis.  
Over time, this breeding scheme likely results in a skewing of the genetic background of the 
mice in favor of a particular complement of 129Sv/Ev and C57BL/6 alleles.  Differences in 
the response of the COX-2-/- animals used in the various experiments could be attributed at 
least in part to distorted representation of 129Sv/Ev and C57BL/6 alleles in control and 
COX-2-/- animals.  Bonner et al. (4) examined COX-1-/- and COX-2-/- mice of mixed genetic 
background using a V2O5 model of pulmonary fibrosis.  V2O5 exposure does not result in 
fibrotic disease in wild-type mice.  While loss of COX-1 did not result in an increase in 
collagen deposition, a measurable increase in fibrosis was observed in the COX-2-/- animals.  
These results correlate well with our studies of the C57BL/6 congenic COX-1-/- mice and the 
F1 COX-2-/- mice in the bleomycin model.  We also failed to observe a difference in the 
development of disease in mice lacking COX-1 expression, and, on the other hand, we found 
that the fibrotic response to bleomycin is exaggerated in the COX-2-/- mice.  Taken together, 
histological and biochemical studies of the COX-deficient mice in both the bleomycin and 
V2O5 models of pulmonary fibrosis and analysis of lung mechanics after exposure to 
bleomycin suggest a role for COX-2-derived prostanoids in limiting fibrotic lung disease.  
A number of lines of evidence indicate that the protective prostanoid produced by the 
COX-2 pathway is PGE2 and that the protective actions of PGE2 are mediated by the EP2 
receptor.  This model, however, is not supported by the studies reported here.  First, we 
found no increase in disease parameters in the mice lacking mPGES1, despite our finding 
that this synthase is responsible for the increase in PGE2 levels measured in the mouse lung 
after exposure to bleomycin.  Two other proteins capable of metabolizing PGH2 to PGE2 
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have been identified, although a role for these proteins in the in vivo production of PGE2 has 
not yet been reported.  However, as the phenotype of the mPGES1-/- does not recapitulate the 
phenotypes of the various receptor deficient mice, it is presumed that some mPGES1-
independent pathways must be active in vivo (39, 53).  It is possible that these alternative 
synthetic pathways provide discrete pools of PGE2 essential for protecting mice against 
bleomycin-induced disease.  We therefore examined mice lacking PGE2 receptors, focusing 
on the two Gs-coupled PGE2 receptors, EP2 and EP4.  No difference in the response of the 
mice to bleomycin was observed in either the EP2-/- or EP4-/- mice compared to controls.  Our 
results differ from a recent study carried out using EP2-/- mice.  In this study, modest 
increases in collagen levels were measured in the EP2-/- animals compared to controls (32).  
The basis for these conflicting results is not apparent.  However, our inability to observe 
changes physiologically, biochemically, and pathologically in mPGES1-/-, PGDH-/-, EP2-/-, 
and EP4-/- mice does not support an anti-fibrotic role for PGE2 in this model.   
Prostacyclin production, similar to PGE2, is dependant on COX metabolism of 
arachidonic acid.  Prostacyclin binds with high affinity to the IP receptor, a seven 
transmembrane receptor which, like the EP2 and EP4 receptors, couples primarily to Gs to 
activate adenyl cyclase.  IP receptors are expressed at high levels on platelets, and 
prostacyclin limits platelet aggregation and thrombi formation.  Loss of COX-2-mediated 
prostacylin production by endothelial cells and the resultant unopposed activity of COX-1-
dependant thromboxane action on platelets may underlie possible increased risks for 
cardiovascular events in patients treated with COX-2 specific inhibitors (15).  Fewer studies 
have examined the role of prostacyclin in fibrotic lung diseases such as idiopathic pulmonary 
fibrosis.    
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A role for prostacyclin in pulmonary fibrosis is consistent with the expression of 
prostacyclin synthase (PGIS) and the IP receptor by many cell types present in the lung.  
PGIS expression has been demonstrated on pneumocytes, fibroblasts, endothelial cells, and 
resident leukocytes, and IP expression has been demonstrated on pneumocytes, fibroblasts, 
smooth muscle cells, and macrophages (12, 27, 40, 42, 44, 55).  In addition, IP receptors are 
expressed by many hematopoietic cells, including lymphocytes and neutrophils, recruited to 
the lung after exposure to bleomycin (37, 61).  We have examined the expression of PGIS 
and IP by quantitative RT-PCR in saline-treated and bleomycin-treated lungs.  As expected, 
expression of both the synthase and the receptor was easily detected in the healthy lung.  
PGIS expression was not increased after induction of fibrosis with bleomycin.  However, a 
small (50%) increase in the expression of the IP receptor was observed using this method 
(Supplemental Figure S3). 
 We recently reported that mice lacking IP receptors have elevated blood pressure, and 
the hearts of these animals showed extensive fibrosis (16).  Interestingly, while fibrosis is an 
expected consequence of elevations in blood pressure and cardiac stress, the extent of fibrosis 
in the IP-deficient mice was exaggerated compared to the modest increase in blood pressure.  
This suggests that, while the fibrosis was likely triggered by the stress conferred by elevated 
blood pressure, the fibrotic response normally may be limited by the presence of IP receptors 
on cardiac fibroblasts.  Consistent with this interpretation, stable prostacyclin analogues can 
inhibit migration of lung fibroblasts and proliferation of cardiac fibroblasts (27, 62).  
Exposure to IP agonists also decreased expression of types I and III collagen by cardiac 
fibroblasts (62).  In fact, bradykinin-mediated decreases in collagen formation by these cells 
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are the indirect consequence of production of a prostanoid, particularily prostacyclin, the 
major prostanoid formed by cardiac fibroblasts (17).   
Studies of dermal fibroblasts further support a role for prostacyclin in regulation of 
fibroblast growth and production of extracellular matrix components.  The prostacyclin 
analogue, iloprost, suppressed type I collagen induction by TGF-β in dermal wounds and 
attenuated induction of connective tissue growth factor (CTGF) (49).  Iloprost was also 
shown to suppress CTGF in the dermis of scleroderma patients (50).  Further studies with 
dermal fibroblasts suggest a mechanism whereby stimulation of the IP receptor leads to PKA 
activation which in turn limits TGF-β induction of collagen and CTGF by suppressing the 
Ras/MEK/ERK cascade (49).  Taken together, these studies support a model in which 
induction of COX-2 in the bleomycin-treated mice leads to increased production of 
prostacyclin.  Prostacyclin acts on IP receptors expressed by fibroblasts to limit their 
response to injury, including their migration to the lung, proliferation, and production of 
collagen.    
We cannot yet rule out the possibility that the increase in disease observed in the IP-/- 
mice is not the consequence of loss of the inhibitory actions of prostacyclin on the fibrotic 
response itself, but rather the result of an enhanced inflammatory response following 
bleomycin treatment.  IP receptors are expressed on many leukocyte populations, and an 
increase in cAMP in these cells would be expected to limit migration and production of 
proinflammtory cytokines.  In fact, the studies with the COX-2 mice in the V2O5 model 
support this interpretation (4).  Future studies in which loss of the IP receptor is limited to 
specific populations should allow us to further define the mechanism by which COX-2-
dependant prostacyclin production limits the development of fibrosis in the mouse lung.   
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In these studies, we show that loss of the prostacyclin receptor has a profound impact 
on the development of bleomycin-induced pulmonary fibrosis.  IP-/- mice showed increased 
disease by all parameters examined.  The magnitude of the physiological, biochemical, and 
pathological changes were similar to that of COX-2-/- mice, suggesting that loss of 
prostacyclin, and not loss of PGE2, is responsible for the enhanced fibrotic response observed 
in our studies.  The importance of COX-2-dependant prostacyclin production in limiting 
thrombotic events by counteracting the prothrombotic actions of thromboxane has been 
extensively explored (7).  The studies reported here suggest that COX-2-dependant 
prostacyclin production may also have an important protective role in fibrotic diseases.  In 
this regard, Murakami et al. recently examined the impact of a prostacyclin agonist on the 
development of fibrosis in the bleomycin model (35).  Interpretation of their findings, 
however, is complicated by the fact that this compound also displays thromboxane synthase 
inhibitory activity.  Treatment of mice with this agent provided protection against bleomycin-
induced fibrosis when mice were treated throughout the entire three week time period over 
which the disease develops.  In light of the reduced COX-2 expression observed in the lungs 
of humans with IPF (60), it will be important to determine whether IP receptor agonists can 
limit the severity of disease in the COX-2-/- mice.  If prostacylin analogues can attenuate 
disease progression, particularly if administered after initial lung injury, then further 
exploration of these agents as a novel therapy for treatment of IPF and other causes of 
pulmonary fibrosis in humans may be warranted. 
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CHAPTER 4 
Role of thromboxane and inflammation in the enhanced disease susceptibility of IP-/- mice
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INTRODUCTION 
 Idiopathic pulmonary fibrosis is a relentless, fatal disease characterized by 
proliferation of mesenchymal cell populations and extracellular matrix deposition.  This leads 
to alterations in lung architecture and impaired gas exchange.  Current concepts highlight the 
pathobiology of pulmonary fibrosis as an epithelial-fibroblastic disorder.  Microinjuries to 
the lung induce epithelial cell activation which causes the release of cytokines and other 
mediators to activate fibroblasts.  This activation includes migration to the injured site, 
proliferation, and transformation into myofibroblasts.  Myofibroblasts disrupt the basement 
membrane and may enhance epithelial cell apoptosis.  The role of inflammation in the 
progression of disease is currently debatable.  The lack in efficacy of corticosteroid therapy 
for patients with idiopathic pulmonary fibrosis has largely prompted the current concept that 
inflammation plays little to no role in disease pathogenesis.  However, inflammatory cells 
can not be ignored due to their release of profibrotic and antifibrotic mediators that can alter 
the phenotype of epithelial and fibroblast cells. 
 In the previous chapter, we demonstrated an important role for prostacyclin in the 
protection against pulmonary fibrosis.  Prostacyclin is best known for its role in preventing 
platelet aggregation and being a potent vasodilator.  Due to these primary roles, prostacyclin 
analogues are the primary treatment for patients with pulmonary hypertension.  However, in 
the context of the pathobiology of pulmonary fibrosis, prostacyclin can inhibit fibroblast 
proliferation and migration (9, 26).  Also, prostacyclin analogues can inhibit collagen 
production in cardiac and dermal fibroblasts (20, 21, 26).  In addition, the prostacyclin 
receptor, IP, is expressed by lymphocytes and neutrophils, which are recruited to the lung 
after bleomycin administration and secrete mediators that play intricate roles in disease 
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development (13, 25).  Thus, prostacyclin has many potential mechanisms for inhibiting the 
progression of bleomycin-induced pulmonary fibrosis. 
 Thromboxane is another lipid mediator produced from COX-derived PGH2.  The 
actions of thromboxane antagonize those of prostacyclin.  The best known role of 
thromboxane is as a vasoconstrictor and a facilitator of platelet aggregation.  However, 
thromboxane also has both pro-inflammatory and pro-fibrotic mechanisms that oppose 
prostacyclin.  The balance between these two mediators has recently been demonstrated to be 
an important homeostatic mechanism, and disruption of this intricate balance leads to disease 
pathogenesis.  Recent studies have demonstrated that loss of prostacyclin increases salt-
sensitive blood pressure, cardiac hypertrophy, and cardiac fibrosis as well as the proliferative 
response to vascular injury (5, 7).  In all cases, simultaneous loss of thromboxane ameliorates 
this increase in disease. 
 In this chapter, we investigate the role that prostacyclin and its counterpart 
thromboxane play in the development of pulmonary fibrosis.  The bleomycin-induced 
fibrosis model is characterized by an initial influx of leukocytes that instigate the fibrotic 
process.  Our data suggests that prostacyclin may have an inhibitory effect on inflammatory 
cell recruitment within the early stages of inflammation, particularily neutrophil recruitment.  
We show that TNF-α, a key pro-inflammatory cytokine in the development of pulmonary 
fibrosis, may not play a role in this increase in neutrophil recruitment and disease 
susceptibility.  Interestingly, we demonstrate that an alteration in the intricate balance 
between thromboxane and prostacyclin may play an important role in disease pathogenesis.
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MATERIALS AND METHODS 
Experimental Animals 
All studies were conducted in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina at Chapel Hill.  All experiments 
were carried out using 8-12 week old mice unless otherwise specified.  Mice lacking IP and 
IP/TP were generated as previously described (5, 23).   
 
Bleomycin Treatment 
Mice were anesthetized with approximately 20µl/g body weight of 2,2,2-tribromoethanol and 
administered 50 µl of saline or bleomycin (.05U unless specified otherwise) diluted in saline by 
intratracheal instillation.   
 
Bronchoalveolar Lavage 
At various time points, bronchoalveolar lavage (BAL) was performed (1.0 ml of Hank’s 
saline solution x 3).  The total number of BALF cells was determined using a 
hemacytometer.  A differential cell count was conducted on a cytospin prepared from 200 µl 
of BAL fluid and stained with Diff-Quik solution (Sigma) according to manufacturer’s 
instructions. 
 
Cytokine Measurements 
Lung samples were homogenized in 2 ml PBS w/ protease inhibitors and sonicated.  After 
centrifugation for 10 minutes at 3500rpm at 4°C, the supernatant was removed and frozen at -
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80°C.  Before use, samples were spun down at max speed to remove particulate matter.  
TNF-α levels were quantitated by using enzyme immunoassay kits (BD Opt EIA). 
 
Measurements of lung mechanics   
Mice were anesthetized 21 days after bleomycin administration with 70-90 mg/kg 
pentobarbital sodium (American Pharmaceutical Partners, Los Angeles, CA), 
tracheostomized, and mechanically ventilated at a rate of 350 breaths/min, tidal volume of 6 
cc/kg, and positive end-expiratory pressure of 3-4 cm H2O with a computer-controlled small-
animal ventilator (Scireq, Montreal, Canada).  Once ventilated, mice were paralyzed with 0.8 
mg/kg pancuronium bromide (Baxter Healthcare Corp., Deerfield, IL).  Using custom 
designed software (Flexivent, Scireq), airway pressure, volume, and airflow were recorded 
using a precisely controlled piston during maneuvers to evaluate lung mechanics. 
Pressure-volume curves were generated by a sequential delivery of 7 increments of air 
into the lungs from resting pressure to total lung capacity followed by 7 expiratory steps during 
which air was incrementally released.  Plateau pressure was recorded when airflow returned to 
zero at each step.  The Salazar-Knowles equation (Equation 1) was applied to the plateau 
pressure measurements obtained between total lung capacity (TLC) and functional residual 
capacity (FRC) during the expiratory phase of the pressure-volume loop to determine static 
compliance  (Cst) of the lung.  
 
V = Vmax – Ae-KP    (Equation 1) 
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Where  Vmax = volume extrapolated to infinite P, V = lung volume above FRC, A and K are 
constants 
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RESULTS 
 
Role of prostacyclin in leukocyte recruitment after bleomycin treatment 
 
 Prostanoids play an important role in modulating the inflammatory response in acute 
and chronic lung diseases.  After exposure to vanadium pentoxide, COX-2-/- mice had a 
significant increase in inflammatory cell infiltration into the lung compared to wild-type mice 
7 days after treatment suggesting an anti-inflammatory role for prostanoids in acute lung 
injury (2).  Consistent with this, we measured a significant increase in neutrophils 7 days 
after bleomycin treatment in the COX-2-/- mice (18.1±6.0 for wild-type and 39.0±4.0 for 
COX-2-/-, p < .05).  To investigate the role of prostacyclin in the inflammatory response, we 
quantitated the total number of leukocytes in BALF 3 and 7 days after bleomycin 
administration in IP-/- and wild-type mice.  Interestingly, quantitation of leukocytes in BALF 
3 days after bleomycin treatment revealed a significant increase in the early inflammatory 
response in the IP-/- mice compared to the wild-type mice (Figure 1A).  To determine 
whether the composition of the inflammatory response differed between groups, differential 
staining was performed to identify the leukocyte populations.  The IP-/- mice exhibited a 
significant increase in neutrophils upon differential analysis of the BALF (Figure 1B).  Thus, 
the magnitude and the composition of the initial inflammatory response are altered in the IP-/- 
mice.   
 Our preliminary studies demonstrated that, in wild-type mice, the initial influx of 
leukocytes is higher 7 days after bleomycin treatment compared to earlier time points 
(34.7±5.4 for day 7 compared to 24.3±2.6 on day 4 and 18.3±3.3 on day 1).  To determine 
whether this increase in inflammatory cell recruitment continued through the peak of 
inflammation, we measured the total cell counts in BALF of IP-/- mice and wild-type mice 7 
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days after bleomycin treatment.  As shown in Figure 2A, by day 7, both groups recruited a 
similar number of inflammatory cells to the lung.  No significant alterations in the 
accumulation of neutrophils, macrophages, or lymphocytes was noted in the BALF 7 days 
after bleomycin treatment (Figure 2B).   
 After V2O5 exposure, along with increased inflammation, the COX-2-/- mice had a 
significant increase in TNF-α levels 7 days after bleomycin treatment (2).  We analyzed 
whole lung homogenates from IP-/- and wild-type mice and demonstrated a significant 
increase in TNF-α levels 7 days after bleomycin administration.  However, no significant 
difference was measured between the two genotypes (108.8 pg/ml increase above salines for 
wild-type mice and 108.7 pg/ml increase above salines for IP-/- mice). 
 
Respiratory Mechanics in Aged IP-/- mice 
 Our collaborators recently reported an enhanced fibrotic response in hearts of IP-/- 
mice, and this response was dramatically increased in 17-month-old mice compared to 6-
month-old mice (7).  To determine if loss of prostacyclin can cause alterations in the 
fibroblast phenotypes in IP-/- mice without an initial inflammatory response, we analyzed the 
lung mechanics and examined the lung architecture of 12-month-old mice.  In previous 
studies, we have used C57BL/6 mice; however, since 129/SvEv are more susceptible to 
fibrosis, we analyzed both strains of mice in these experiments.  Analysis of static 
compliance measurements demonstrated no difference between the IP-/- mice and wild-type 
mice in either strain (Figure 3).  In addition, histological analysis of the lungs revealed no 
alterations in lung architecture in the IP-/- mice. 
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Role of the thromboxane/prostacyclin balance in bleomycin-induced pulmonary fibrosis 
 Opposite of prostacyclin, thromboxane promotes fibroblast proliferation and lung 
inflammation (12).  We demonstrated in the previous chapter that prostacyclin protects 
against bleomycin-induced pulmonary fibrosis.  Since thromboxane has both pro-fibrotic and 
pro-inflammatory properties, we investigated the hypothesis that, contrary to prostacyclin, 
loss of this mediator may be protective against pulmonary fibrosis.  We examined mice 
lacking the thromboxane receptor, TP.  Congenic C57BL/6 TP-/- and wild-type mice were 
administered bleomycin or saline, and disease was assessed 21 days later by lung mechanics.  
As expected, no difference was observed between the static compliance of the saline-treated 
TP-/- and wild-type lungs.  After bleomycin administration, both TP-/- and wild-type mice had 
a similar decrease in static compliance, so, unlike prostacyclin, loss of thromboxane alone is 
not enough to alter disease susceptibility (Figure 4A).   
 The balance of thromboxane and prostacyclin is important for maintaining 
cardiopulmonary homeostasis, and alterations in this balance can contribute to disease 
pathogenesis.  Unrestrained thromboxane, upon loss of prostacyclin in the IP-/- mice, may be 
important for enhancing disease progression.  To test this hypothesis, double knockouts, 
129/SvEv IP-/-/TP-/- mice, were administered bleomycin and disease progression was 
compared to 129/SvEv IP-/- mice and wild-type mice.  As with the C57BL/6 IP-/- mice, the 
129/SvEv IP-/- mice had a significant decrease in static compliance compared to the wild-type 
mice.  Interestingly, the IP-/-/TP-/- mice did not have a statistically significant decrease in 
static compliance compared to the wild-type mice (Figure 4B).  Although the static 
compliance was not completely returned to wild-type values in the IP-/-/TP-/- mice, these mice 
appear to have an ameliorated fibrotic response to bleomycin. 
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Figure 4.1 
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Figure 4.1.  Enhanced inflammatory response and neutrophilia in IP-/- mice 3 days after 
bleomycin administration.  A)  A significant increase in cellularity was measured in the 
bronchoalveolar lavage fluid (BALF) of IP-/- mice compared to wild-type mice 3 days after 
bleomycin treatment.  * p < .05 compared to corresponding saline value.  # p < .05 compared 
to wild-type bleomycin value.  n = 6.  B)  Differential staining of leukocytes revealed an 
increased number of neutrophils in the BALF of the IP-/- mice compared to the wild-type 
mice.  * p < .05 compared to wild-type bleomycin value.  n = 6.
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Figure 4.2 
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Figure 4.2  Similar magnitude of inflammatory cell recruitment 7 days after bleomycin 
administration in the IP-/- mice compared to the wild-type mice.  A)  Total inflammatory 
cell counts were similar in the BALF of IP-/- mice and wild-type mice 7 days after bleomycin 
treatment.  * p < .05 compared to corresponding saline value.  n = 10.  B)  Differential 
staining of leukocytes revealed similar recruitment of neutrophils, macrophages, and 
lymphocytes to the lungs of IP-/- mice compared to the wild-type mice 7 days after bleomycin 
treatment.  n = 10. 
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Figure 4.3 
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Figure 4.3  Similar lung mechanics in 12-month-old IP-/- and wild-type mice.  Static 
compliance was measured in anesthetized, paralyzed, and mechanically ventilated mice and 
determined by fitting the Salazar-Knowles equation to pressure-volume curves.  Two 
different background strains, C57BL/6 and 129/SvEv, were analyzed.  C57BL/6 IP+/+, n = 5; 
C57BL/6 IP-/-, n = 9; 129/SvEv IP+/+, n = 7; 129/SvEv IP-/-, n = 6. 
 169
Figure 4.4 
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Figure 4.4  Analysis of lung mechanics in TP-/-, IP-/-/TP-/-, and wild-type mice after 
bleomycin administration.  Lung mechanics were measured in anesthetized, paralyzed, and 
mechanically ventilated mice 21 days following bleomycin or saline instillation.  A) Static 
compliance (Cst) determined by fitting the Salazar-Knowles equation to pressure-volume 
curves revealed similar disease susceptibility in the TP-/- and wild-type mice after bleomycin 
administration.  * p < .05 compared with corresponding saline values.  n = 8-9 animals.  B) 
129/SvEv IP-/- mice demonstrate an increased susceptibility to disease, and this enhanced 
response is ameliorated in double knockout mice (129/SvEv IP-/-/TP-/-).  * p < .05 compared 
with wild-type bleomycin value.  n = 4-7 animals. 
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DISCUSSION 
 The magnitude of the initial inflammatory response in the bleomycin-induced fibrosis 
model is often correlated with enhanced fibrosis at later stages (19).  However, numerous 
studies have also demonstrated an increase in fibrosis without alterations in the inflammatory 
response.  For example, pulmonary fibrosis is more severe in mice deficient in GM-CSF 
despite the fact that the recruitment of inflammatory cells is similar compared to wild-type 
animals (10).  In this chapter, we demonstrate that loss of prostacyclin signaling caused an 
increase of inflammatory cell recruitment to the lungs after the initial injury.  In particular, a 
significant increase in neutrophils was observed.  If future experiments confirm these 
preliminary studies, this suggests that prostacyclin may play an inhibitory role in the initial 
influx of leukocytes, especially neutrophils, after bleomycin treatment.  
 The data presented here only begins to unravel the complexity of the inflammatory 
process in the prostacyclin deficient mice.  Of particular interest is the fact that the IP-/- mice 
had a significant increase in total cells and neutrophils in the BALF 3 days, but not 7 days, 
after treatment.  The IP-/- mice may have an earlier peak in the inflammatory cell recruitment 
and then remain constant while the wild-type mice peak later.  The possibility also exists 
that, at a certain point, large numbers of inflammatory cells become trapped in the 
interstitium, so cell counts from the BALF may not reflect the total number of cells actually 
recruited to the lung.  Histological analysis or leukocyte purification from whole lung 
collagenase digests would reveal the localization and number of cells in the alveolar space 
and the pulmonary interstitium.  In addition to cell recruitment, variations in cell count could 
reflect alterations in apoptosis and subsequent removal by macrophages.  Failure to clear 
unwanted cells by apoptosis can lead to abnormal repair and continued release of toxic 
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mediators.  Further experimentation will be necessary to determine the exact mechanism of 
cell recruitment and cell death in the IP-/- mice.   
 The alterations in the inflammatory response may or may not be relevant in 
enhancing disease susceptibility, especially since the precise cause-effect relationship of 
inflammation and disease progression is unclear.  However, enhanced neutrophilia has been 
linked to a worse prognosis for disease progression.  In one study, neutrophils were shown to 
induce apoptosis of lung epithelial cells, possibly leading to impaired reepithelialization, 
aberrant remodeling, and enhanced disease progression (18).  Also, in an additional study, 
mice deficient in γ-glutamyl transpeptidase (GGT) were protected from pulmonary fibrosis, 
yet inflammation after exposure to bleomycin was generally similar to wild-type mice (16).  
However, on closer analysis, the GGT-/- were observed to have fewer neutrophils and more 
lymphocytes and macrophages than wild-type.  Immunohistochemical analysis showed high 
expression of matrix metalloproteinase 9 (MMP-9) in neutrophils, as well as alveolar 
epithelia, and this expression was lacking in the GGT-/- mice.  The authors conclude that an 
increased number of neutrophils and MMP-9 expression can enhance disease progression, so 
the GGT-/- animals were protected from disease as a result of decreased neutrophil infiltration 
and subsequent MMP activity.   
 MMP-9 is responsible for the degradation of extracellular matrix, primarily type IV 
collagen.  Underneath the alveolar epithelium is the basement membrane, which is composed 
of type IV collagen, fibronectin, laminin, and proteoglycans.  Disruption of this basement 
membrane and impaired re-epithelialization are key factors in the progression of pulmonary 
fibrosis.  MMP-9 has been implicated as a factor responsible for the breakdown of the 
basement membrane and extracellular matrix components to perpetuate the fibrotic response 
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(8, 17).  In support of its role in fibrosis, MMPs are highly expressed in the lung parenchyma 
and in the airways of IPF patients (8).  In addition, studies have demonstrated that a 
substantial amount of MMPs are stored in the granules of neutrophils (1).  Thus, the 
increased neutrophil recruitment in the IP-/- mice may lead to basement membrane disruption 
due to enhanced MMP-9 activity.  Our preliminary experiments have demonstrated no 
significant increase in MMP-9 expression by RT-PCR in whole lung homogenates of IP-/- 
mice (data not shown).  However, the localization or activation of MMP-9 may be more 
important than mRNA expression.  Thus, immunohistochemical examination and 
zymography are required to confirm whether MMP-9 plays a role in enhanced disease 
progression. 
 Besides MMPs, neutrophils have a large number of toxic molecules in their granules, 
such as neutrophil elastase (3).  Similar to MMP-9, neutrophil elastase can degrade elastin, 
collagen type III and IV, laminin, and fibronectin (24).  Neutrophil elastase can also activate 
MMPs by cleaving their pro-enzyme form (15).  In support of its role in disease progression, 
the amount of neutrophil elastase is enhanced in the BALF of IPF patients (14).  Also, an 
inhibitor of neutrophil elastase limited the fibrotic response to bleomycin treatment in mice 
(22).  Enhanced neutrophilia in the IP-/- mice may lead to alterations in any number of toxic 
enzymes, such as neutrophil elastase, which could be responsible for altering disease 
progression in the IP-/- mice. 
 The bleomycin-induced fibrosis model is currently the best characterized and most 
often utilized mouse model for studying idiopathic pulmonary fibrosis.  Unfortunately, this 
model is characterized by an initial influx of leukocytes that is responsible for perpetuating 
the fibrotic response.  In the human disease, the initial cause is unknown, and the role of 
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inflammation in disease progression is debatable and most likely not as dramatic as its role in 
the bleomycin model.  Thus, when using this model to find novel therapeutics, this difference 
in the initial inflammatory response must be taken into account.  A recent study demonstrated 
that the inflammatory phase is the first ten days after bleomycin administration and the 
fibrotic phase follows thereafter.  This group demonstrated a peak in pro-inflammatory 
mediators from days 3-9, and pro-fibrotic mediators were elevated from day 9 through the 
end of the experiment suggesting a “switch” between these two phases (4).  Novel 
therapeutics that are efficacious after administration during the fibrotic phase provide 
promise to patients with pulmonary fibrosis who usually present during late stages of disease.  
In this regard, a recent study examined the impact of a prostacyclin agonist on the 
development of fibrosis in the bleomycin model (11).  Treatment of mice with this agent 
provided protection against bleomycin-induced fibrosis; however, protection was only noted 
when mice were treated throughout the entire three week time period over which the disease 
develops and not when given after the inflammatory phase.  This is consistent with our 
finding that prostacyclin plays a role in the initial inflammatory response.  However, in light 
of the reduced COX-2 expression observed in the lungs of humans with IPF, it will be 
important to determine whether delivery of prostacyclin analogues to COX-2-/- mice during 
the fibrotic stage could alter disease progression.  This would shed light on whether 
prostacyclin indeed plays a role strictly in the inflammatory response or if it plays a role in 
the fibrotic process as well. 
 To determine if prostacyclin may play a role in altering fibrotic mediators without an 
initial inflammatory response, we analyzed the lung architecture and respiratory mechanics in 
12-month-old mice lacking the prostacyclin receptor.  IP-/- mice have enhanced cardiac 
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fibrosis as they age, so if prostacyclin is an important pro-fibrotic mediator, loss of this 
signaling over a lifetime may trigger alterations in the phenotype of lung fibroblasts.  
However, no difference was measured in the static compliance of these mice on either the 
C57BL/6 or 129/SvEv background.  Upon histological analysis, no differences were noted in 
the architecture of the lung.  Interestingly, the 129/SvEv strain had small areas of increased 
inflammation in their lungs at 12 months of age; however, this was not dependent on loss of 
IP. 
 The balance of thromboxane and prostacyclin has recently been implicated as 
essential for homeostasis, and alterations lead to enhanced disease susceptibility.  For 
example, loss of cardioprotective prostacyclin and continued production of thromboxane is 
implicated in the increased risk of thrombotic events in patients taking COX-2-specific 
inhibitors (5).  Also, in fibroblasts from IPF patients, altered prostanoid metabolism was 
measured, and the investigators highlighted the physiological imbalance between 
prostacyclin and thromboxane as important for altering fibroblast phenotypes toward 
fibrogenesis.  They concluded that the lower ratio of prostacyclin to thromboxane may play 
an important role in the pathogenesis of IPF (6).  Our data supports their conclusions.  We 
demonstrated that the enhanced disease in the IP-/- mice after bleomycin treatment was 
ameliorated with simultaneous deletion of TP.  If future experiments confirm these 
preliminary studies, our data suggests that an essential balance exists between thromboxane 
and prostacyclin in the bleomycin-induced fibrosis model.  A shift in prostanoid profiles may 
lead to enhanced inflammation and subsequent fibrosis. 
 In this chapter, our data suggests that prostacyclin may play a role in the early 
inflammatory response to bleomycin-induced lung injury by inhibiting the initial influx of 
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leukocytes, especially neutrophils.  This is consistent with the fact that IP is expressed on 
neutrophils, as well as other leukocyte populations (13, 25).  Previous studies with the COX-
2-/- mice demonstrated a significant increase in the key proinflammatory cytokine, TNF-α, 7 
days after bleomycin treatment, and the investigators suggest that this increase contributes to 
the enhanced disease observed in the COX-2-/- mice.  However, we did not measure a 
significant increase in TNF-α in the IP-/- mice compared to the wild-type mice 7 days after 
bleomycin treatment.  In addition, our studies demonstrated enhanced neutrophil recruitment 
in the COX-2-/- mice 7 days after bleomycin treatment while the IP-/- mice had enhanced 
neutrophil recruitment 3 days after treatment.  These variations raise the question whether the 
enhanced disease in the COX-2-/- mice and the IP-/- mice is through the same mechanism.  
One possible explanation is that the background of these mice is different and could be 
causing the slight alterations in the temporal regulation of these pathways.  However, further 
experimentation is necessary to determine the mechanisms of cell recruitment and cell death 
to truly answer whether the COX-2-/- and the IP-/- mice respond similarily to bleomycin-
induced lung injury.    
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CHAPTER 5 
CONCLUSIONS 
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 Idiopathic pulmonary fibrosis is a deadly disease that currently has no therapies 
available to improve life expectancy or the quality of life for patients suffering from this 
progressive disease.  The traditional anti-inflammatory treatment of corticosteroids has not 
proven beneficial.  Recently, research has emphasized the importance of profibrotic 
mediators and alterations in epithelial and mesenchymal cell characteristics in disease 
pathogenesis.  Thus, novel therapeutic agents that target these mediators and cell types 
warrant investigation.  Prostanoids are lipid mediators that are both anti-
inflammatory/antifibrotic as well as proinflammatory/profibrotic.  The data presented here 
advances our understanding of the role that prostanoids play in the development of 
pulmonary fibrosis and suggests potential therapeutic targets. 
 Prostaglandin E2 (PGE2) is a prostanoid that has received the most attention for being 
an antifibrotic mediator of this disease and having a protective role through its Gs-coupled 
receptor, EP2.  Patients with IPF have decreased PGE2 levels in BALF, and fibroblasts from 
these patients are defective in PGE2 production (3, 13).  PGE2 also alters the activity and 
gene expression of fibroblasts (2, 4, 7).  In a number of different studies, alterations in PGE2 
levels are suggested to be responsible for changes in disease susceptibility and fibrotic 
phenotypes (8, 11).  However, often times, the analysis of other prostanoids is omitted.  Our 
data suggests that other prostanoids, aside from PGE2, play an important role in disease 
development and should not be overlooked. 
 We used genetically modified mice to determine if alterations in PGE2 levels or loss 
of the PGE2 Gs-coupled receptors can alter disease susceptibility to bleomycin-induced lung 
fibrosis.  We show that, although loss of the PGE2 synthase, mPGES1, significantly reduces 
lung PGE2 levels, it does not cause enhanced disease.  Consistent with this, loss of signaling 
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through the PGE2 Gs-coupled receptors also does not cause enhanced disease.  In addition, 
enhanced PGE2 levels due to loss of the catabolic enzyme PGDH does not protect against 
development of pulmonary fibrosis.  Surprisingly, our studies demonstrate that increased 
disease susceptibility in mice lacking COX-2 is due to specific loss of prostacyclin, which 
signals through a Gs-coupled receptor also capable of increasing intracellular cAMP.  Our 
study provides evidence for a protective role for COX-2-derived prostacyclin in the 
development of pulmonary fibrosis. 
 The importance of prostacyclin in regulating cardiovascular homeostasis is a more 
traditional and well-established role for this lipid mediator.  Our data, along with other 
studies, demonstrates a new role for prostacyclin in the complex regulation of inflammation 
and fibrosis.  Although studies have begun to demonstrate a role for prostacyclin in fibroblast 
proliferation and collagen deposition, most studies still neglect this underappreciated lipid 
mediator in favor of PGE2.  Our data challenges the current concept that PGE2 is the 
protective COX-2-derived prostanoid in pulmonary fibrosis and suggests a possible anti-
proliferative and anti-inflammatory role for prostacyclin.   
  We evaluated the development of lung disease in the various mouse lines using 
traditional histological and biochemical methods.  However, in addition to this, we evaluated 
the change in mouse lung mechanics after exposure to bleomycin.  We show that bleomycin-
induced fibrosis results in a decrease in static compliance and an increase in tissue elastance.  
We believe that this is the first demonstration of the use of these methods for evaluation of 
the impact of genetic alterations on the development of fibrotic lung disease in this model.  
Therefore, this data not only challenges the current concepts of the role of prostanoids in lung 
diseases but also demonstates a highly sensitive and novel method for analyzing disease 
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susceptibility that is physiologically based and more relevant to measurements acquired from 
patients with this disease.   
 The data presented here suggests that prostacyclin may play a protective role in the 
development of pulmonary fibrosis.  Enhancing signaling through the IP receptor may be a 
novel therapeutic treatment for pulmonary fibrosis.  Prostacyclin analogues, such as iloprost, 
increase intracellular cAMP levels through the IP receptor and are common for the treatment 
of pulmonary hypertension.  Since these compounds are already in clinical use, our data 
supports the testing of these compounds in trials for treatment of IPF and other fibrotic lung 
disorders.  As an additional treatment option, combining prostacyclin analogues with 
phosphodiesterase inhibitors may further enhance this signaling cascade.  Phosphodiesterase 
inhibitors prevent the inactivation of cAMP and may help prolong the effect of the 
prostacyclin analogues.  This would also elevate signaling through the EP2 and EP4 
receptors and take advantage of any possible role for PGE2 in disease development.  
Although we were unable to define a role for PGE2 in bleomycin-induced fibrosis, we can 
not completely exclude a possible role for PGE2 in human IPF and other fibrotic lung 
diseases due to differences between the mouse model and human disease pathogenesis.   
 The importance of prostacyclin in inflammation and tissue repair demonstrated by 
these experiments enhances the understanding of other diseases with similar pathological 
mechanisms.  An enhanced neutrophilic infiltration in the IP-deficient mice suggests an 
inhibitory role for prostacyclin in early inflammatory responses.  Although the role of 
inflammation in IPF is controversial, the pathogenesis of other interstitial lung diseases is 
more dependent on inflammation.  Thus, the data from these chapters may support a role for 
prostacyclin in other interstitial lung diseases.  Many other human diseases can be classified 
 184
as remodeling diseases due to basic pathogenic mechanisms including epithelial cell injury, 
chronic inflammation, and mesenchymal cell activation.  Airway remodeling in asthma and 
vascular remodeling in atherosclerosis are examples of diseases that have similar underlying 
mechanisms.  In this regard, prostacyclin receptor deficient mice were also more susceptible 
to airway remodeling, as well as inflammatory cell infiltration, in a model of allergic asthma 
(9).  This report strengthens our conclusions that prostacyclin is involved in inflammation 
and tissue repair and demonstrates the importance of prostacyclin in the underlying 
mechanisms of remodeling diseases.   
 Interestingly, these studies also indicate that current therapeutics for IPF and other 
diseases may have effects that have not been previously considered.  For example, along with 
increasing the probability of thrombotic events, the selective COX-2 inhibitors may also 
promote fibrosis in susceptible patients since they alter the delicate prostacyclin/thromboxane 
balance.  As discussed earlier, glucocorticoids are the traditional treatment for patients with 
IPF due to their anti-inflammatory properties.  However, as discussed in chapters 1 and 2, 
inhibition of COX-2 expression is one of the mechanisms that account for the anti-
inflammatory actions of glucocorticoids.  Thus, glucocorticoids could be limiting the 
production of the protective COX-2 metabolite prostacyclin, and as our data suggests, this 
can have severe negative effects on the inflammatory and fibrotic response.  This 
demonstrates the importance of understanding the mechanisms behind the actions of 
glucocorticoids since these are the most widely prescribed drugs in the United States.   
 In Chapter 2, we actually explored the complex interactions between the 
glucocorticoid receptor and prostanoid metabolism.  We were interested in determining the in 
vivo role of the putative PGE2 synthase, cPGES, and how it effects the progression of 
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fibrosis, so we created a mouse line lacking cPGES/p23.  Through analysis of embryonic 
tissues and fibroblasts from these mice, we were unable to establish a role for cPGES/p23 in 
the direct production of PGE2 from COX-derived PGH2.  However, we demonstrated that 
cPGES/p23 is an important co-chaperone for the Hsp90/GR complex and is required for both 
DNA-binding-dependent and -independent mechanisms of GR signaling.  Thus, an indirect 
mechanism exists in which overexpression or loss of cPGES/p23 may effect prostaglandin 
production through glucocorticoid signaling.  However, further experimentation is necessary 
to establish whether cPGES/p23 may also effect prostanoid production through an 
independent mechanism yet to be established.  An independent role for cPGES/p23 in growth 
and proliferation was suggested by our data.  This is consistent with the recent findings that 
cPGES/p23 is upregulated in cancer tissues and increases proportionately according to tumor 
grade in breast cancer cell lines (10).  Further exploration of the cPGES/p23-null mice and 
the primary cell lines established from these mice has the potential to unravel the mystery 
behind cPGES/p23 in cancer and tumor growth.  In addition, elucidating the role for 
cPGES/p23 in proliferation could shed light on a basic mechanism behind enhanced 
fibroblast proliferation in the setting of lung fibrosis. 
 Interestingly, other novel roles for p23 have recently been demonstrated that involve 
basic mechanisms important in pulmonary fibrosis.  cPGES/p23 has been shown to associate 
with human telomerase reverse transcriptase (hTERT) and aid in proper active telomerase 
complex assembly (5).  Another study showed that the p23 yeast homologue, Sba1, is 
required for telomere length maintenance in a telomerase DNA-binding-dependent manner 
(12).  Recently, a few studies have implicated telomerase in the pathogenesis of pulmonary 
fibrosis.  Mutations in hTERT have been demonstrated in familial cases of idiopathic 
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pulmonary fibrosis (1).  Also, loss of telomerase expression causes enhanced fibroblast to 
myofibroblast transition (6).  Future research is still necessary to elucidate the role of 
telomerase in idiopathic pulmonary fibrosis, as well as, the role of cPGES/p23 in telomerase 
function.  However, it is interesting to speculate that cPGES/p23 may play a role in the 
progression of pulmonary fibrosis.  A loss of cPGES/p23 expression may cause a loss of 
telomerase expression and enhance the fibrotic response through increased fibroblast to 
myofibroblast transition, and, as discussed above, upregulation of cPGES/p23 may lead to 
enhanced fibroblast proliferation through an independent mechanism.   
 We originally began investigating the role of cPGES/p23 to better understand its role 
as a PGE2 synthase and how loss of this protein may effect PGE2 production and subsequent 
fibrosis.  We, however, did not find a role for cPGES/p23 in direct PGE2 synthesis.  
Fortuitously, we discovered a role for cPGES/p23 in growth and proliferation as well as 
glucocorticoid receptor function, and other studies have suggested a role for cPGES/p23 in 
telomerase complex formation.  Altered expression of cPGES may effect the pathogenesis of 
fibrotic lung disease through any one of these different pathways.  Thus, cPGES/p23 may 
still turn out to be an important therapeutic target for idiopathic pulmonary fibrosis. 
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